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Abstract
As obesity is becoming more prevalent, there is concern for maternal health 
during pregnancy, parturition and beyond, alongside the impact that maternal 
obesity has on offspring health. Appetite regulation by gut hormones is one 
target for obesity ‘treatment’, although little is known about this fundamental 
system during different female reproductive stages. The main aims of this 
thesis were to study the orexigenic stomach-secreted hormone ghrelin and 
the anorexigenic colon-secreted hormones peptide-YY (PYY) and glucagon­
like peptide-1 (GLP-1) in female rats during their oestrous cycle, pregnancy 
and lactation. Changes in gut dimensions during pregnancy and lactation 
were also studied. In addition, lactation litter sizes were adjusted to explore 
the effects of different nutritional demands on both the dams and their male 
and female pups.
Reduced food intake has been reported during oestrus in rats. Here, 
significantly reduced fasted stomach contents leading into oestrus occurred 
with significantly increased circulating GLP-1 during proestrus. Ghrelin- 
positive stomach cells were significantly higher after parturition compared 
with non-pregnant and pregnant dams; this change may initiate and sustain 
lactation-associated hyperphagia, with significantly increased plasma ghrelin 
evident by late lactation. Paradoxical high levels of PYY and GLP-1 were 
found early in lactation when food intake was high, which may be related to a 
significant increase in gut growth from early to late lactation. Maternal gut 
size was significantly increased by late lactation and lactation litter size 
appeared to influence these changes. Only male offspring had altered satiety
hormones, with significantly decreased descending colon PYY and GLP-1 
levels when raised in large litters.
In conclusion, gut hormones and gastrointestinal modifications were altered 
during different reproductive states in females and in their male offspring at 
weaning. Further study is required to elucidate whether these changes may 
persist, influencing future health status, and whether they can be reliably 
modified for therapeutic purposes.
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CHAPTER 1: GENERAL INTRODUCTION
1.1. Introduction
Obesity is a leading global cause of disease and premature death and yet 
The World Health Organisation (WHO) describes it as preventable, given the 
correct interventions (WHO, 2014). Worldwide, it was estimated that 35% of 
adults over the age of 20 were overweight in 2008, with 11% of adults falling 
into the obese category (WHO, 2014). In the UK, it is estimated that by the 
year 2030, obesity and obesity-related disease will cost the National Health 
Service £2 billion a year (Ng and Wilding, 2014). Of most concern is that in 
excess of 40 million children worldwide, under the age of 5 years, were 
overweight or obese in 2012 (WHO, 2014). Maternal body mass gain is a 
natural consequence of pregnancy, however many women are already 
overweight and will further over-consume during pregnancy, which, combined 
with interrupted sleep and mealtime patterns, can result in additional 
postpartum body mass retention. The influence of pregnancy and lactation on 
subsequent body mass and the metabolic health of both mothers (Rooney 
and Schauberger, 2002) and their offspring (Heerwagen et al., 2010) is now 
well established. To understand why body mass is gained and retained at 
these times and to enable the development of appropriate treatments, it is 
essential to determine how appetite regulation and the gastrointestinal 
system are altered during pregnancy, lactation and the later postpartum 
period. However, males have preferentially been used in many studies of 
appetite regulation because the reproductive cycle, pregnancy, lactation and
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the later postpartum period all present complicating factors to consider 
experimentally (reviewed by Asarian and Geary, 2013).
The regulation of appetite is one mechanism by which whole body energy 
homeostasis is maintained, however the incidence of obesity is increasing in 
part due to the increased availability of calorie-dense, high fat foods and an 
increasingly sedentary lifestyle creating an ‘obesogenic’ environment. 
Appetite is regulated by both the nervous and endocrine systems and in 
humans, social and emotional cues can also influence appetite and food 
choice. Food palatability also plays a large role in when humans may choose 
to eat, even when not hungry, and has been referred to as ‘non-homeostatic’ 
eating (Berthoud, 2006). Short-term appetite can play a role in meal initiation 
and be programmed by a certain situation or time of day, whilst long-term 
homeostatic appetite is a result of the body sensing an energy deficit. To 
regulate long-term homeostatic appetite, the hypothalamus provides neural 
control, while the enteroendocrine cells (EGs) of the gut provide hormonal 
control. These are summarised below (sections 1.2, 1.3 and 1.4).
1.2. Hypothalamic regulation of appetite
The hypothalamus plays a pivotal role in the regulation of food intake, 
containing receptors for many of the gut-derived appetite-influencing 
hormones (Figure 1.1), and receives and relays information regarding 
nutrient availability to maintain whole body energy homeostasis. The arcuate 
nucleus (ARC) of the hypothalamus contains an orexigenic (appetite- 
stimulating) and an anorexigenic (appetite-inhibiting) subset of first order
2
neurons; the orexigenic neurons co-express neuropeptide-Y (NPY), agouti- 
related protein (AgRP) and gamma-aminobutyric acid (GABA) and the 
anorexigenic neurons co-express pro-opiomelanocortin (POMC) and cocaine 
and amphetamine regulated transcript peptide (CART) (reviewed by Valassi 
et at., 2008). These neurons from the ARC have axons that extend to second 
order neurons of other brain regions, including the paraventricular nucleus 
(PVN) (Valassi et al., 2008). Although not a focus of this work, proposed 
hypothalamic mechanisms of action for ghrelin and PYY will be summarised 
in section 1.6.
MC4R
GABAR
GHSR
GABAR
Orexigenic Anorexigenic
Projections to 
multiple brain 
areas
GHSR
Figure 1.1. The arcuate nucleus (ARC) of the hypothalamus and appetite regulation
(3V, third ventricle; PVN, paraventricular nucleus; POMC/CART, pro-opiomelanocortin 
(purple)/cocaine and amphetamine regulated transcript; NPY/AgRP/GABA, neuropeptide-Y 
(blue)/agouti-related protein (red)/gamma-aminobutyric acid (purple); a-MSH, a-melanocyte 
stimulating hormone; GHSR, growth hormone secretagogue receptor; INSR, insulin receptor; 
ObR, leptin receptor; MC4R, melanocortin 4 receptor; GABAR, gamma-aminobutyric 
receptor; YRs, Y receptors). (Modified from Briggs and Andrews, 2011).
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1.3. The gastrointestinal tract
The mammalian gastrointestinal (Gl) tract is separated into several main 
subdivisions, including the mouth, oesophagus, stomach, small intestine 
(duodenum, jejunum, ileum), large intestine, rectum and the anus, which are 
collectively responsible for the breakdown and absorption of food and the 
excretion of waste products (Figure 1.2).
I -i----------—------ Anus
Figure 1.2. The human gastrointestinal tract
(Modified from the National Institute of Diabetes and Digestive Kidney Diseases (NIDDK) 
image library, NIDDK, n.d.)
In the mouth, food is broken down both physically (chewing) and 
enzymatically (saliva) before it is swallowed, entering the oesophagus and 
being delivered to the stomach. Digestion of carbohydrates, proteins and 
lipids begins in the mouth (Goodman, 2010). Food is further digested by the 
stomach mechanically mixing its contents with gastric acid, secreted by 
parietal cells, and a number of digestive enzymes including pepsin and 
lipase, secreted by gastric chief cells, that break down proteins and lipids
Gastric fundus
Gastric corpus L Stomach
Gastric pylorus J
Ascending colon T
Transverse colon L Large intestine
Descending colon J
Duodenum
Small intestine
Rectum
Oesophagus
r
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respectively (Goodman, 2010). Gastric emptying releases food into the small 
intestine, where enzymes in the brush border of gut enterocytes are involved 
in digestion and nutrient transportation into the bloodstream, alongside 
digestion by pancreatic and liver enzymes. The small intestine has a large 
surface area due to the presence of villi and microvilli on the epithelial 
mucosa and is the main gut area where water is absorbed. Any remaining 
water and electrolytes are absorbed in the large intestine and the gut 
microbiota metabolise any remaining nutrients, such as short-chain fatty 
acids (Goodman, 2010). Indigestible content is formed into faeces which are 
temporarily stored before excretion as waste.
Nutrients such as carbohydrates, proteins and lipids are absorbed by 
specialised gut epithelial cells, enterocytes, and pass through the portal 
blood and into the liver before transportation to other areas of the body 
(Goodman, 2010). The processes of secretion, digestion, absorption and 
motility depend on the co-ordinated actions of different intestinal cell types, 
including different types of epithelial cells and also muscle cells. This co­
ordination is achieved by the intrinsic and extrinsic innervation of the gut and 
also by the endocrine system of the Gl tract.
The gut endocrine system is of great importance due to its essential role in 
whole body energy homeostasis. Appetite and some gut functions, such as 
gastric emptying, are influenced by circulating peptide hormones that are 
produced and secreted by ECs located in the mucosal epithelium of the gut. 
These hormones act in the central nervous system (CNS), in control centres
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of the brain, and peripherally in the body. Hormone signals from the gut act 
on neurons of the hypothalamus either by travelling across the blood-brain 
barrier via the circulation or via the vagus nerve by activation of gastric vagal 
afferents (Figure 1.3).
VILLI ►
Enteroendocrine 
< cells
L— .
Extrinsic 
afferents ► 4  CRYPT
Intrinsic 
afferents ►
Figure 1.3. Enteroendocrine cells in gut mucosal epithelium
Cross-section of the intestinal wall, illustrating that enteroendocrine cells in the epithelium 
(EPI) of the gut are associated with intrinsic afferents of the enteric nervous system and 
extrinsic vagal afferents (Bertrand, 2009).
Figure 1.4 outlines principal areas of the human Gl tract that produce and 
secrete key gut hormones involved in appetite regulation and their main 
actions, including those studied in this thesis. These Gl areas (Figure 1.4) 
are broadly similar in rodents, although rats have a caecum, rather than an 
appendix, which connects the small and large intestine and is required for 
fermentation of cellulose. The hormones studied here are ghrelin, peptide-YY 
(PYY) and glucagon-like peptide-1 (GLP-1). Details of these hormones and 
their mechanisms of action will be described later (section 1.6).
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Figure 1.4. Principal sites of synthesis of the appetite-regulating peptide hormones in 
humans
The stomach, intestines and adipose tissue release hormones that induce hunger or satiety 
by interaction with the hypothalamus, via the circulation or by interaction with the vagus 
nerve. (PYY, peptide-YY; GLP-1, glucagon-like peptide-1; CCK, cholecystokinin; AgRP, 
agouti-related protein; NPY, neuropeptide-Y; POMC, pro-opiomelanocortin). (Modified from 
Larder and O'Rahilly, 2012).
1.4. Enteroendocrine cells of the gut
Gut ECs have been studied to understand their possible role in pathologies 
such as Gl cancers and in obesity and eating disorders. The epithelial cells of 
the gut differentiate from pluripotent stem cells at the base of intestinal crypts 
(Gunawardene et a/., 2011), migrating upwards as they do so (Figure 1.5). 
As well as ECs, other epithelial cells of the gut, which also develop from 
these stem cells, include mucus-secreting goblet cells and absorptive 
enterocytes.
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Figure 1.5. Development of endocrine cells of the mammalian gastrointestinal tract
Pluripotent stem cell daughter cells migrate upwards and differentiate into one of the four 
represented cellular lineages (Gunawardene et al., 2011).
ECs are found throughout the entire length of the gut and can be 
characterised either as ‘open’ type cells, which have microvilli that extend 
into the lumen of the gut or as ‘closed’ type cells, which do not (Sternini et al., 
2008). Both of these cell types produce and secrete different products, 
including peptide hormones and neurotransmitters, singly or in combination 
and have been named as shown below (Table 1.1).
Table 1.1. Summary of some of the enteroendocrine cell types found in the 
gastrointestinal tract and their principal locations
(* also known as gastric inhibitory peptide). (Gunawardene etal., 2011; Sternini et al., 2008).
Principal Gut Locations Cell Type Product Secreted
Throughout the 
gastrointestinal tract
Enterochromaffin
cells Serotonin (5-HT)
Stomach (throughout) 
Stomach (pylorus) 
Stomach (corpus)
X/A-like cell 
G-cells 
D-cells
Ghrelin
Gastrin
Somatostatin
Proximal small intestine 
Small intestine
l-cells
K-cells
Cholecystokinin (CCK) 
Glucose-dependent 
insulinotropic peptide* (GIP)
Distal large intestine L-cells
Peptide-YY (PYY) 
Glucagon-like peptides (GLP) 
Oxyntomodulin (OXM)
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1.4.1. Enteroendocrine cells during development
A number of studies have aimed to determine at what stage of development 
ECs appear in the Gl tract, with many such studies focussing on ghrelin since 
its discovery as the only orexigenic gut hormone to be identified to date. 
Expression of ghrelin mRNA in the stomach of male and female rat pups has 
been detected from 1 week of age, with a gradual increase until 4 to 5 weeks 
of age (Sakata et al., 2002). The same authors reported the presence of 
ghrelin-immunopositive cells in the stomach from 1 week of age, with a 
higher cell density in females than in males, although cell density increased 
with age in the males which was not the case in the females. Furthermore, 
ghrelin immunopositive cells showed an age-dependent localisation in the 
stomach, where they were predominantly located at the base of the fundic 
glands at 2 weeks of age and started appearing at the glandular neck by 3 
weeks of age. Another study documented similar findings, with an increase in 
stomach tissue ghrelin concentrations from 1 to 5 weeks of age in rats 
(Hayashida et al., 2002). They additionally reported the presence of ghrelin- 
immunopositive cells in the foetal stomach at days 18, 20 and 22 of 
gestation; these cells increased in number with gestational age. It is likely 
that prior to birth, ghrelin has a more important role in the rat foetal pancreas 
than in the stomach, due to much higher concentrations present here 
(Chanoine and Wong, 2004).
Colonic ECs have been reported to appear by embryonic day 14.5 in mice. 
All colonic ECs expressed PYY at this stage, prior to further differentiation at 
later stages when glucagon was found to co-express with PYY throughout
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much of gestation, which the authors state is similar to the normal secretory 
profile of L-cells (Upchurch et al., 1996). An earlier study also reported that 
PYY was present at an early stage, with PYY mRNA expression being 
evident in the foregut from embryonic day 11 (Jazin et al., 1993). Together, 
these studies may suggest a role for PYY in the early development and 
growth of the gut.
The pre- and postnatal stages of development may represent critical times at 
which the ECs secreting appetite-regulatory hormones could be altered and 
could influence gut growth (Gomez et al., 1995), which may change the way 
the gut and gut hormones respond to appetite and food intake in later life. It 
is also possible that changes to the gut and gut hormones may affect 
hypothalamic circuitry relating to appetite and body mass control, which in 
rodents, is not fully mature until approximately 21 days postnatally, thus the 
suckling period presents a critical time period during which this regulatory 
system could be altered. In humans, this system is less easily affected by 
postnatal changes, as hypothalamic maturation occurs during the third 
trimester of pregnancy (Prior and Armitage, 2009), however early changes in 
gut development still represent a time in which this system could be 
influenced.
1.5. Regulation of food intake and body mass
Humans and rodents are the main species utilised in the majority of studies 
involving appetite and food intake. Whilst humans are classed as being meal- 
feeders by day, rodents tend to consume multiple smaller meals, after an
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initial larger meal, throughout the nocturnal period when they are active. 
Despite these differences, feeding regulation has been shown to be very 
similar between the species. One way in which the different feeding patterns 
has been taken into account in comparison studies is to standardise 
measurements by taking them at the same time of day, if multiple samples 
are required for a study. Due to the different secretory profiles of hormones 
throughout a 24 hour day, taking samples at the most relevant times for the 
hormone of interest is critical, as differences in their highest concentration 
between different days or experimental interventions may be lost if they are 
measured at a daily nadir, or anywhere in-between. If gut hormones are to be 
measured, fasting is generally used as a method to standardise 
measurements across days and subjects, especially in ad libitum fed rodents, 
in order to obtain a value that can be reliably compared between subjects. In 
rodent studies of gut appetite hormones, it is important to take samples when 
most physiologically relevant to them, which is during the dark phase. Taking 
samples from rodents during the light period arguably does not allow an 
accurate comparison between human and rodent studies. A degree of 
compromise needs to be struck between the daily profile of the peptide being 
measured and the possibility of standardising subjects by fasting.
Gut hormones play key roles in the regulation of feeding and body mass, 
although in humans, food intake is also influenced by learned behaviour and 
both social and emotional cues. Human studies report large variations in day- 
to-day food intake (Bray et al., 2008), yet on average, adults will only gain 
around 0.5 kg in body mass each year of their lives (Bessesen, 2011),
11
suggesting a finely tuned regulatory system. This value, however, does not 
consider physiological states such as pregnancy or lactation, which 
temporarily alter this regulatory system (section 1.8) yet their effects may last 
years. Table 1.2 gives an overview of the main hormones and 
neurotransmitters that have been identified to be involved in appetite 
regulation and their expected effect on food intake in mammals. Table 1.2 
also outlines the principal site of synthesis for each hormone and 
neurotransmitter, although many of these peptides are found in multiple 
locations both inside and outside the gut. For example, ghrelin and 
somatostatin distribution in the gut is primarily in the stomach, with 
decreasing amounts along the small intestine and into the large intestine. 
PYY and GLP-1 are located primarily in the large intestine, most 
concentrated in the rectum, with decreasing amounts back up through the 
large intestine and into the small intestine.
Alongside influencing food intake and gut function, it has been suggested 
that some gut hormones may also influence subconscious spontaneous 
physical activity (SPA), such as fidgeting. For example, Pfluger et al. (2011) 
concluded that the orexigenic hormone ghrelin further helped maintain 
energy homeostasis by decreasing SPA during chronic elevation of ghrelin to 
conserve energy. These authors have suggested that decreased SPA could 
be a protective mechanism to promote lipid storage in adipose tissue, thus 
maintaining energy stores during a period of fasting (Pfluger etal., 2011).
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Table 1.2. An overview of the main peripheral and central peptides and 
neurotransmitters involved in mammalian feeding and body mass regulation and their 
principal sites of synthesis
(* synthesised in many additional areas).(Volkow etal., 2011, Akil etal., 1984, Rodgers et 
al., 2002, Gibson etal., 2010, Wilding, 2002).
Product Principal sites of synthesis
Effect on 
feeding
Peripheral
Ghrelin Stomach A
Somatostatin Stomach
Cholecystokinin (CCK) Small intestine
Peptide-YY (PYY) Large intestine
Glucagon-like peptide-1 (GLP-1) Large intestine; pancreas
Pancreatic polypeptide (PP) Large intestine; pancreas >f
Oxyntomodulin (OXM) Large intestine
Serotonin (5-HT) Throughout the Gl tract
Insulin Pancreas
Amylin Pancreas 1
Leptin Adipose tissue 4
Adiponectin Adipose tissue t
Central
a-melanocyte stimulating 
hormone (a-MSH) Hypothalamus 1
Agouti-related protein (AgRP) Hypothalamus t
Cocaine and amphetamine- 
regulated transcript (CART) Hypothalamus 1
Dopamine Ventral tegmental area* t
Melanin-concentrating hormone 
(MCH) Hypothalamus t
Neurotensin Hypothalamus 4
Neuropeptide Y (NPY) Hypothalamus
Noradrenaline Central nervous system >
Opioids (endogenous) Central nervous system A
Orexin A and B Hypothalamus t
Pro-opiomelanocortin (POMC) Hypothalamus 4
Our current understanding of the roles of regulatory peptides in feeding and 
the regulation of body mass has advanced in recent years but still remains 
incomplete. As obesity is becoming more prevalent worldwide, these 
endogenous hormones are valid targets for potential obesity treatments. Due
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to their complex inter-regulatory actions and the apparent redundancy of 
some pathways this may prove difficult to achieve, as targeting a single 
peptide or receptor may not have the desired effect or may even cause 
unwanted side-effects. One review has discussed evidence of the difficulties 
involved in developing a drug that has the potential to be used as an obesity 
treatment. PYY, GLP-1 and oxyntomodulin (OXM) have all decreased food 
intake and body mass when given to rodents and humans (reviewed by 
Chaudhri et al., 2008). However, these authors point out that both PYY and 
GLP-1 cause nausea and vomiting at high concentrations, likely due to their 
effects on the inhibition of gastric emptying and like OXM, they are also 
rapidly broken down in the circulation by the enzyme dipeptidyl peptidase IV 
(DPP IV), thus requiring a DPP IV-resistant drug analogue. If a 
pharmacological agent was successfully manufactured to manipulate 
endogenous hormone actions to decrease appetite in obese individuals, it 
would have to maintain a physiologically acceptable hormone balance so that 
other body systems and pathways did not overcompensate and render any 
effect temporary. A good example of this problem is a study by Sainsbury et 
al. (2002) that used a knockout mouse model with a hypothalamic-specific 
deletion of the Y2 receptor (the receptor for NPY and PYY) and found that 
the expected decreases in food intake and body mass were only transient, 
suggesting compensatory mechanisms took place in order to maintain whole 
body homeostasis in the longer term (Sainsbury et al., 2002).
One recent advance is the development of liraglutide, a GLP-1 receptor 
agonist that remains in the circulation for 11 to 13 hours (reviewed by Ng and
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Wilding, 2014). Liraglutide was first approved by the European Medicines 
Evaluation Agency (EMEA) in 2009 for the treatment of type 2 diabetes, 
improving glycaemic control, but it has also been shown to cause a sustained 
mean body mass loss of 7.6 kg after 2 years of treatment. Due to the obvious 
attraction of body mass loss and increased glycaemic control, liraglutide has 
recently been submitted as an anti-obesity drug to both the EMEA and the 
US Food and Drug Administration (Ng and Wilding, 2014). However, 
liraglutide is similar to other GLP-1 treatments in that 14% of patients in 
clinical trials have reported vomiting as a side effect. An increased resting 
pulse rate has also been reported after 2 years of treatment with liraglutide 
(Ng and Wilding, 2014). More long-term studies would need to establish 
whether the medical benefits of obesity treatment with liraglutide outweigh 
these possible side effects.
The only current demonstrated long-term ‘cure’ for obesity is gastric bypass 
surgery, with Roux-en-Y bypass (RYGB) among the most well studied due its 
use in 70 to 75% of bariatric procedures (reviewed by Beckman et al., 2010). 
Briefly, this procedure involves reducing stomach volume by bypassing the 
distal stomach and a portion of the proximal small intestine, which creates 
not only a restriction in food intake but also results in malabsorption of 
nutrients (Beckman etal., 2010). Beckman etal. (2010) reviewed the findings 
of the most robust studies in this area and documented that RYGB increased 
circulating levels of PYY and GLP-1, with PYY levels being consistently 
elevated above baseline levels regardless of fed state. These authors also 
pointed out that most studies were in agreement that levels of both total and
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acyl ghrelin (peptide forms are described in section 1.6.1.1) were decreased 
compared with control levels in circulation. Although gastric bypass results in 
long-term body mass loss that is beneficial to the health of morbidly obese 
individuals by improving their metabolic status, later body mass gain and 
health complications are not unheard of. A long-term study of obese patients 
that had a RYGB procedure found that body mass loss was maximal 4 years 
after the procedure, after which there was a tendency to regain some body 
mass by postoperative year 7 (Spivak et al., 2012). These authors also 
documented that 9% of patients who underwent RYGB experienced a 
‘serious life-threatening complication’, examples of which included intra­
abdominal bleeding and bowel obstruction caused by an internal hernia. A 
recent review expressed concern for long-term health problems that are as 
yet to be fully characterised. This review proposed that not only are 
malabsorption of vitamin D and calcium likely to become an issue years after 
RYGB, despite supplementation, but that elevated PYY levels and reduced 
ghrelin levels may result in a decline in bone mineral density (Hage and El- 
Hajj Fuleihan, 2014). These authors stressed the requirement for future 
studies to monitor and address changes in bone mineral density in relation to 
gut hormones postoperatively to protect the future health of bypass patients.
1.6. Appetite hormones in the gastrointestinal tract
Whilst many peptide hormones are involved in appetite regulation (see Table 
1.2), this thesis has focussed on three; the orexigenic gut peptide ghrelin, 
produced primarily by the stomach, and the anorexigenic gut peptides PYY 
and GLP-1, produced primarily throughout the large intestine. Ghrelin and
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PYY can be studied together as gut peptides with some opposing actions. 
PYY and GLP-1 are co-secreted by L-cells in the distal gut and both are 
implicated in satiety. The known properties of these three peptides are 
described below. The anticipated benefit of studying multiple hormones 
together is to provide a more in-depth understanding of appetite regulation, 
due to the complex interaction between the gut hormones in the regulation of 
appetite during dynamic reproductive states.
1.6.1. Ghrelin
Ghrelin was first isolated from rat stomach as the endogenous ligand for the 
growth hormone secretagogue receptor (GHSR) and was so named as ‘ghre’ 
is the root of the word ‘grow’, thus describing its stimulatory role in causing 
growth hormone (GH) release from the anterior pituitary gland (Kojima et al., 
1999). To date, ghrelin is the only orexigenic peptide to have been isolated 
that is produced outside the CNS, and its role in energy homeostasis and 
feeding stimulation is a major area of research. Ghrelin has also been shown 
to increase gastric motility and to increase body mass and adiposity 
(reviewed by Lim et al., 2010). Ghrelin is predominantly secreted from 
stomach X/A-like cells and is released in response to both homeostatic 
(energy deficit) and non-homeostatic (no energy deficit) hunger. The 
secretion of ghrelin is influenced by a number of factors including stomach 
distension and a rise or fall in the levels of appetite-regulatory hormones 
such as PYY (see section 1.6.4). The GHSR has been identified in multiple 
locations including the pituitary and adrenal glands, hypothalamus, pancreas,
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myocardium and the spleen (Lim et al., 2010), although the role of ghrelin in 
some locations has not yet been established.
An early study of ghrelin levels in relation to appetite demonstrated that 
ghrelin levels were highest in humans (1 male and 9 females) 1 to 2 hours 
prior to meal onset and rapidly decreased to their lowest levels approximately 
1 hour after meal onset (Cummings et al., 2001). Further studies have also 
explored the role of ghrelin in other areas (Table 1.3) including reproduction, 
which will be discussed in detail later (section 1.7.2).
Table 1.3. Some of the additional effects of ghrelin in mammals
(Modified from Kojima and Kangawa, 2005).
Target Effect of ghrelin
Gastric acid T
Overall gastric motility A
Gut mucosa turnover t
Growth hormone (GH) t
Adrenocorticotropic hormone (ACTH) T
Cortisol T
Prolactin t
Insulin m
Blood glucose t
Cardiac output r
Blood pressure
1.6.1.1. The ghrelin peptide forms and ghrelin O-acyl transferase 
(GOAT)
Encoded by the ghrelin gene, which in humans is on chromosome 3p25-26, 
the 117-amino acid preproghrelin (reviewed by Kojima and Kangawa, 2005) 
is cleaved to produce the 28-amino acid peptide ghrelin (Kojima et al., 1999).
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Ghrelin is present in two main forms, acyl ghrelin, known as ‘physiologically 
active’ ghrelin and desacyl ghrelin, which is known as the ‘inactive form’. 
Total ghrelin is a combination of the acyl and desacyl forms of the ghrelin 
peptide. Both acyl and desacyl ghrelin forms are present in gut tissue and in 
the circulation of rodents and humans (Hosoda et al., 2000). There is also a 
third ghrelin fragment cleaved from the C-terminal end known as obestatin 
(Kobelt et al., 2008), which has been suggested to act as an antagonist to the 
orexigenic properties of ghrelin, although its role remains controversial. A 
number of other minor fragments are derived from the ghrelin peptide, 
although again, their roles are not well characterised (Kojima and Kangawa, 
2005).
Acyl ghrelin is the endogenous ligand for the GHSR, thus stimulating GH 
secretion (Kojima et al., 1999). Briefly, high levels of ghrelin can stimulate 
hypothalamic release of growth hormone releasing hormone (GHRH) which 
in turn releases GH from the pituitary; GH production can be inhibited by high 
levels of somatostatin (reviewed by Zizzari et al., 2011). Total ghrelin has 
been found to induce GH secretion both directly, by stimulating the release of 
GHRH (Wren et al., 2002) and indirectly, by inhibition of hypothalamic 
somatostatin release (Tolle etal., 2001). Tolle et al. (2001) additionally tested 
desacyl ghrelin in their experiments and found no effect on GH levels, 
suggesting that acylation by ghrelin O-acyl transferase (GOAT) was 
necessary for their reported effects. GOAT modifies the ghrelin peptide at its 
third serine residue by the addition of a fatty acid to its hydroxyl group (Figure 
1.6), so that it can bind to the GHSR (Kojima and Kangawa, 2005). GOAT,
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also known as MBOAT4, belongs to the membrane-bound O-acyltransferase 
(MBOAT) super-family of enzymes and was first identified in the mouse 
genome (Yang et al., 2008). The fatty acid transferred to ghrelin by GOAT is 
usually octanoic acid, however one study demonstrated the ability of GOAT 
to additionally utilise decanoic and tetradecanoic acids in their cell culture 
system (Gutierrez et al., 2008).
Human « Rat
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n-octanoyl group (C8:0)
Figure 1.6. Ghrelin is modified at serine 3 by addition of n-octanoic acid
This image shows the difference between human and rat ghrelin (Kojima and Kangawa, 
2005).
One study in GOAT knockout mice reported no change in food intake or body 
or fat mass (Zhao et al., 2010). However after severe calorie restriction in 
that study, the GOAT knockout mice were moribund after 1 week and the 
authors suggest that acyl ghrelin may play a vital role in maintaining glucose 
levels at a viable level via GH secretion, thus preventing death from 
hypoglycaemia (Zhao et al., 2010). This once again stimulated interest in 
exploring additional roles of ghrelin, after earlier conflicting observations from 
other knockout models. For example, ghrelin knockout mice have been 
reported to have the same food intake, body mass, blood chemistry and 
organ masses and pathology as wild-type littermates and responded in a
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similar way to a 24 hour fasting period (Sun et al., 2003), with another study 
reporting that ghrelin knockouts additionally did not have an altered gastric 
emptying rate (De Smet et al., 2006). Additional work by Sun et al. using a 
GHSR knockout model reported similar findings in that there was no 
difference in either food intake or body composition of these mice and that 
serum ghrelin levels increased after fasting, although an injection of ghrelin 
failed to increase food intake in the knockouts as it did in the wild-type mice 
(Sun et al., 2004). These authors suggested that their findings indicated 
alternative pathways through which growth and body composition can be 
mediated in the absence of GHSR. Alternative pathways adopted during 
development to compensate for the lack of the only peripherally derived 
orexigenic hormone seem plausible as a safeguard to the system, which, if 
such pathways exist, demonstrates the essential requirement of this part of 
the appetite regulatory system.
1.6.1.2. Actions of ghrelin in the hypothalamus 
The exact mechanisms by which ghrelin acts within the hypothalamus are not 
completely established, but Figure 1.7 portrays a currently accepted likely 
model. In the regulation of feeding, ghrelin stimulates the orexigenic 
NPY/AgRP/GABA neurons in the ARC of the hypothalamus, stimulating 
NPY/AgRP/GABA peptide release from their nerve terminals in the PVN 
(reviewed by Briggs and Andrews, 2011). GABA release from the same ARC 
neurons inhibits the POMC/CART production of the anorectic peptide a-MSH 
and therefore decreases the anorexigenic tone within the hypothalamus
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GABAR
GHSR
GABAR
(Briggs and Andrews, 2011). It is the combined actions of a stimulation of 
NPY/AgRP/GABA and an inhibition of POMC/CART that increases appetite.
GHSR
Ghrelin signals 
to increase food 
intake
Circulating ghrelin activates 
NPY/AgRP/GABA and PVN neurons
Figure 1.7. Simplified model for ghrelin action in the hypothalamus, resulting in an 
increase in appetite
(3V, third ventricle; ARC, arcuate nucleus; PVN, paraventricular nucleus; POMC/CART, pro­
opiomelanocortin (purple)/cocaine and amphetamine regulated transcript; NPY/AgRP/GABA, 
neuropeptide-Y (blue)/agouti-related protein (red)/gamma-aminobutyric acid (purple); a- 
MSH, a-melanocyte stimulating hormone; GHSR, growth hormone secretagogue receptor; 
INSR, insulin receptor; ObR, leptin receptor; MC4R, melanocortin 4 receptor; GABAR, 
gamma-aminobutyric receptor; YRs, Y receptors). (Modified from Briggs and Andrews,
2011 ).
1.6.2. Peptide-YY (PYY)
PYY is an anorexigenic gut peptide secreted postprandially as a satiety 
hormone and is released in a biphasic manner, with levels increasing before 
L-cells are in physical contact with nutrients in the gut lumen and a larger 
sustained peak when nutrients reach the distal small intestine (reviewed by
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De Silva and Bloom, 2012). PYY plasma levels increase in proportion to meal 
size from approximately 15 minutes after meal initiation, with levels remaining 
increased for up to 5 hours compared to baseline levels after a large evening 
meal in humans (Adrian etal., 1985). Studies using PYY knockout mice have 
since confirmed PYY's role as a satiety regulating peptide, with knockouts 
being both hyperphagic and obese, a phenotype which was reversed with 
intraperitoneal PYY injections (Batterham et al., 2006). PYY has also been 
demonstrated to have an inhibitory effect on gut motility, delaying gastric 
emptying, inhibiting gastric acid secretion and mediating an ‘ileal-brake 
mechanism’, which occurs due to the presence of fat in the lumen of the 
ileum and inhibits motility in the upper Gl tract (reviewed by Ueno et al., 
2008). See Table 1.4 for additional examples of the physiological actions of 
PYY.
Table 1.4. Some of the additional effects of PYY in mammals
(Modified from Ballantyne, 2006).
Target Effect of PYY
Gastric acid
Intestinal secretions 4
Overall gastric motility 4
Insulin 4
Blood pressure t
Vasoconstriction
Glomerular filtration rate
Nf
Postprandial natriuresis A
In addition to its established role in satiety signalling, reduced levels of PYY 
have been suggested to facilitate pubertal maturation in humans, with PYY 
levels being at their lowest levels in both sexes at the middle stages of 
puberty when GH levels are maximal (Lloyd et al., 2010).
1.6.2.1. The PYY peptide
The 36-amino acid PYY peptide was first isolated from the mucosa of porcine 
small intestine, and was so named due to the tyrosine (Y) residues at its C 
and N terminals (Tatemoto and Mutt, 1980). PYY is secreted from L-cells 
located predominantly in the colon and rectum and is a member of the 
pancreatic polypeptide family, which also includes the peptides NPY and 
pancreatic polypeptide (PP) (reviewed by Batterham and Bloom, 2003). 
PYYi_36 is the full length peptide, which is cleaved by dipeptidyl peptidase IV 
(DPP IV) in the circulation to form PYY3.36, which is known as the ‘active’ 
form (Batterham and Bloom, 2003); both forms are found in gut tissue 
(Eberlein etal., 1989) and in the circulation (Grandt etal., 1994). PYYi.36acts 
as an agonist for all five mammalian Y receptors discovered to date with 
different affinities, while PYY3.36 preferentially binds to Y2 and has also been 
shown to bind Y5, although to a lesser extent (reviewed by Blomqvist and 
Herzog, 1997). A study using a Y2 receptor knockout mouse model 
demonstrated the importance of this receptor, with an intraperitoneal injection 
of PYY3 -36 having no effect on inhibiting food intake, as it did dose- 
dependently in wild-type mice (Batterham et al., 2002).
Some studies have reported that when delivered directly to the brain, PYY 
can have an orexigenic effect (Hagan and Moss, 1995, Morley et al., 1985). 
One study reported that intracerebroventricular infusion of PYY increased 
food and water intake by significantly more than the potent orexigenic 
hormone NPY, with which PYY shares hypothalamic receptors (Hagan and 
Moss, 1995). A review article documenting the differences between PYYi_36
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and PYY3-36 suggested that PYY1-36 may act through the Y1 receptor to elicit 
such an effect, which is not seen with peripheral infusion due to PYY1-36 
breakdown into PYY3-36 in the circulation (Ballantyne, 2006). It remains 
unclear whether PYY may have additional roles in supporting appetite 
stimulation and whether the above studies are representative of what may 
occur with endogenous PYYi .36 in the peripheral circulation.
16.2.2. Actions of PYY in the hypothalamus
PYY is released postprandially from the Gl tract and activates Y receptors on 
the NPY/AgRP/GABA neurons in the ARC of the hypothalamus. Our 
knowledge is far from complete on the exact mechanisms by which PYY 
reduces appetite and the following is provided as an overview (Figure 1.8).
PYY3-36 induces satiety by binding to hypothalamic Y2 receptors on NPY 
neurons within the ARC, initiating a number of processes. Firstly, PYY3.36 
bound to Y2 receptors blocks the binding of its orexigenic family member 
NPY, which binds to the same receptor (Blomqvist and Herzog, 1997). 
Secondly, it has been reported that PYY3.36 reduces GABA release from the 
orexigenic NPY/AgRP/GABA neurons in the ARC, which was thought to 
disinhibit the anorexigenic POMC/CART neurons, a hypothesis that was 
supported by a non-significant increase in POMC mRNA after ARC injection 
of PYY3-36 (Batterham et al., 2002). An increase in POMC activity, in turn, 
increased the levels of a-MSH, further increasing the anorexigenic tone 
within the ARC (Batterham etal., 2002).
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PYY signals to 
decrease food 
intake
MC4R
GABAR
GHSR
GABAR
Circulating PYY blocks NPY/AgRP/GABA neurons from 
NPY activation and disinhibits POMC/CART neurons
Figure 1.8. Simplified model for PYY action in the hypothalamus, resulting in a 
reduction of appetite
(3V, third ventricle; ARC, arcuate nucleus; PVN, paraventricular nucleus; POMC/CART, pro­
opiomelanocortin (purple)/cocaine and amphetamine regulated transcript; NPY/AgRP/GABA, 
neuropeptide-Y (blue)/agouti-related protein (red)/gamma-aminobutyric acid (purple); a- 
MSH, a-melanocyte stimulating hormone; GHSR, growth hormone secretagogue receptor; 
INSR, insulin receptor; ObR, leptin receptor; MC4R, melanocortin 4 receptor; GABAR, 
gamma-aminobutyric receptor; YRs, Y receptors). (Modified from Briggs and Andrews,
2011).
1.6.3. Glucagon-like peptide-1 (GLP-1)
GLP-1 is an incretin hormone involved in glycaemic control (Edwards et al., 
1999) with an important role in the enhancement of pancreatic (3-cell insulin 
secretion in response to an increase in circulating glucose (Schmidt et al., 
1985). In the gut, the vast majority of L-cells co-secrete GLP-1 and PYY, with 
one recent study reporting no detectable human L-cells in culture positive for
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only one of these peptides (Habib et al., 2013). Like PYY, GLP-1 is also 
released postprandially in a biphasic manner as a satiety signal in proportion 
to meal size (De Silva and Bloom, 2012). It is well established that 
intravenous infusion of GLP-17-36 reduces energy intake in humans in a dose- 
dependent manner, likely partly due to a reduction in gastric emptying rate 
(Delgado-Aros et al., 2002, Verdich et al., 2001). In response to a meal, 
plasma GLP-17.36 levels are elevated 15 minutes from the start of food 
consumption and GLP-17.36 infusion does not affect food palatability, 
indicating that GLP-17.36 causes a true reduction in appetite (Flint et al., 
1998) rather than causing food aversion. Additional actions of GLP-1 are 
listed below (Table 1.5). Some studies have implicated a role for GLP-1 in 
cardiovascular health, with protective effects and increased myocardial 
performance after myocardial infarction in both rodent and human studies 
(reviewed by Holst, 2007).
Table 1.5. Some of the additional effects of GLP-1 in mammals
(Modified from Ng and Wilding, 2014).
Target Effect of GLP-1
Gastric acid
Intestinal secretions 1
Overall gastric motility 1
Insulin t
Blood glucose 1
Blood pressure t
Heart rate t
Vasodilatation T
Postprandial natriuresis t
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1.6.3.1. The GLP-1 peptide
GLP-1 is derived from the 160-amino acid proglucagon in the gut alongside 
GLP-2, glicentin and OXM (reviewed by Holst, 2007). In the pancreas, 
proglucagon is cleaved into glucagon, amongst other fragments (Holst, 
2007). In gut tissue, GLP-1 is found predominantly in the intact and 
‘biologically active’ form (GLP-17.36) (Hansen et a/., 1999). In the circulation, 
GLP-17.36 has a very short half-life of approximately 2  minutes due to rapid 
degradation by DPP IV, resulting predominantly in the ‘biologically inactive’ 
GLP-1 g-36 form (Kieffer et al., 1995, Mentlein et al., 1993). It is estimated that 
only approximately 1 0  to 15% of intact GLP-17.36 secreted by the gut reaches 
the systemic circulation after degradation in both the gut and liver (Holst and 
Deacon, 2005). This is partly due to the presence of DPP IV in the brush 
border and capillary endothelium of the gut (Hansen eta!., 1999).
GLP-1 acts through the GLP-1 receptor (GLP-1 R), which has been found in 
multiple locations including the heart, pancreatic islets, stomach parietal cells 
and in the hypothalamus (Holst, 2007, Schmidtler et al., 1994, Shughrue et 
al., 1996). Exending.39 is a well defined specific antagonist for GLP-1 R and 
studies utilising these properties have confirmed GLP-Ts role as an 
anorexigenic gut hormone. The Bloom group have demonstrated a significant 
increase in both food intake and body mass after daily intracerebroventricular 
injection of exending.39 in schedule-fed male rats, whereas rats injected with 
GLP-17-36 had significantly reduced food intake and body mass compared to 
saline-treated controls (Meeran et al., 1999). GLP-1 R knockout mice have 
not been shown to have altered appetite or body mass, however they do not
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show inhibition of food intake after intracerebroventricular injection of GLP-1, 
which the wild-type mice did (Scrocchi et al., 1996). It remains to be 
established whether GLP-1 could be acting through another receptor and/or 
pathway that is yet to be identified or whether GLP-1’s anorexigenic effects, 
in terms of the whole appetite regulatory system, are dispensable.
1.6.3.2. Proposed actions o f GLP-1 in the regulation of food intake 
In contrast to ghrelin and PYY, the central mechanisms by which GLP-1 
exerts its inhibitory effects on appetite remain largely uncharacterised. GLP-1 
receptors have been located in multiple regions of the rat hypothalamus 
(Shughrue et al., 1996) but it seems to be unlikely that intact GLP-17.36 
secreted by the gut reaches these receptors due to its rapid degradation by 
DPP IV (section 1.6.3.1). Further work needs to be done to fully elucidate the 
mechanisms by which GLP-1 induces satiety. A better understanding of GLP- 
1 action may be gained from studying its effects alongside other gut 
hormones, for example PYY, with which it is co-secreted from gut L-cells.
1.6.4. Interactions between ghrelin, peptide YY (PYY) and 
glucagon-like peptide-1 (GLP-1) in appetite regulation
The possible interactions between orexigenic and anorexigenic hormones in 
the regulation of appetite have been studied far less than the peptides have 
been individually. Intravenous co-infusion of ghrelin with either PYY3.36 or 
with GLP-1 in male rats has demonstrated ghrelin’s ability to increase both 
food intake and the rate of gastric emptying compared to rats that received 
PYY3.36 or GLP-1 only, suggesting that ghrelin can attenuate the effects of
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PYY and GLP-1 (Chelikani et al., 2006). Another study in male rats reported 
that GLP-1 7-36 significantly attenuated the increased food intake caused by 
ghrelin, upon intracerebroventricular injection of these peptides 
(Schusdziarra et al., 2008). In support of the inhibitory role of GLP-1 on 
ghrelin levels was the finding that GLP-17.36 significantly reduced the 
secretion of pre-stimulated ghrelin in isolated male rat stomach (Lippi et al., 
2004). One study looked at the combined effects of PYY3-36 and GLP-17-36 in 
both rodents and humans. In male lean, obese (ob/ob) and diabetic (db/db) 
mice and in male rats, intraperitoneal co-injection of PYY and GLP-1 
significantly enhanced feeding inhibition compared to saline control or 
separate injection of the peptides, although the effects were not as long 
lasting in the ob/ob and db/db mice (Neary et al., 2005). These results were 
replicated in the human part of the study, with 4 men and 6  women studied. 
Co-infusion of PYY and GLP-1 reduced energy intake at a buffet meal by 
27%, compared to 15% with PYY only infusion and no effect was seen with 
GLP-1 only infusion (Neary et al., 2005). The findings of that study suggest 
that co-secreted PYY and GLP-1 may act together to reduce food intake to a 
homeostatically appropriate level.
Infusion of GLP-17-36 significantly reduced postprandial plasma total ghrelin 
levels in human males 150 to 360 minutes after a meal compared to when 
participants had received the saline control infusion (Hagemann et al., 2007). 
These authors also measured plasma insulin, with which ghrelin had an 
inverse relationship (Hagemann et al., 2007). They suggested that ghrelin
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levels may have been altered by GLP-1 indirectly, with GLP-1 affecting 
insulin levels, which in turn may have affected ghrelin levels.
Ghrelin is known to increase gastric acid secretion in rats in a dose- 
dependent manner (Masuda et al., 2000); it is likely that ghrelin also 
regulates gastric acid secretion in humans. One study has shown that 
intravenous infusion of PYY or GLP-17.36 reduces gastric acid secretion 
significantly, by 68% and 67% respectively in men and women (Wettergren et 
al., 1994), which suggests that ghrelin, PYY and GLP-1 may all interact to 
regulate gastric acid secretion.
In human males, intravenous infusion of GLP-1 was not found to reduce 
plasma total ghrelin levels compared to controls, however after 120 minutes 
of GLP-1 infusion, plasma total PYY levels were significantly decreased. 
Furthermore, the increase in plasma PYY caused by CCK infusion was 
attenuated by CCK-GLP-1 co-infusion (Brennan et al., 2007). It seems 
unlikely that GLP-1 would have an inhibitory effect on PYY due to their 
similar postprandial release and effects. One explanation for the finding of 
Brennan et al. (2007) could be that GLP-1 infusion inhibited endogenous and 
exogenous CCK, thus attenuating the PYY increase caused by CCK. This 
explanation could be supported by the fact that GLP-1 infusion alone only 
caused a significant reduction in plasma PYY 120 minutes into the infusion.
In conclusion, evidence exists for the direct and indirect interactions of 
ghrelin, PYY and GLP-1 in the regulation of food intake, however more work
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is needed to clarify the precise mechanisms by which this occurs. Moreover, 
more studies need to include females to further elucidate appetite regulation 
by gut hormones when changes in food intake are known to occur during the 
reproductive cycle, pregnancy and lactation. Many developed treatments to 
control appetite and reduce food intake and body mass would be aimed at 
and used by females of reproductive age, with potential unintended effects 
on fertility and offspring development, yet only males are used in the majority 
of such studies. Specific examples of studies that have established 
differences in appetite hormones during the oestrous cycle (Chapter 3), 
pregnancy (Chapter 4) and lactation (Chapter 5) will be described in the 
introductions to the relevant chapters.
1.7. The female rodent reproductive cycle
The rodent reproductive cycle, the oestrous cycle, comprises the stages of 
proestrus, oestrus, metestrus and diestrus and is typically a 4 day cycle 
(Figure 1.9), although an extra day spent in diestrus is common (Adler and 
Feder, 1981). Rodents are nocturnally active mammals that eat the majority 
of their food during the dark phase and Figure 1.9 illustrates the relationship 
of the light/dark cycle to the oestrous cycle. An undisturbed lighting schedule 
is vital to preserve a normal cycling pattern in rodents, so it is important to 
minimise any light that may enter the room during the active (dark) period if 
attempting to monitor the cycle or to successfully mate the rodents (Goldman 
et al., 2007).
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Figure 1.9. Representation of a standard 4 day rodent oestrous cycle
Demonstrating the hormonal events that occur during the light and dark phases (white and 
shaded blocks along the X axis) leading up to ovulation at oestrus. (Modified from Goldman
et al., 2007).
Leading up to ovulation, metestrus and diestrus are the luteal phase of the 
cycle governed by luteinising hormone (LH) which, alongside oestrogens, 
stimulates ovulation and prepares the uterus for implantation, with follicle- 
stimulating hormone (FSH) acting on the ovaries to secrete oestrogens. 
During diestrus, ovarian secretion of oestradiol increases and then peaks 
during proestrus, which stimulates the hypothalamic release of gonadotropin 
releasing hormone (GnRH). In turn, GnRH stimulates the pituitary gland to 
secrete LH and bring about ovulation, together with an increase in circulating 
progesterone 10 to 12 hours later. The stage of oestrus can vary in length 
from 12 to 20 hours, depending on whether mating occurs. Ovulation will 
typically occur just after the onset of the dark period (Becker et al., 2005). 
Dams can commonly spend a second day in the stage of diestrus, where this
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stage is prolonged for approximately 30 hours before ovulation begins, which 
extends the cycle to 5 days in duration (Adler and Feder, 1981).
The most accurate method by which cycle stage can be determined is to 
quantify plasma or serum hormones (Becker et al., 2005), however many 
researchers make use of less invasive, costly and time consuming methods. 
Vaginal cytology (methodology described in section 2.2) is the gold standard 
for staging the oestrous cycle, although there are other indicators of cycle 
stage that can be used to augment this technique, such as the oestrus 
dance. Despite its name, behavioural oestrus typically begins during 
cytologically identified proestrus, between 6 and 12 hours before ovulation 
(Adler and Feder, 1981). Lordosis behaviour (ear-wiggling, hopping, darting, 
freezing) can even be assessed without a male rat being present, by 
stimulation of the flanks of the rat (Adler and Feder, 1981). A further, but 
terminal, method of proestrus confirmation (Adler and Feder, 1981) is the 
analysis of uterine wet mass, which is heaviest during proestrus between 12 
and 16 hours prior to ovulation.
1.7.1. Oestrogens and appetite
In addition to known effects on appetite, it is well established that sex steroid 
hormones, particularly oestrogens, play a role in sustaining GH secretion 
(reviewed by Ho et al., 1996). This is partly what fuelled the interest in 
investigating appetite hormones, such as ghrelin, in relation to ovarian 
hormones. Research linking food intake and reproductive cycle stage has 
been published on rodents, pigs, goats, sheep, primates and humans
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(reviewed by Dye and Blundell, 1997). A link has now been established 
between oestrogens and food intake, and many species including rats, mice 
and humans have reduced food intake leading up to ovulation due to the 
latent effects of an earlier ovarian peak in oestradiol secretion (reviewed by 
Asarian and Geary, 2006). Putting this into context, in rodents, food intake is 
reduced during oestrus due to high levels of oestradiol at proestrus. One 
study has additionally established that rats show increased locomotor activity 
during oestrus, but that this did not contribute to the decrease in food intake 
in that study (Eckel et al., 2000). These authors suggested that there are 
distinct independent mechanisms by which food intake is reduced at oestrus.
1.7.2. Ghrelin and the reproductive cycle
Many studies (reviewed by Butera, 2010) have examined the effects of 
oestradiol on ghrelin’s orexigenic properties by artificial manipulation of these 
hormones, with a main focus on the effects on food intake. One of the earlier 
studies in this area reported that ghrelin cell density in the stomach and 
ghrelin levels in plasma rapidly increased soon after ovariectomy (OVX) in 
rats, and that these effects were reversed by oestradiol treatment (Matsubara 
et al., 2004). This finding suggests that the well established body mass gain 
after OVX/menopause may be due to decreased restraint of ghrelin by a lack 
of oestrogen, resulting in increased hunger signalling. The study by 
Matsubara et al. (2004) also established that oestrogen receptor-a (ERa) is 
present in the nuclei of ghrelin-immunoreactive ECs, which they suggested 
was evidence for a direct relationship between oestrogen and ghrelin in the 
stomach. These authors also suggest that the existence of ERa in the
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stomach could further implicate differential ghrelin expression and release by 
the stomach in relation to the cyclical changes in oestrogen. One other key 
study in this area is from the Geary group, which established that 
intraperitoneal injection of ghrelin significantly increased appetite in males 
and OVX females, but had no significant effect in normally cycling (combined 
stages) females, and that changes in appetite were attenuated by oestrogen 
treatment, suggesting attenuation by oestrogen levels (Clegg et al., 2007). 
When cycle stage was taken into account, there was a significant increase in 
food intake caused by ghrelin only during metestrus and diestrus, when 
endogenous oestrogen levels are lowest (Clegg e ta i , 2007).
There are fewer human studies that have measured ghrelin levels throughout 
the course of a menstrual cycle available for comparison. One group has 
reported that there was no difference in serum total ghrelin concentrations 
between the early follicular (approximately proestrus in rats), late follicular 
(approximately oestrus) and mid-luteal (approximately early diestrus) phases 
of the menstrual cycle in regularly cycling women and that injection of total 
ghrelin did not alter serum concentrations of oestradiol (Messini et al., 2009). 
Observation across a whole menstrual cycle in one study reported no 
significant difference in either acyl ghrelin, desacyl ghrelin or the ratio 
between the two forms through the cycle (Dafopoulos et al., 2009). A later 
study by this group found that plasma acyl ghrelin was not changed by acute 
treatment of oestradiol in normally cycling women in the follicular phase 
(cycle days 3 to 9), post-menopausal women or women following OVX 
(Dafopoulos et al., 2010). However, peri-menopausal women have been
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found to have higher serum acyl ghrelin concentrations than in pre- and post­
menopausal women (Sowers et al., 2008). Moreover, continued combined 
hormone replacement therapy (HRT; oestrogen plus progesterone) reduced 
circulating total ghrelin compared to women who only briefly underwent HRT 
(Soni etal., 2011). These latter two studies do suggest a link between ghrelin 
levels and the hormones involved in the menstrual cycle, but due to 
conflicting evidence from human studies as described above, more in-depth 
study would be required to further our understanding of ghrelin’s possible role 
in the reproductive cycle in women.
1.7.3. PYY and the reproductive cycle
Until now, there has been no study to investigate the potential changes in 
endogenous PYY levels during a natural and complete reproductive cycle, 
however one study has investigated the effect of PYY3.36 treatment on food 
intake in OVX non-human primates treated with reproductive hormones. This 
study reported that intracerebroventricular injection of PYY3.36 significantly 
reduced food intake in weeks 1 and 2 of oestradiol only treatment, but only 
reduced food intake in week 1, not week 2, of oestradiol plus progesterone 
treatment (Papadimitriou etal., 2007). Indeed, a study in OVX rats implicated 
a role for the Y2 receptor in reproduction, with a 3 day treatment of oestradiol 
increasing Y2 binding, and oestradiol plus progesterone treatment on day 4 
reducing Y2 binding in some hypothalamic regions (Parker et al., 1996). 
Taken together, these two studies provide evidence that high levels of 
oestradiol could support a PYY-induced reduction in appetite.
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1.7.4. GLP-1 and the reproductive cycle
Limited work has looked at the possible relationships between GLP-1 levels 
and the reproductive cycle. One study (Brennan et al., 2009) has compared 
the follicular and luteal phases of the menstrual cycle of women and reported 
that fasted baseline levels of GLP-1 were not significantly different but that 
during the follicular phase, both gastric emptying rate and energy intake at a 
buffet meal were significantly reduced. However, when the participants of 
that study were given a glucose load, GLP-1 levels were significantly reduced 
during the follicular phase when compared to the luteal phase, which may 
suggest a difference in GLP-1 regulation between the two phases of the 
cycle.
Despite limited available data, it seems entirely plausible that ovarian 
hormones affect appetite by interaction with gut appetite hormones. 
Accordingly, females and information about their reproductive cycle stage 
should also be used in studies exploring the hormonal regulation of appetite 
in order for results to be representative of the population. Further work needs 
to establish the effects of the reproductive cycle on levels of ghrelin, PYY and 
GLP-1 in order to elucidate the potential role of these gut hormones in 
appetite modulation during these events.
1.8. Pregnancy and lactation
Pregnancy and lactation are times of maternal adaptation in order to support 
foetal and postnatal development. It is well known that hyperphagia occurs 
during these periods in order to meet the additional energy demands required
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by the growing offspring, but females can often gain surplus body mass due 
to over-consumption (reviewed by Ladyman et al., 2010). Obesity can lead to 
the development of hypertension and insulin resistance, which can both also 
occur during pregnancy, meaning that a pre-existing condition can be 
compounded and cause multiple maternal health complications. A study 
which highlights the multiple complications that can occur due to maternal 
obesity through a high fat diet (HFD) in pregnant non-human primates 
reported a stillbirth rate of 35% compared to 6% in those fed a control diet 
(Frias et al., 2011). This study found a reduction in uterine and placental 
volume blood flow, with increased placental infarction sites, which are all 
likely to increase the risk of stillbirth. Furthermore, the females that 
developed insulin resistance during pregnancy were found to be more at risk 
of complications in their study.
1.8.1. Maternal diet: effects on offspring health
Many studies have explored the role of maternal diet on offspring metabolic 
programming and adult health, with focus often on either dietary deficit or 
excess. The Barker hypothesis, which is also referred to as the ‘thrifty 
phenotype’ hypothesis, outlines how maternal under-nutrition during 
pregnancy can lead to poor foetal and childhood growth, with a predisposition 
to the development of metabolic disorders in adult life (reviewed by Hales 
and Barker, 2001). It is well established that offspring of under-nourished 
mothers have impaired insulin secretion, which is suggested to occur 
because the offspring are developmental^ and/or epigenetically programmed 
to a postnatal environment similar to that in utero (i.e. nutritional deficit).
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Exposure to a more than adequate diet in adulthood can then increase the 
incidence of type 2 diabetes and obesity in these offspring (Hales and 
Barker, 2001) as nutrients are ‘unexpectedly’ available in excess. So far, less 
work has been done to investigate epigenetic modifications to offspring when 
mothers are over-nourished during pregnancy. It is thought that an increase 
in circulating glucose and lipid in overweight and obese mothers can lead to 
foetal epigenetic modifications to genes involved in lipid metabolism, and 
many others, increasing the risk of insulin resistance and obesity in childhood 
and later life (reviewed by Heerwagen et al., 2010). Below in this brief review, 
focus will be placed on some of the effects of a maternal HFD during 
pregnancy and lactation, or offspring over-nutrition, on offspring health due to 
its relevance to the growing incidence of obesity.
An observation that hypertension is more likely to occur in offspring of HFD 
fed mothers has led to examination of the effects on vascular tissue. 
Impaired femoral artery endothelium-dependent relaxation and abnormal 
fatty acid composition of the aorta has been described in adult (160 days old) 
female offspring of rat dams that were fed a HFD during pregnancy and the 
lactation period, which the authors suggest could increase the risk for the 
development of hypertension and atherosclerosis (Ghosh et al., 2001). 
Another study of adult (180 days old) male and female offspring of rat dams 
fed a HFD found that feeding the offspring a HFD after weaning prevented 
the changes they reported in vascular endothelial function in the offspring fed 
a control diet from weaning (Khan et al., 2004). These authors suggested 
that their findings could demonstrate foetal adaptations to a maternal HFD,
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with preparation for receiving the same nutrition during postnatal life, similar 
to the ‘thrifty phenotype’ hypothesis as described previously. However, 
hypertension was still evident in the female offspring, suggesting only a 
partial adaptation to the foetal environment (Khan etal., 2004).
A maternal HFD has also been found to affect the liver of offspring. One 
study in mice reported that from one week after weaning onwards, male 
offspring of dams fed a HFD throughout pregnancy and lactation had 
significantly increased levels of liver triglycerides and increased hepatic liver 
droplet size (Ashino et al., 2012). Examination of the same male offspring at 
28 and 82 days of age found that they had significantly increased fat mass 
compared to the control offspring, despite no difference in food intake 
between the groups (Ashino et al., 2012). A study in rats examined the 
generational effects of a maternal HFD on male offspring, with grandparent 
dams fed either a control or a HFD throughout pregnancy and lactation and 
offspring parents fed a control diet throughout. Male offspring exposed to a 
HFD through their grandmothers were found to have larger hepatic lipid 
droplets, combined with a reduction in their liver expression of genes 
encoding antioxidant defence proteins and an increased level of several 
cellular senescence markers in the liver when compared to the controls 
(Zhang et al., 2011). These two studies demonstrate that a HFD can affect 
hepatic health in male offspring in both mice and rats, which could lead to 
increased incidence of non-alcoholic fatty liver disease in adulthood.
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It has also been found that a low level of maternal ghrelin concentration in 
mice appeared to have an adverse effect on the uterine programming of their 
female offspring and caused subnormal fertility rates through reduced 
implantation, despite normal ovarian function and embryo production (Martin 
et al., 2011). These authors suggested that their findings could have serious 
implications for the fertility of women born to obese mothers who would have 
had blunted ghrelin levels due to their obesity.
Using a model of pup over-nutrition by decreasing litter size in rodents, 
without changing maternal diet, studies have determined that offspring body 
mass and adiposity are increased in comparison to control/standard litter 
sizes (Balonan and Sheng, 2000, Faust et al., 1980, Fiorotto et al., 1991, 
Plagemann et al., 1999, Plagemann et al., 1992, Schmidt et al., 2001, 
Widdowson and McCance, 1963). These studies will be described in more 
detail in the introduction to Chapter 7.
The findings of the above studies, and many others not cited here, clearly 
demonstrate that diet-induced obesity during pregnancy and lactation 
increases the likelihood of a number of clinical complications during these 
times for both the mothers and their offspring. There is not space to fully 
describe the mechanisms of foetal programming here, but evidence is 
growing that epigenetic changes are important. Such changes are beyond 
the scope of this thesis and are not discussed further here (see reviews by 
Hales and Barker, 2001, Heerwagen et al., 2010). Possible effects of
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maternal diet on the EC populations and regulation of appetite by gut 
hormones has not yet been investigated.
1.8.2. Maternal health in the later postpartum period
A long-term study of women, with an average follow-up period of 8.5 years, 
reported that the mean gain in body mass 6 months postpartum was 1.7 kg 
and increased to 6.3 kg at the long-term follow-up appointment (Rooney and 
Schauberger, 2002). These authors also described that women who were 
able to return to their pre-pregnancy body mass by 6 months postpartum 
were lighter than women who had retained their ‘pregnancy weight’ in the 
long term. Furthermore, it was reported that breastfeeding provided no short­
term body mass reduction, but at the long-term follow-up appointment, 
women who breastfed for a minimum period of 3 months gained significantly 
less body mass than women who breastfed for a shorter length of time 
(Rooney and Schauberger, 2002). An earlier study found that Caucasian 
women who gained below the recommended body mass during pregnancy 
retained as much of their pregnancy body mass as those who gained the 
recommended amount, however this was race-dependant (Keppel and Taffel, 
1993). These findings demonstrate the possibility that some part of the 
maternal adaptation to facilitate pregnancy and lactation may result in long­
term maternal changes, but information to explain this phenomenon is 
limited. More work needs to be done to establish whether physical maternal 
adaptations to pregnancy and lactation, such as increased gut size (Burdett 
and Reek, 1979, Campbell and Fell, 1964, Crean and Rumsey, 1971, Cripps 
and Williams, 1975, Datta et al., 1995, Taylor et al., 2009) persist
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postpartum. It would also be of interest to determine whether these maternal 
changes could potentially contribute to retention of increased body mass 
after the lactation period has ended. Studies on maternal gut adaptations to 
pregnancy and lactation in rats will be described in Chapters 4, 5 and 6.
1.8.3. Hormonal control of appetite in pregnancy and 
lactation
Hyperphagia during pregnancy and lactation in humans and other mammals 
occurs to support these metabolically demanding states (reviewed by 
Ladyman et al., 2010) and the role of leptin in supporting hyperphagia has 
been well established.
Leptin is an anorexigenic hormone released by adipose tissue; circulating 
leptin concentrations are proportionate to the total adipose tissue mass 
(reviewed by Friedman, 2011, Ladyman et al., 2010). Leptin levels rise 
throughout pregnancy as the female accumulates adipose reserves, as they 
would in an obese state. However, adipose deposition is beneficial during 
pregnancy to build lipid reserves which are then utilised during lactation. 
Developing a resistance to leptin supports hyperphagia and allows further 
adipose accumulation. Leptin resistance has been widely documented as an 
adaptation to support pregnancy (reviewed by Friedman, 2011, Ladyman et 
al., 2010) and is established to begin during mid-gestation. Leptin resistance 
during pregnancy has been shown to occur by multiple mechanisms in the 
pregnant rat. Of primary importance to leptin resistance is the failure of the
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NPY/AgRP/GABA and POMC/CART neurons in the ARC to respond in the 
usual way to increases in leptin levels (reviewed by Ladyman et al., 2010).
A study using the leptin-deficient ob/ob mouse model treated pregnant mice 
with leptin until withdrawal of treatment at various stages of gestation and 
found no difference in the outcome of the pregnancy (in terms of litter size 
and pup mass and appearance), concluding that the main role of leptin 
resistance in pregnancy is to increase maternal food intake (Mounzih et al., 
1998). Intracerebroventricular administration of leptin had been shown to 
decrease both food intake and body mass in nulliparous rats, but had no 
effect in rats at days 13 and 18 of pregnancy (Trujillo et al., 2011), 
demonstrating a central leptin resistance at those stages of pregnancy. That 
study also documented that leptin resistance in day 13 and 18 pregnant rats 
resulted from a reduction in the levels of leptin crossing the blood-brain 
barrier combined with alterations to the normal hypothalamic cascade 
mechanisms (Trujillo et al., 2011), a finding consistent with others (Ladyman 
et al., 2009).
A reduction in leptin transport across the blood-brain barrier in late pregnancy 
has been described in rats, caused by high prolactin levels (ready to 
stimulate lactation) (Trujillo et al., 2011). That study also reported that 
hypothalamic mRNA for NPY and AgRP increased in relation to the 
development of pregnancy-associated hyperleptinaemia and POMC mRNA 
decreased. However, Ladyman et al. (2009) found no difference in NPY,
45
AgRP or POMC mRNA in response to hyperleptinaemia during pregnancy in 
the same breed of rat.
High leptin levels at time of parturition (Figure 1.10) are also suggested to 
increase maternal investment in the pregnancy by reduced infanticide in 
Siberian hamsters (French et al., 2009). These authors suggest that 
increased leptin acts to signal to the dams that there are adequate energy 
reserves to invest in feeding their offspring.
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Figure 1.10. A schematic depicting the hormones that support pregnancy alongside 
energy balance and food intake in rodents
(E2, oestradiol; P4, progesterone; PRL, prolactin; PL, placental lactogen). (Modified from 
Augustine et al., 2008).
The hyperphagia of lactation is likely to be facilitated by a rapid reduction in 
leptin levels (Figure 1.10). One study has demonstrated the ability of central
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and peripheral leptin administration to reduce appetite and body mass in 
lactating rats from day 8 postpartum (earliest point studied), showing that 
there is no lactation-associated leptin resistance as is present during 
pregnancy (Woodside et al., 2000). As leptin concentration is proportional to 
adiposity, mobilisation of adipose reserves during lactation is the likely cause 
of a reduction in leptin levels, and rats prevented from lactating had 
significantly higher plasma leptin and adiposity compared to control lactating 
dams (Woodside et al., 2000).
Leptin has also been studied with other appetite-regulatory hormones. In one 
study, leptin injection decreased plasma total ghrelin levels in male mice 
(Ueno et al., 2004) and another study reported that leptin-induced satiety in 
male rats was reversed by injection of total ghrelin (Shintani et al., 2001). 
These studies suggest another way in which leptin may be regulated during 
pregnancy and lactation in rodents. Some work has been done examining the 
gut hormones ghrelin, PYY and GLP-1 in relation to appetite modulation 
during pregnancy and lactation, but evidence for their involvement is still 
limited. Below is a summary of the main findings of others, with a more 
detailed review given in the introductions to Chapters 4 (pregnancy) and 5 
(lactation).
1.8.3.1. Ghrelin in pregnancy and lactation
The orexigenic properties of ghrelin have led to investigation of its possible 
role in the hyperphagia of pregnancy and lactation, although many findings 
have been contradictory. Two studies that have measured total ghrelin levels
47
in the stomach tissue of pregnant rats reported no significant differences 
between the stages of pregnancy studied (Shibata et al., 2004, Taylor et al., 
2009). Both of these studies also quantified plasma total ghrelin levels, 
however one study found a significant difference between days 10 and 15 of 
pregnancy (Shibata et al., 2004) and the other found no difference between 
these days and additional pregnancy time-points (Taylor et al., 2009). What 
these two studies do have in common is that they demonstrate that total 
ghrelin levels remained unsuppressed during pregnancy, demonstrating a 
dissociated relationship between ghrelin and leptin during a rat pregnancy. 
Taylor et al. (2009) went on to explore maternal total ghrelin levels at various 
lactation time-points and reported that both ghrelin and leptin levels appeared 
to normalise from the onset of weaning (Taylor et al., 2009). Neither the 
study by Taylor et al. nor Shibata et al. found a significant difference in total 
ghrelin levels at the lactation time-points studied.
Human studies are also often contradictory and difficult to compare due to 
different stages of pregnancy being studied. One study has reported no 
change to levels of fasted plasma acyl ghrelin in early pregnancy (Moshtaghi- 
Kashanian et al., 2011) and another documented a significant reduction in 
both fasted plasma total and acyl ghrelin during later pregnancy (Tham et al., 
2009). A further study compared women at each trimester of their pregnancy 
and reported no significant differences in acyl ghrelin levels (Valsamakis et 
al., 2010). In lactating women, one study found that acyl ghrelin levels were 
highest at the start of lactation, with a gradual drop in the levels as lactation 
progressed (llcol and Hizli, 2007).
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Another difficulty in the comparison of studies measuring ghrelin levels is the 
difference between which form of ghrelin is quantified, whether it is the total 
form or the acyl or desacyl portion. A study in rats found a non-significant 
trend for acyl ghrelin to decrease with pregnancy, however, there was a 
significant increase in desacyl ghrelin by day 19 of pregnancy (Nakahara et 
al., 2006), demonstrating that although total ghrelin concentrations may not 
be different in some studies, it is possible that the ratio of acyl and desacyl 
ghrelin may have been altered by the pregnant or lactating state.
1.8.3.2. PYY in pregnancy and lactation
Information regarding possible roles of PYY in the appetite changes 
occurring in pregnancy and lactation is still very limited. In rats, there is 
agreement that circulating levels of PYY increase throughout pregnancy 
(Taylor et al., 2009, Tovar et al., 2004) with a PYY peak reported at day 5 of 
lactation (Suzuki et al., 2014, Taylor et al., 2009). Why PYY levels increase 
during pregnancy and into early lactation remains to be established, as 
hyperphagia is evident from mid-pregnancy onwards in rats. As an 
endogenous satiety factor, it seems reasonable to anticipate that overall PYY 
levels would decrease in order to facilitate hyperphagia. Furthermore, high 
PYY levels have been reported in gut tissue (Taylor et al., 2009) and in the 
hypothalamus (Suzuki et al., 2014) at day 5 of lactation, suggesting a 
systemic increase in PYY during this time of negative energy balance. It is 
possible that there could be a level of maternal resistance to PYY during 
pregnancy, as previously described for leptin (section 1.8.3), or increased 
PYY could be due to the reported physical increase in the size of the gut
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(Taylor et al., 2009) but this remains to be established. Human studies have 
not reported a difference in circulating PYY levels during pregnancy (Larson- 
Meyer et al., 2010) and lactation (Valsamakis et al., 2010). What is apparent 
from these observations is the need for further study of PYY during 
pregnancy and lactation in order to elucidate its roles and establish what 
changes may be taking place at these times.
1.8.3.3. GLP-1 in pregnancy and lactation
Few studies have examined the levels of GLP-1 during pregnancy and 
lactation. The majority of studies involving GLP-1 are in relation to its role as 
an incretin. A level of insulin resistance is known to develop during 
pregnancy in both rats and women (Leturque et al., 1984, Vrachnis et al., 
2012), which is likely to affect GLP-1 levels. Future studies will need to 
address how the pregnant and lactating state may alter GLP-1 levels and 
how this may link with appetite regulation during these times.
1.9. Concluding statement
It is clear that there are complex changes occurring in appetite-regulating 
hormones throughout the reproductive cycle, pregnancy and lactation. The 
studies described above, and others, have provided answers to some 
questions, but more extensive characterisation of the changes that occur is 
still required. Further understanding of the underlying hormonal control 
regulating appetite at these times may lead to a greater comprehension of 
the underlying physiology of pregnancy and lactation, which may in turn
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uncover possible medical treatments to prevent some of the aforementioned 
complications associated with maternal over-eating in both mothers and their 
offspring.
1.10. Aims
The main aim of the work in this thesis was to start to address the sex bias 
that is evident in the existing literature on gut appetite hormones by exploring 
the roles that ghrelin, PYY and GLP-1 may have in appetite changes during 
the rodent oestrous cycle (Chapter 3), pregnancy (Chapter 4) and lactation 
(Chapter 5). The lactation period was further investigated by manipulation of 
postpartum litter size and its effects on both dams (Chapter 6) and their male 
and female offspring (Chapter 7). Specific aims included:
o To investigate and compare concentration changes of the gut appetite 
hormones ghrelin, PYY and GLP-1 in both fed and fasted plasma and 
(fasted) gut tissue concentrations during the reproductive cycle, 
pregnancy and lactation.
o To further elucidate reported changes in maternal gut size during 
pregnancy and lactation, with inclusion of lactation litter size 
manipulation to ascertain whether increased gut size may be related 
to maternal demand.
o To determine whether relationships exist between any changes in 
plasma or gut hormone concentrations and changes in gut size.
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o To explore whether male and female pups from different lactation litter 
sizes have different levels of ghrelin, PYY and GLP-1 in gut tissues 
and/or the peripheral circulation.
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CHAPTER 2: METHODS
2.1. Animals
This work was licensed under the Home Office Animals (Scientific 
Procedures) Act 1986 and had approval from The Open University Ethics 
Committee. Female Wistar rats were housed in groups of 4 and maintained 
under a 12 hour reverse light cycle (lights off between 11.00 and 23.00) in 
the Biomedical Research Unit (The Open University) with free access to 
standard diet and water. All procedures were carried out during the dark 
phase.
Female nulliparous Wistar rats (Harlan, UK) used in the work described in 
Chapter 3 (n=43) were housed in standard cages and given time to adjust to 
the reverse light cycle prior to the study. Rats were regularly handled prior to 
all studies to reduce stress during regular weighing, oestrous monitoring and 
when briefly separating dams from their newborn litters. All cages of 
reproductively cycling females were kept in the same Scantainer along with 1 
cage of male rats to keep females cycling normally.
2.1.1. Breeding
Rats used in the work described in research Chapters 4, 5, 6 and 7 were 
bred in-house from an additional group of animals (2 to 3 females per cage, 
n=14; n=3 males) purchased from Harlan (UK). To obtain initial litters from 
the colony, females were introduced to a male (1 to 2 females per male) in
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his home cage for a period of 5 days and litters (un-manipulated) were kept 
to maturity for future pregnancy and lactation time points. Original breeding 
females had 1 to 2 litters each before dissection.
2.1.2. Study design
Nulliparous females were culled at each stage of the oestrous cycle (Chapter 
3) to determine changes to gut appetite hormones during the oestrous cycle. 
The oestrus dance (section 2.2.1) was used for accurately time mating 
females for the pregnancy time points of days 4, 12 and 18 of pregnancy 
(Chapter 4), and for some lactation time points when appropriate females 
presented with the dance. Dams for the lactation time points of days 0, 5, 10 
and 25 of lactation (Chapter 5) had litters standardised to 8 ± 1 pups each by 
day 2 postpartum and pups remained with dams throughout the study. 
Additional groups of dams had their postpartum litter size manipulated to 
either 4 or 12 pups and were dissected at day 25 of lactation to investigate 
the effects of lactation litter size on both the dams (Chapter 6) and their male 
and female offspring (Chapter 7). Figure 2.1 illustrates where the pregnancy 
and lactation time points studied fall within the context of a typical 21 day rat 
pregnancy and 25 day lactation period. Sample groups were optimised based 
on the findings of Taylor et al. (2009).
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Figure 2.1. Timing of sample groups during a standard rat pregnancy and lactation 
period after mating at proestrus
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2.2. Oestrous monitoring
The gold standard of cycle stage determination in rodents is vaginal cytology, 
with preference towards vaginal lavage rather than a cotton swab due to 
collection of an increased number of cells with undisturbed morphology 
(Becker et al., 2005). Daily oestrous monitoring was undertaken at 24-hourly 
intervals to observe all cycle stages (Chapter 3).
As guided by the literature (Becker et al., 2005, Goldman et al., 2007, 
Marcondes et al., 2002), proestrus (Figure 2.2 A) was identified by the 
presence of a large number of spherical nucleated cells, which resulted in a 
very cloudy cell suspension. Leucocytes were often present but in very small 
numbers, with cornified (keratinised, non-nucleated) cells being rare. A 
predominance of cornified cells confirmed oestrus (Figure 2.2 B), with a 
number of these cells becoming spindle-shaped in appearance. Metestrus 
(Figure 2.2 C) was characterised by an abundance of leucocytes with a small 
number of cornified, particularly spindle-shaped, cells present. During 
diestrus (Figure 2.2 D), few cells of any cell type were present, which was 
characteristic of the stage in itself. A diestrus lavage would typically contain a 
lot of mucus, sticking leucocytes together in lines.
Many study animals were found to be in transition stages of the cycle, so in 
cases where no clear stage existed, the ratio of nucleated to cornified to 
leucocytic cells (Ramos et al., 2001), alongside the observed cycle pattern of 
the rat, was used to stage the cycle.
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Figure 2.2. Representative images for each stage of the rat oestrous cycle
(x100 magnification).
In addition to cytology, a number of groups have demonstrated that the 
electrical resistance of the inner lining of the rat vagina can be used to help 
identify oestrus, with a significantly increased electrical resistance at this 
stage (Ramos et al., 2001, Singletary et al., 2005). As described by Ramos et 
al. (2001), a standard electrical meter with resistance measurement 
capability was adapted to accompany vaginal lavage as a method of cycle 
stage determination. Prior to vaginal lavage, the male terminal of the meter 
was inserted into the vagina until the reading was stable and was repeated 3 
to 5 times to record an average resistance reading. The meter was set to 
2000 kO to obtain the reading, as Ramos et al. (2001) demonstrated 
successful readings within this range.
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2.2.1. The oestrus dance
Whilst handling the animals prior to oestrous monitoring, a distinct behaviour 
was observed, which was identified to be an oestrus dance (Figure 2.3). 
When in proestrus (confirmed by vaginal lavage), stimulation of the back of 
the rat near the hind legs would result in presentation of lordosis with ear 
wiggling, hopping, darting and freezing, without a male rat being present or 
even visible, as described by Adler and Feder (1981). The majority of 
females would present an obvious oestrus dance, so it was used as a further 
confirmation of proestrus. Alongside this, animals were observed to have a 
general agitated demeanour and would be a lot more physically active during 
proestrus. For the breeding colony of Wistars used in this study, the females 
would begin showing this sexual behaviour shortly after lights out.
Figure 2.3. The oestrus dance occurred during proestrus
2.3. Sample collection
2.3.1. Protocol for animal fasting
All adult rats used in this study were fasted for 4 to 5 hours prior to culling, as 
a way to standardise gut hormone measurements. Rodents consume most of 
their food, approximately 85%, during the hours of darkness (Asarian and
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Geary, 2002, Eckel et al., 2000, Murakami et al., 2002). Therefore to study 
appetite hormones during the most physiologically relevant dark phase, these 
animals were placed on a reverse lighting schedule (lights off at 11.00) and it 
was possible to remove the diet prior to the beginning of dark period at 
approximately 08.00. It was planned so that removing the diet before lights- 
off would provide a longer period of fasting than simply the 4 to 5 hours 
between removal of diet and culling. All but 1 of the nulliparous animals lost 
body mass (3.5 ± 0.22%, n=43; Chapter 3) during the fasting period, which 
supported this possibility. Figure 2.4 shows the protocol for fasting.
08.00 
Diet removed
12.00-13.00
Culls begin
Light period
23.00 11.00 22.00v______________   yv________   y
Rest period Active period
Little food consumption Majority of food consumption
Figure 2.4. Protocol for fasting of study animals on a reverse lighting schedule
Other studies quantifying levels of ghrelin have fasted animals for a much 
longer time period than in the current study, due to the finding that ghrelin is 
increased in the fasted state. It is common for studies using both rats and 
mice to fast the animals for 24 hours (Lim et al., 2009, Stengel et al., 2009, 
Sun et al., 2007, Toshinai et al., 2001, Tschop et al., 2000), with some 
studies extending the fasting time to 48 hours (Toshinai et al., 2001, Tschop 
et al., 2000, Zhao et al., 2008), or even to 72 hours (Tovar et al., 2004). 
Studies in humans often use an overnight fast prior to serum or plasma
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hormone measurement (Sowers et al., 2008, Tham et al., 2009, Valsamakis 
et al., 2010).
In this study, it was important that all of the animals were all fasted for an 
equal time period for comparison purposes, but at the same time it was 
important to minimise fasting length due to the use of pregnant dams. In the 
very early stages of pregnancy, such as the day 4 time point, the stress 
caused by an extended period of fasting may be sufficient for foetal 
resorption due to maternal stress.
2.3.2. Matched fed and fasted blood sample collection
Matched fed and fasted plasma samples were obtained from each dam to 
allow a fed and fasted comparison of ghrelin, PYY and GLP-1 concentrations 
in each individual animal. Fed blood samples were obtained from each rat by 
a small incision with a scalpel blade to one tail vein at the tail tip. Rats used 
for the work described in Chapter 3 had a fed blood sample taken from 
13.00, after completion of oestrous monitoring. Rats were introduced into a 
tube-type restrainer (Vet-Tech Solutions Ltd) and topical cryo-analgesia 
(Cryogesic, Ethyl Chloride BP fine spray, Acorus Therapeutics Ltd) was 
applied to the tail tip. Dams used for work described in all other results 
chapters were anaesthetised using isofluorane (IsoFlo, Abbott) in an 
anaesthetic chamber until no pedal reflex was present. Rats were then 
transferred to a mask and eyes were lubricated (Lubrithal, VetXX Ltd) to 
prevent them from drying out. A small volume of blood was then collected 
through a minor incision to the tail as outline above. For all study animals, a
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small amount of finger pressure was applied to the tail to accelerate this 
procedure and reduce time spent either in the restraining tube or under 
anaesthetic. When blood started to clot, or enough blood was collected, tails 
were gently cleaned using water and wounds coated with a spray-on 
dressing (OpSite, Smith & Nephew Medical Ltd). After the procedure, rats 
were placed into a clean cage, with free access to food and water.
Fed blood samples were all immediately acidified 1:10 in buffer (0.1 M 
ammonium acetate, 0.5 M NaCI, pH 3.6) as recommended (Stengel et al., 
2009) for optimal peptide preservation and recovery (see section 2.3.2.1). 1 
ml of the fasted trunk blood (see below) collected from each animal was also 
immediately acidified 1:10 in buffer, with the remainder left un-acidified. 
Animals were left overnight after the tail bleed and food was removed from 
the cage at 08.00 the following day, prior to culling from 12.00. Rats were 
culled by anaesthetised decapitation, upon which a fasted blood sample was 
obtained from trunk blood. All blood was collected into 10 ml EDTA coated 
tubes (TekLab) with additional protease inhibitor (aprotinin; Trasylol, Bayer) 
and blood volume was recorded.
2.3.2.1. The RAPID methodology for optimal peptide recovery 
The RAPID (Reduced temperatures, Acidification, Protease inhibition, 
Isotopic exogenous controls, and Dilution; Figure 2.5) processing for blood 
samples is recommended by Stengel et al. (2009) as a method by which 
endocrine peptide recovery can be improved by reducing the peptide 
breakdown that occurs during standard blood processing. Stengel et al.
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(2009) reported that the acyl to total ghrelin ratio was 1:19 using standard 
processing, but when using RAPID, they reported a 1:5 ratio, which they 
state demonstrated a more accurate ghrelin measurement as a result of 
RAPID processing. That study also measured PYY1-36 and PYY3-36, reporting 
that almost 40% more of both peptide forms were recovered using the RAPID 
methodology compared to standard processing. For these reasons, it was 
decided to use the RAPID methodology to improve peptide yield and allow 
analysis of different peptide forms in plasma for the studies in this thesis. It 
was intended from the study onset to quantify the acyl portion of ghrelin 
alongside the total form by LC/MS-MS but although the samples exist, it was 
not possible to complete this aspect of the study.
immediately Dilute blood 1:10 in ice-cold
Blood withdrawal acid bufTer
(containing enzyme inhibitors)
Sep-Pak chromatography
take
supernatant
l~
Centrifuge 
(3,000 g, 10 min, 4 °C)
Dry' the eluted peptides by Store lyophilized peptide
vacuum centrifugation powder at -80 °C
I before useMeasure peptide Dissolve peptide in diluentconcentration 
e.g. byRIA to original plasma volume)
Figure 2.5 RAPID methodology flow diagram
(Modified from Stengel et al., 2009).
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2.3.3. Centrifugation of blood samples
All blood samples were kept on ice and then centrifuged immediately after 
dissection had been completed, using a bench-top refrigerated centrifuge 
(Heraeus Labofuge 400R) at 3000 g for 10 minutes at 4 °C. Plasma was 
aliquotted into Eppendorf tubes using sterile 3 ml plastic pipettes and stored 
at -80 °C. A vacuum centrifuge (Genevac SF50 or Concentrator Plus) was 
used overnight to dry down a small proportion of all fasted acidified plasma 
samples and the total volume of fed acidified plasma from animals in 
Chapters 4, 5 and 6 immediately after aliquotting; cycling females from 
Chapter 3 did not have fed acidified plasma dried down. All dried plasma 
powder was stored at -20 °C until assayed.
2.3.4. Gastrointestinal tissue sample collection
Samples of stomach and descending colon were taken from animals used in 
the work described in Chapter 3, and samples of stomach, ascending colon 
and descending colon were taken from animals used in all other chapters 
(Table 2.1). For pups (Chapter 7), whose colon tissue was smaller, 
measurements were amended accordingly, with care taken for consistency 
between litters.
Table 2.1. Dissection protocol for gut sample collection
Gut area Protocol for sample collection
Stomach Locate and dissect out
Ascending colon Dissect out 5 cm of colon tissue immediately below caecum
Descending colon Dissect out 5 cm of colon tissue 2 cm above the rectum
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2.4. Physical measurements
Live body mass (in g) of all animals in the colony was recorded a minimum of 
twice per month prior to their use in the study. Additional body mass 
recordings were taken from animals being studied, with measurements 
always taken before the tail bleed and again before dissection. Regular 
measurement of body mass was also used as a method to improve the 
animal/handler relationship prior to any experimental procedure beginning. 
Body length was measured after culling, measuring from between the front 
paws to the anus. In dams used for the pregnancy and lactation time points, 
rectal temperature was recorded using a digital thermometer whilst animals 
were anaesthetised prior to the tail bleed.
2.4.1. Measurement of tissues and gut contents
Multiple measurements were taken during dissection of all adult females to 
obtain information about body composition and how this changed between 
sample groups. Table 2.2 outlines the measurements taken during 
dissections, however in Chapter 3, the small intestine was not fully emptied 
before weighing and so no comparisons were possible between small 
intestine tissue mass of proestrus controls and subsequent pregnant and 
lactating sample groups. Dams used for the day 25 of lactation time point 
also did not have fully emptied small intestine tissue (Chapters 5 and 6). 
Small and large intestines were free-floated in phosphate-buffered saline 
(PBS; pH 7.4), with care taken not to stretch the tissue, in order to obtain 
more accurate length measurements. Due to the use of the intestinal tissue 
for multiple methods of analysis (peptide extraction; immunostaining) and
63
time limitations, it was not possible to use nicardipine hydrochloride to 
maximally relax smooth muscle for complete standardisation of length 
measurements. Measurements of gut circumference, however, were 
standardised by measurement after 20 minute incubation in PBS containing 
the calcium channel blocker nicardipine hydrochloride (10'6 M; Sigma). Gut 
tubes were then cut open and measured using graph paper, with the aid of a 
light microscope.
Table 2.2. Protocol for measurements made of the gastrointestinal tract and other 
organs in each adult female
Tissue Protocol
Stomach
Full stomach weighed, opened along 
greater curvature, emptied and re­
weighed
Small intestine
Length recorded
Full small intestine weighed, emptied 
and re-weighed
Duodenum
~1 cm of mid duodenum maximally 
relaxed in nicardipine for 
circumference measurement
Caecum
Length recorded
Full caecum weighed, emptied and 
re-weighed
Large intestine
Length recorded
Full large intestine weighed, emptied 
and re-weighed
Ascending colon
(Proximal 5 cm of large intestine) 
~1 cm of proximal tissue for 
circumference measurement
Descending colon
(Distal 5 cm of large intestine) 
~1 cm of proximal tissue for 
circumference measurement
Uterus Full uterus weighed, emptied if fluid- filled, and re-weighed
Abdominal cavity adipose tissue
All white adipose tissue in the 
abdominal cavity removed and 
weighed
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For pups (Chapter 7) only stomach tissue was examined for size changes 
due to time restrictions, with colon only being collected for peptide level 
analysis (see above).
In dams used for pregnancy and lactation studies, stomach and caecum 
contents were collected into Universal tubes at the appropriate stages of the 
dissection protocol and frozen (-20 °C) until use. Measurement of pH was 
made for each thawed sample using a digital pH meter (HI 5424, Hanna 
Instruments). Caecum contents were analysed using selected ion flow tube 
mass spectrometry (SIFT-MS; see appendix 1) from one group of pregnant 
and one group of lactating dams, as guided by significant pH differences. The 
caecum contents of two proestrus controls and the day 12 of pregnancy and 
day 10 of lactation groups were separated into portions of roughly equal 
mass (~1 g) for SIFT-MS analysis. Samples were placed into a sealed bag, 
which was filled with zero air before incubation at 37 °C for 1 hour in order to 
optimise the release of the volatile compounds from the samples for the 
analysis. Sample bags were then loaded onto the SIFT and each sample was 
analysed using 3 different precursor ions: H30+, NO+ and O2+. All 
compounds were measured in parts per billion.
2.5. Radioimmunoassays
Radioimmunoassay kits were purchased for the total peptide forms of ghrelin, 
PYY and GLP-1 (Millipore, UK). The total forms of each peptide were chosen 
for analysis to allow quantification regardless of any peptide degradation that 
may have either occurred during sample processing or by natural causes
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(see section 1.6). Biologically active GLP-1 (GL.P-I7.36), for example, is 
rapidly truncated at the N terminal into the biologically inactive form (GLP-19. 
36) by dipeptidyl peptidase IV (DPP IV) (Kieffer et al., 1995, Mentlein et al., 
1993). Thus, measuring only the biologically active forms of GLP-1 may not 
be a good representation of the true peptide concentration from the gut L- 
cells due to rapid degradation even before reaching the peripheral circulation.
2.5.1. Samples
Half of each rat stomach and a small section of mid-ascending colon 
(Chapter 4 onwards) and mid-descending colon from both adults and pups 
were collected into cryovials and immediately frozen on dry ice and stored at 
(-80 °C) after dissection to quantify tissue peptide content. All samples were 
later thawed and diluted to 1 ml per 100 g of tissue in 0.5 M glacial acetic 
acid and were then placed (in cryovials) in a boiling 100 °C water bath for 20 
minutes. After cool enough to touch, the liquid portion of the samples was 
aliquotted into Eppendorf tubes using sterile 3 ml pipettes and stored at -20 
°C until assayed. When tissue samples had to be diluted prior to their 
addition to a radioimmunoassay, they were diluted using distilled water.
As all fed plasma collected was acidified, this was analysed for each peptide. 
Fasted acidified plasma was used in ghrelin assays as recommended (see 
section 2.3.2.1) to stabilise the peptide form and for PYY and GLP-1 assays, 
neat un-acidified fasted plasma was used because concentrations of both of 
these peptides were expected to be lowest in the fasted state.
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2.5.2. Assay procedure
All radioimmunoassays were performed according to the manufacturer’s 
protocols provided and were used to analyse both plasma and tissue 
extracts, as outlined above. Briefly, the assay was set up using the 
recommended volumes of standards and quality controls and samples were 
added to the tubes at optimised volumes (see below). Counts from the 
standards provided the standard curve for the assay and the quality controls 
were a known low and a high concentration of the peptide, provided by the 
manufacturer, to check assay performance. All tubes (excluding total count 
and non-specific binding tubes) were incubated (4°C) overnight with the 
antibody for the appropriate peptide followed by a further overnight 
incubation (4°C) with the radiolabelled (125l) tracer. The secondary antibody 
contained polyethylene glycol to allow separation of bound and unbound 
antibody prior to counting bound radioactivity using a gamma counter. This 
method of radioimmunoassay is competition based, so the number of binding 
sites available to the radiolabelled tracer is limited by the number of antibody 
binding sites occupied by the standard/sample after the first incubation. Thus, 
the lower the radioactive count obtained at the end of the assay, the higher in 
concentration the standard or sample, which is then quantified using the 
standard curve generated from the percentage of total binding calculated for 
each standard.
Some sample dilutions and appropriate calculation modifications were made 
so that samples had good separation on the standard curve. Sample dilutions 
were optimised in pilot assays, resulting in dilution factors as described below
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for each peptide. For all calculation modifications, a calculation for the 
change in sample volume was made first, followed by a separate calculation 
for any dilution made to that sample prior to its addition to the assay tubes.
2.5.3. Total ghrelin radioimmunoassay
Samples of fed and fasted acidified plasma and stomach tissue extract were 
analysed for total ghrelin concentration. The ghrelin radioimmunoassay kits 
had a lower and upper detection limit of 93 pg/ml and 6000 pg/ml 
respectively in a sample size of 100 pi. During preliminary testing, ghrelin 
was found to be extremely concentrated in all sample types, so they were all 
diluted 10 times by the addition of 10 pi of sample to each assay tube, rather 
than 100 pi as suggested in the protocol. One ghrelin radioimmunoassay kit 
was further tested and replicate tubes were spiked separately with a known 
concentration (1 pg/ml) of an acyl and a desacyl ghrelin standard to confirm 
the assay was properly recovering both forms of the peptide, using low 
sample volumes (5 pi). Results from the ghrelin spiking confirmed that the 
assay was equally efficient at recognising both acyl and desacyl ghrelin and 
recovering the expected amounts.
No difference was found in the concentration of ghrelin between the fed and 
fasted plasma samples in Chapter 3, so fed plasma was not analysed for 
ghrelin concentration from Chapter 4 onwards, due to cost. Dams from 
Chapter 6 who were mothers of the pups used in Chapter 7 did have fed 
plasma ghrelin quantified in order to match a sample between dam and pup, 
as pups were assumed to be fed due to keeping them with the dams during
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the fasting period. However, due to different sample preparation at this stage 
of the study (fed plasma samples were dried down after Chapter 3) no direct 
comparison could be made between matched fed and fasted plasma ghrelin 
concentrations in Chapter 6. Adding to the 10 times dilution described above, 
stomach tissue extract was additionally diluted 1:250 for animals in Chapter 4 
and 7, and 1:400 for animals in Chapters 3, 5 and 6 prior to its addition to the 
assay.
The intra-assay and inter-assay coefficients of variation (%CV; Table 2.3) 
were calculated separately for each assay batch, with a batch change 
between analysis of the oestrous cycle samples and the remaining samples. 
Intra-assay variation was calculated from total binding reference (B0) tubes at 
the beginning and end of assays. The inter-assay %CV was calculated from 
the quality control (QC) used in each assay that was closest in concentration 
to the samples analysed. A %CV of <15% was considered acceptable and 
any samples outside this were reanalysed. The kit protocol stated that the 
assays do not have any cross-reactivity with other related hormones.
Table 2.3. Ghrelin radioimmunoassay intra- and inter-assay coefficients of variation
(n=number of assays)
Intra-assay coefficient 
(%)
Inter-assay coefficient 
(%)
Oestrous cycle 10.7 4.7
(batch 1) (n=3) (n=3)
Pregnant/lactating/pups 13.6 12.4
(batch 2) (n=4) (n=4)
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2.5.4. Total peptide-YY (PYY) radioimmunoassay
Fasted non-acidified plasma and fed acidified plasma were analysed using 
the PYY radioimmunoassay kits, alongside ascending and descending colon 
extracts. The manufacturer’s stated sensitivity of the PYY kits was 15.6 pg/ml 
with a 100 pi sample volume (78.1 pg/ml with a 20 pi sample volume). Fasted 
non-acidified plasma samples were added to the assay as suggested in the 
kit protocol. Fed (acidified) plasma samples from animals used in Chapter 3 
were added to kits at 150 pi, rather than 20 pi, because they were more dilute 
from the acidification process, creating a concentration factor of 0.67. Pup 
plasma (Chapter 7) was treated in a similar way and added to kits at 180 pi 
volume (x 0.56 concentration). Animals used in Chapters 4, 5 and 6 had fed 
acidified plasma samples that were dried using vacuum centrifugation and so 
each sample was reconstituted to its original equivalent plasma volume 
(minus the buffer volume) with distilled water. After this, 70 pi (Chapters 5 
and 6) or 90 pi (Chapter 4) of the reconstituted fed plasma was added to 
each assay, resulting in a concentration factor of either 1.43 or 1.11 
respectively. Sample dilutions for ascending colon (Chapter 4 onwards) and 
descending colon (all animals) are outlined below (Table 2.4). The kit 
protocol for the PYY radioimmunoassays stated that there was no detectable 
cross-reactivity with other related peptides, including GLP-1. The intra-assay 
and inter-assay %CVs for PYY radioimmunoassays are shown in Table 2.5 
and were calculated per kit batch.
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Table 2.4. Optimal dilutions made for PYY quantification
Dilutions were optimised for each sample group and are displayed by chapter number. 
Ascending colon tissue was not taken from study animals in Chapter 3.
Ascending colon 
extract
Descending colon 
extract
Chapter 3 No data 1:20
Chapters 4, 5 and 6 1:80 1:80
Chapter 7 1:60 1:60
Table 2.5. PYY radioimmunoassay intra- and inter-assay coefficients of variation
(n=number of assays)
Intra-assay coefficient 
(%)
Inter-assay coefficient 
(%>
Oestrous cycle 6.0 2.9
(batch 1) (n=1) (n=3)
Pregnant/lactating/pups 8.1 13.4
(batch 2) (n=7) (n=7)
2.5.5. Total glucagon-like peptide-1 (GLP-1) 
radioimmunoassay
Fasted non-acidified plasma samples were extracted and added to each kit 
as outlined in the assay protocol. Stated detection limits for the GLP-1 
radioimmunoassays were 3-333 pM with a 300 pi extracted sample size. 
Double the volume of fed acidified plasma underwent the kit extraction 
protocol in order to double the concentration and bring these samples onto 
the standard curve. Briefly, for extraction, 95% ethyl alcohol was added to 
each sample which was then incubated on ice for 30 minutes and centrifuged 
at 10,000 rpm for 10 minutes in a microfuge. The supernatants were 
decanted and dried down using a vacuum centrifuge (Genevac SF50 or 
Concentrator Plus) before reconstitution in sample hydrating solution 
(provided in the kit). Colon tissue concentrations of GLP-1 were sufficiently
concentrated and did not require extraction (Table 2.6). In order to convert 
concentrations from pmol to pg/ml, all concentrations were multiplied by 
3.297, as 1 pmol/l of GLP-1 is equivalent to 3.297 pg/ml. The intra-assay and 
inter-assay %CVs for GLP-1 radioimmunoassays are shown in Table 2.7 and 
were calculated per kit batch. The manufacturer stated that there was a 
<0.01% detection of GLP-2 and 0.2% detection of glucagon in cross­
reactivity tests.
Table 2.6. Optimal dilutions made for GLP-1 quantification
Dilutions were optimised for each sample group and are displayed by chapter number. 
Ascending colon was not taken from study animals in Chapter 3.
Ascending colon 
extract
Descending colon 
extract
Chapter 3 No data 1:30
Chapters 4, 5 and 6 1:80 1:70
Chapter 7 1:80 1:50
Table 2.7. GLP-1 radioimmunoassay intra- and inter-assay coefficients of variation
(n=number of assays)
Intra-assay coefficient 
(%)
Inter-assay coefficient 
(%)
Oestrous cycle 4.3 6.3
(batch 1) (n=3) (n=3)
Pregnant/lactating/pups 7.2 10.6
(batch 2) (n=6) (n=3)
2.6. Immunofluorescence
2.6.1. Tissue preparation
After dissection, half of each rat stomach was pinned flat (pinned around the 
tissue edges), mucosa side down in a glass petri dish containing Sylgard.
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Stomach and approximately 2 cm of proximal ascending colon (Chapter 4 
onwards) and distal descending colon were fixed intact overnight in 4% 
paraformaldehyde. After 3 x 1 0  minute PBS washes, tissue was transferred 
into 30% sucrose, 0.1% sodium azide solution in PBS and maintained at 4 °C 
until blocking.
2.6.2. Tissue blocking and cryosectioning
Tubes of colon were pinned to cork disks (Figure 2.6 A) and coated (inside 
and outside) in OCT-embedding medium (Fisher). Colon samples were then 
frozen in isopentane cooled in liquid nitrogen, with care taken so that tissue 
did not come into direct contact with the isopentane. The body of each 
stomach was cut out (Figure 2.6 B and C) and this portion was placed into a 
plastic rectangular mould containing OCT, before freezing in isopentane 
cooled in liquid nitrogen. Sections of colon were made cross-sectionally. 
Frozen stomach tissue blocks were transversely sectioned on a cryostat 
(Leica CM1900), starting from the straight edge of the tissue adjacent to the 
oesophageal opening. All sections were cut at a thickness of 10 pm and 
collected onto electrostatically charged slides (SuperFrost Plus, Fisher). If not 
for immediate use, slides were stored at -80 °C until staining.
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Pin
CD
Colon
Cork disc
B.
Fundus
Pylorus
Body
Figure 2.6. Fixation protocol for colon and stomach tissue
Tubes of colon tissue (A) were pinned to cork for cryoblocking and (B) the body of each 
stomach was removed (C) and blocked for cryosectioning, with notation (*) of tissue 
orientation made on each plastic mould.
2 .6 .3 .  Immunofluorescence protocol
All slides were allowed to adjust to room temperature (RT) before application 
of normal serum (10%) for 90 minutes to block background fluorescence. 
Serum was washed from slides with 3 x 10 minutes PBS before primary 
antibody incubation overnight (18 to 24 hours) at RT. Slides were thoroughly 
washed ( 3 x 1 0  minutes PBS) and the secondary antibody was applied for 
120 minutes (RT), followed by a further 3 x 10 min PBS wash. When a 
fluorescently labelled secondary antibody was used, slides were then 
mounted with Citifluor (Agar Scientific) and coverslipped. When a biotinylated 
secondary had been applied, sections were incubated with streptavidin 
fluorescein for 120 minutes (RT) before a final 3 x 1 0  min PBS wash and 
mounting with Citifluor. Negative controls were performed for each test, 
which included slides incubated with antibody-dilution solution only, primary 
antibody only, secondary antibody only and, when appropriate, streptavidin 
fluorescein only.
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2.6.4. Optimisation of antibody dilutions
All primary antibodies were optimised for each tissue type prior to EC 
quantification. Table 2.8 details both optimal antibody dilutions and the 
combinations of primary and secondary antibodies used for all 
immunofluorescence experiments.
Table 2.8. Optimised concentrations of each primary and secondary antibody
Table shows pairings used between primary and secondary antibodies.
Primary antibody Dilution Secondary antibody Dilution
Goat anti-ghrelin 
Santa Cruz 
Biotechnology
1:800
Biotinylated horse anti­
goat IgG 
Vector
6 ug/ml
Streptavidin
fluorescein
Vector
4 ug/ml
Rabbit anti-PYY 
Abeam 1:600
Goat anti-rabbit IgG 
Alexa Fluor 488 
Invitrogen
1:200
Rabbit anti-GLP-1 
Phoenix
Pharmaceuticals
1:600
Goat anti-rabbit IgG 
Alexa Fluor 488 
Invitrogen
1:200
2.6.5. Groups selected for immunofluorescence
To identify whether the immunoreactive (IR) cell densities of ghrelin 
(stomach), PYY (colon) and GLP-1 (colon) changed between pregnancy and 
lactation in comparison with proestrus controls, animals from one group of 
pregnant dams and one group of lactating dams were selected. Groups were 
selected to have one sample group that had a high tissue peptide 
concentration and one sample group that had a low tissue peptide 
concentration. Tissue peptide concentrations were determined by
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radioimmunoassays. For stomach ghrelin cell quantification, day 12 pregnant 
(low stomach ghrelin concentration) and dams on the day of birth (high 
ghrelin stomach concentration) were chosen as samples with a low and a 
high stomach tissue ghrelin concentration.
Experiments to determine PYY and GLP-1 immunopositive cells in ascending 
and descending colon tissue were performed using day 12 pregnant dams 
(low tissue peptide concentrations) and day 5 lactating dams (high tissue 
peptide concentrations). Immunostaining for PYY and GLP-1 in ascending 
and descending colon tissue did not yield quantifiable results, because 
staining for both peptides was inconsistent. The way in which the tissue was 
treated was consistent and the tissue had typical morphology. It is possible 
that due to the standardised method of sample collection, whereby the same 
section of gut was taken for staining from each dam, the most informative 
regions of gut for this method of analysis may have been missed. Cell density 
may vary along the length of the gut tissue, with gut growth also likely to 
affect cell density in different gut regions. Due to gut growth, it is likely that 
the above protocol for gut dissection would need to be standardised per rat, 
rather than the use of a standard protocol for all rats. Future work to 
determine the most suitable gut regions for staining of PYY and GLP-1 would 
have to explore using the full length of the colon to characterise the best 
areas for immunostaining.
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2.6.6. Quantification of immunofluorescence
Serial images of each section stained for the chosen groups were obtained 
using an Olympus BX fluorescence microscope. In order to perform a manual 
cell count of each immunopositive cell, serial images were taken of the 
entirety of each section of tissue stained using a x10 objective lens and all 
immunopositive cells were counted from these images. The programme 
ImageJ was used to aid manual cell counting, using the cell counter plugin to 
mark each immunopositive cell in each image. In order to count these images 
blind, an online list randomiser (http://www.random.org/lists/) was used to 
assign a random number to each animal number. Each image was then 
renamed using this random number and cell counting was completed before 
counts were un-blinded for statistical analysis.
Automated cell counting was trialled for this study using the ImageJ tool that 
counts between set intensities. This was found not to be suitable due to large 
differences in background intensity caused by mucosal folding, which was 
prevalent in both stomach and colon sections. Thus, criteria had to be set to 
determine positive cells for manual counting.
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Figure 2.7. Ghrelin immunoreactive cells in rat stomach tissue
Cells counted could either be (A) clear or (B) obscured as long as cell appearance was 
consistent (x100 magnification).
Ghrelin cells in stomach tissue (Figure 2.7 A) were counted as positive when 
they were of consistent size, had clear edges and visible nuclei. In sections 
of tissue where the mucosa had folded over and obscured positive cells 
(Figure 2.7 B), nuclei were not always visible and so cells were counted 
when cell edges were still clearly defined and the cells were of a size 
consistent with IR cells in non-folded regions of the same section.
In colon tissue (Figure 2.8), PYY and GLP-1 immunopositive cells had a 
characteristic ‘tail’ and all cells with this morphology and a visible nucleus 
were counted. Flowever, it was not possible to conduct this work for this 
thesis for reasons stated above (section 2.6.5).
C E L L
A NOT CELLA r~ - .
Figure 2.8. A representative image of L-cell staining for PYY/GLP-1 in descending 
colon
(x100 magnification).
For measurement of mucosal area, serial images were also taken of each 
section using a x4 objective lens in order to measure mucosal area more 
easily. ImageJ was additionally utilised for tissue section measurements; the 
freehand drawing tool was calibrated to the scale bar on images and used to 
draw around the mucosal epithelium in each image, so that cells could be 
expressed per mucosal area (cells per mm2). The maximum mucosal and 
muscle (all muscle layers) thickness in each image for each tissue section, 
as judged by eye, was measured using ImageJ to obtain a mean maximal 
mucosal and muscle thickness (in mm) for each section. Thickness was 
measured in this way because gut mucosa is quite difficult to section 
uniformly, due to the natural folds of the tissue. By obtaining the mean 
maximal mucosal and muscle thicknesses, there is a lesser likelihood of 
measurements being influenced by amount of gut contents present at 
dissection or by changes in tissue orientation when sections were cut. In 
order to partially control for this, it would have been desirable to use 
nicardipine (see section 2.4.1) to maximally relax the tissue and standardise 
measurements.
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2.7. Statistical analysis
All means in the results chapters are expressed ± standard error of the mean 
(SEM). Unless otherwise specified, data sets were analysed by one-way 
ANOVA with a Tukey post-hoc test and P<0.05 was considered significant. 
On figures, post-hoc significance is denoted as stars where *** is P<0.001, ** 
is P<0.01 and * is P<0.05. Within columns on tables, a>b is P<0.001, c>d is 
P<0.01 and e>f is P<0.05.
Non-homogeneous data sets underwent natural log transformation to 
normalise distribution and allow parametric analysis. When log 
transformation did not normalise the data, results were analysed by the non- 
parametric Kruskal-Wallis test with follow-up pairwise comparisons (Mann- 
Whitney), with Bonferroni correction. Matched fed and fasted concentrations 
of peptides were analysed using a paired samples t-test and SIFT-MS 
analysis of caecum contents was analysed using an independent samples t- 
test.
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CHAPTER 3: ANALYSIS OF CHANGES IN GUT 
APPETITE HORMONES DURING THE OESTROUS 
CYCLE
3.1. Introduction
There is a well documented link between the hormones of the reproductive 
cycle and cyclic changes to appetite (reviewed by Asarian and Geary, 2006, 
Butera, 2010, Eckel, 2011). Food intake has been associated with levels of 
oestradiol in the circulation and rats reportedly consume less during oestrus, 
following the earlier peak in oestradiol secretion by the ovaries during 
proestrus (Asarian and Geary, 2006). In one study, a significant reduction in 
food intake at oestrus was found to be accompanied by a reduction in water 
consumption and was due to a decrease in intake, but not a decrease in 
meal frequency in ad libitum fed rats (Eckel et a/., 2000). Eckel et al. (2000) 
also reported a significant decrease in body mass in ad libitum fed rats during 
oestrus. Wade (1975) hypothesised that oestradiol transiently alters the 
homeostatic set point to which body mass is regulated and causes an indirect 
reduction in body mass by causing hypophagia. This hypothesis was tested 
by injecting ovariectomised (OVX) rats with oestradiol, which reduced food 
intake and subsequently body mass, but only for the first 3 weeks of 
treatment. Thereafter, food intake recovered to control levels and body mass 
stabilised to approximately 12% below that of the non-treated OVX control 
rats. On withdrawal of oestradiol treatment, both food intake and body mass 
increased above control levels (Wade, 1975). One additional study in OVX
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female rats further demonstrated that cyclic administration of ‘near 
physiological’ oestradiol levels allowed maintenance of feeding patterns and 
body mass, both of which were lost in non-treated OVX control rats (Asarian 
and Geary, 2002).
Despite the described observations of cyclic changes to food intake and body 
mass during the reproductive cycle, the possible roles of appetite-regulating 
gut hormones have been little explored. Cholecystokinin (CCK) has been the 
most widely investigated appetite hormone in relation to the oestrous cycle. A 
review by Asarian and Geary (2006) summarises that during oestrus, 
oestradiol increases the anorexigenic actions, although not concentrations of 
CCK, thus reducing food intake, and that ERa is required for this effect 
(Geary, 2001). Ghrelin concentrations during the oestrous cycle have also 
been investigated and a relationship between ghrelin and oestrogen is 
established, but the mechanisms of action are not well explored.
3.1.1. Effects of ghrelin during the oestrous cycle
Many studies (reviewed by Butera, 2010) have examined the effects of 
oestradiol on ghrelin’s orexigenic properties by artificial manipulation of these 
hormones, with a main focus on the effects on food intake. One study that 
provides the most comprehensive picture of the inhibitory effect of oestradiol 
on ghrelin in rats by Clegg et al. (2007) demonstrated that infusion of ghrelin 
increased food intake in males and in OVX females, but not in either 
oestrogen-treated males or intact females, suggesting that oestrogen 
somehow attenuates ghrelin’s ability to stimulate appetite. In OVX females
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treated with cyclic oestradiol to mimic the oestrous cycle, ghrelin infusion 
increased food intake on the equivalent days of metestrus and diestrus (low 
oestrogen levels), but had no effect during proestrus and oestrus (high 
oestrogen levels), which was also replicated in normally cycling rats (Clegg et 
a!., 2007). Butera’s review (2010) of the work in their lab also concluded that 
injection of ghrelin during diestrus, but not proestrus, increased food intake 
and that this occurred due to increased meal frequency but not individual 
meal size. These findings suggest that during times of high oestradiol 
(proestrus and oestrus), endogenous ghrelin levels may be reduced, or 
ghrelin’s actions could be attenuated by high oestradiol levels. The finding of 
increased meal frequency but not meal size during diestrus (Butera, 2010) is 
contrary to what Eckel et at. (2000) reported, described previously, where 
there is a decrease in meal size but not frequency at oestrus. Taken 
together, these studies may suggest that independent mechanisms are 
responsible for the increase in food intake at diestrus and the decrease in 
food intake at oestrus.
As well as assessing the influence of oestradiol levels on the effects of 
ghrelin on food intake, one study has shown that an injection of ghrelin 
significantly decreased serum oestradiol at each stage of the cycle (Fang et 
al., 2012), suggesting that the relationship between oestradiol and ghrelin 
may be reciprocal.
The relationship between oestradiol and ghrelin expression in the rat 
stomach has been explored by a number of groups. One of the first studies
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reported that ghrelin cell density in the stomach tissue of young rats 
increased significantly just 3 days post-OVX in 4 week old females, and 5 
days post-OVX in 9 week old females, with a significant sustained increase in 
plasma ghrelin immediately after OVX (Matsubara et al., 2004). From 7 days 
post-OVX in that study, ghrelin cell density and plasma ghrelin started to 
reduce in both groups, but it remains to be established whether this reduction 
would continue with time and reach intact control levels. Matsubara et al. 
(2004) also reported that the OVX-induced ghrelin increase in plasma and in 
both stomach ghrelin cell density and mRNA were reversed by treatment of 
oestradiol, although it remains to be seen whether these effects are 
reproducible in fully mature adult female rats. Another study using female rat 
isolated stomach cells demonstrated that oestrogen treatment upregulated 
stomach ghrelin mRNA expression in a dose-dependent manner (Sakata et 
al., 2006). Using both male and female rats, these authors further 
demonstrated that ghrelin and oestrogen cells are located in close proximity 
in the stomach by analysis of cells immunopositive for acyl ghrelin and 
aromatase (Sakata et al., 2006). Together, these findings suggest that 
oestrogen from the stomach could potentially have the ability to upregulate 
stomach ghrelin expression in vivo, but without knowing the effect of 
oestrogen treatment on stomach cells from male rats, this may only be the 
case in females. In male rats, stomach ghrelin mRNA is reported to be 2.5 
fold higher in fasted (48 hours) male rats compared with those in the fed 
state, but that portal-vein oestradiol was not changed with fasting (Zhao et 
al., 2008). This finding suggests that oestradiol does not contribute to gastric
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ghrelin mRNA expression in fasted male rats; this study did not include 
females.
Although the studies described here have established that there are 
relationships between oestradiol, the reproductive cycle and ghrelin, no 
studies have yet quantified ghrelin concentration in both fed and fasted 
plasma and in gut tissue from rats allowed to cycle normally. In addition, 
there is very little research looking into the potential changes of PYY and 
GLP-1 concentrations during a naturally occurring reproductive cycle, despite 
the relationships between ghrelin, PYY and GLP-1 in appetite regulation (see 
section 1.6.4). One may expect that during oestrus, when food intake is 
lowest, PYY and GLP-1 may contribute to the anorexigenic tone, whilst 
ghrelin levels remain attenuated due to the peak of oestradiol during 
proestrus.
3.2. Objectives
The objectives for this part of the study were:
o to investigate if there are changes in the concentrations of the appetite 
hormones ghrelin, PYY and GLP-1 during the rodent oestrous cycle by 
quantification of both fed and fasted plasma and (fasted) gut tissue 
hormone concentrations at each stage of the oestrous cycle;
o to establish whether concentrations of these appetite hormones 
change in accordance with the appetite changes reported by others.
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This work was also carried out as a baseline for further experimental work 
described in Chapters 4, 5 and 6. To investigate whether circulating and/or 
gut concentrations of ghrelin, PYY and GLP-1 change during pregnancy and 
lactation, it was necessary to explore their interactions in nulliparous females 
and the role they have in the regulation of appetite during the reproductive 
cycle. It was also necessary to establish the baseline body and gut 
measurements in these reproductively cycling animals in order to determine 
how the gut architecture might change to accommodate increased food 
intake during pregnancy and lactation.
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3.3. Methods
3.3.1. Animals
Cycle stage was determined as outlined in Chapter 2 (section 2.2). To 
minimise the body mass range of the animals, cages of rats were chosen for 
daily oestrous monitoring in the order of heaviest mean cage body mass; 2 to 
5 cages were monitored at a time.
Rats were monitored for a minimum of 2 complete cycles (often up to 4 
cycles) to obtain sample groups at each stage of the oestrous cycle. A fed 
blood sample was taken the day before a required cycle stage was predicted 
in order to dissect animals at that predicted stage (proestrus n=12; oestrus 
n=11; metestrus n=9, diestrus n=11). A number of animals did not progress 
as predicted with their oestrous cycle (for example, with an additional day 
spent in diestrus), so there is a mis-match between the number of animals in
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the fasted state cycle stages (as above) and the numbers obtained for the 
fed cycle stages (proestrus n=14; oestrus n=7; metestrus n=6, diestrus 
n=16).
3.3.2. Sample collection
Samples of fed and fasted plasma were taken as outlined in Chapter 2 
(section 2.3.2). On culling, multiple measurements of the gut were made and 
gut samples were collected (section 2.3.4).
3.3.3. Measurements of food intake and body mass
In addition to weekly weighing, a sub-group of the animals undergoing 
oestrous monitoring was weighed daily to ascertain whether cycle stage 
influenced body mass, as described by Eckel et al., (2000). Food intake per 
cage was estimated by weighing a full food hopper every Friday at 10.30 and 
weighing the hopper again every Monday at 10.30. This allowed an 
approximate measure of average food intake whilst the animals were 
minimally disturbed, for comparison with future breeding animals. Data 
collected for approximate food intake was then calculated for mean daily food 
intake per cage and divided by the number of rats in the cage. Body mass 
was measured both prior to fed blood sample withdrawal and culling.
3.3.4. Determination of cycle stage
Starting at 11.00 (lights off) rats were removed from the home cage, placed 
onto a towel with their heads covered and lightly restrained by hand to begin
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oestrous monitoring. Vaginal lavage was carried out using a small volume 
(<0.5 ml) of distilled water in a sterile 3 ml plastic pipette, with care taken only 
to insert the fine tip of the pipette into the vagina. Water was expelled and 
collected approximately 3 times, or until the suspension became cloudy, 
before placing the solution into a double cavity microscope slide. Viewing of 
slides was aided using a black and white on-screen filter on a commercially 
available light microscope (Bresser 5201000 LCD microscope). The black 
and white on-screen filter allowed for clear viewing of cell morphology without 
need for fixation or staining, thus reducing analysis time.
Measurement of electrical resistance in the vagina was additionally used as a 
tool to help identify the stage of oestrus (section 2.2). However, even 
between replicate readings, measurements were not consistent enough to 
show any difference between cycle stages and were not used as part of this 
study.
3.3.5. Peptide assays
Radioimmunoassays to determine peptide concentrations of ghrelin, PYY 
and GLP-1 in plasma and tissue extracts were performed as detailed in 
Chapter 2 (section 2.5).
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3.4. Results
3.4.1. Total ghrelin peptide analysis
3.4.1.1. Matched fed and fasted plasma comparison
For the full group, there was a non-significant trend (P=0.051) for fed plasma
ghrelin concentrations (180.4 ± 6.66 ng/ml) to be higher than in the matched 
fasted plasma samples (174.1 ± 5.83 ng/ml). When data were split by cull 
day cycle stage, there was no difference between fed and fasted plasma 
ghrelin levels in the matched samples at any cycle stage. Fed and fasted 
plasma ghrelin concentrations positively correlated with each other (a= 0.890, 
P<0.001; Figure 3.10).
3.4.1.2. Concentration change with cycle stage
Concentrations of ghrelin in fed acidified plasma were not significantly 
different between cycle stages (Table 3.1). Fasted acidified plasma ghrelin 
(Figure 3.1) showed a non-significant trend to be different between the cycle 
stages (P=0.056), being least concentrated during proestrus. Concentrations 
of ghrelin in stomach tissue extracts were similar between each cycle stage 
(Table 3.1).
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Table 3.1. Ghrelin concentrations in fed plasma and in stomach tissue at each cycle 
stage
Stomach tissue concentrations expressed as pg per g of wet weight of tissue (WWT; number 
of rats in brackets).
Fed plasma (ng/ml) Stomach tissue (gg/g WWT)
Proestrus 202.3 ± 12.92 (14)
12.5±0.65
(12)
Oestrus 173.1 ± 12.03 (7)
14.3 ±1.20 
(11)
Metestrus 187.4 ±23.66 (6)
12.4 ±1.09 
(9)
Diestrus 160.6 + 6.85 (15)
14.4 ± 1.84 
(11)
225 i
Proestrus Oestrus Metestrus Diestrus
Figure 3.1. Ghrelin concentrations in fasted plasma at each cycle stage
(Proestrus, n=12; oestrus, n=11; metestrus, n=9; diestrus n=11).
3.4.2. Total peptide-YY (PYY) analysis
3.4.2.1. Matched fed and fasted plasma comparison 
Matched fed and fasted plasma sample analysis for the whole group found 
that PYY concentrations were significantly (f(41)=13.397, P<0.001) higher in 
the fed state (453.6 ± 20.05 pg/ml) than the fasted state (177.6 ±7.18 pg/ml).
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There was no correlation between PYY concentrations in fed and fasted 
plasma.
3A .2.2. Concentration change with cycle stage 
The concentrations of PYY in fed acidified plasma were not significantly 
different with cycle stage. Fasted non-acidified plasma concentrations of PYY 
were also not significantly different between the groups (Table 3.2).
Table 3.2. PYY concentrations in fed and fasted plasma at each cycle stage
(Number of rats in brackets).
Fed plasma 
(pg/ml)
Fasted plasma 
(pg/ml)
Proestrus 496.8 ± 55.94 (14)
176.6 ± 10.64 
(12)
Oestrus 456.0 ± 19.61 (7)
161.3 + 5.90 
(11)
Metestrus 444.8 ± 23.87 
(6)
175.5 ±6.51  
(9)
Diestrus 415.5 + 13.95 (15)
196.6 ±24.21  
(11)
Concentrations of PYY in the descending colon (Figure 3.2) did not 
significantly differ between the cycle stages due to large variations in 
concentration at each stage.
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Proestrus Oestrus Metestrus Diestrus
Figure 3.2. PYY concentrations in descending colon tissue at each cycle stage
(Proestrus, n=12; oestrus, n=11; metestrus, n=9; diestrus, n=11).
3.4.3. Total glucagon-like peptide-1 (GLP-1) peptide 
analysis
3.4.3.1. Matched fed and fasted plasma comparison 
GLP-1 concentrations in fed plasma (101.6 ± 13.15 pg/ml) were significantly 
(f(41)=5.266, P<0.001) higher than in fasted plasma (28.4 ± 15.17 pg/ml) in 
the whole group. Fed and fasted plasma GLP-1 concentrations did not 
correlate with each other.
3.4.3.2. Concentration change with cycle stage 
GLP-1 concentrations in fed acidified plasma (Figure 3.3) were significantly 
(Kruskal-Wallis, x2=7.871, 3 df, P=0.049) more concentrated in proestrus 
than in diestrus (P=0.034). Fasted non-acidified plasma concentrations of 
GLP-1 were similar at proestrus (27.9 ± 4.56 pg/ml), oestrus (29.1 ± 3.96 
pg/ml), metestrus (23.8 ± 2.90 pg/ml) and diestrus (32.0 ± 6.22 pg/ml).
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Figure 3.3. GLP-1 concentrations in fed plasma at each cycle stage
(Proestrus, n=14; oestrus, n=7; metestrus, n=6; diestrus, n=15; * P<0.05).
In descending colon tissue (Figure 3.4), GLP-1 was significantly more 
concentrated (F(3, 39)=3.921, P=0.015) at proestrus than during oestrus 
(P=0.045) and diestrus (P=0.029).
Proestrus Oestrus Metestrus Diestrus
Figure 3.4. GLP-1 concentrations in descending colon tissue at each cycle stage
(Proestrus, n=12; oestrus, n=11; metestrus, n=9; diestrus, n=11; * P <0.05).
93
3.4.4. Relationships between
GLP-1 in all animals
Plasma concentrations of both fed ( a = 0 .606 , P<0.001) and fasted (r=0.514, 
P<0.001) ghrelin were significantly positively correlated with fed plasma GLP- 
1 concentrations (Figure 3.5).
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Figure 3.5. Fed and fasted plasma ghrelin significantly correlated with fed plasma 
GLP-1
(n=43 animals at various cycle stages; *** P<0.001).
There was also a significant positive correlation between the concentrations 
of PYY and GLP-1 in descending colon tissue (a= 0.545, P<0.001; Figure 3.6).
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Figure 3.6. Descending colon PYY and GLP-1 significantly correlated with each other
(n=43 animals at various cycle stages; *** P<0.001).
3.4.5. Body and gut size of norma
female Wistar rats
At the time of culling, animals had a mean age of 38 ± 0.49 weeks (32 -  44 
weeks) and a mean body mass of 269.2 ± 2.59 g (239.6 -  303.9 g). There
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were no significant differences in age (P=0.180) or body mass (P=0.673) 
between the different groups. The mean daily food intake (see section 3.3.3) 
of all animals was calculated to be 15.5 ± 0.09 g over 26 weeks. Although 
fasted prior to dissection, a small amount of stomach contents were often 
present in these study animals (0.7 ± 0.06 g; 0.04 -  1.80 g), due to free 
access to water and ingestion of other non-food material.
Body mass did not correlate with age or body length, but significantly 
positively correlated with tissue wet weights of stomach (a=0.497, P=0.001; 
1.6 ± 0.02 g; Figure 3.7 A) and small intestine (r=0.549, P<0.001; 7.0 ± 0.12 
g; Figure 3.7 B). Mass of abdominal cavity white adipose tissue (15.1 ± 0.59 
g; Figure 3.7 C) significantly positively correlated with body mass (r=0.656, 
P<0.001).
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Figure 3.7. Correlations between body mass and gut tissue in normally cycling female 
rats
Body mass significantly correlated with (A) stomach tissue wet weight, (B) small intestine 
wet weight and (C) abdominal cavity white adipose tissue (WAT). (n=43 animals at various 
cycle stages; ** P<0.01; *** P0.001).
3.4.5.1. Physical changes that occurred by cycle stage 
As expected, no differences were found between gut measurements at each 
of the cycle stages but were established as a baseline to inform on the
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magnitude of any changes to the gut during pregnancy and lactation in 
subsequent chapters.
Intact uterus mass was found to be significantly highest at proestrus (F(3, 
39)=7.998, P<0.001), when the uterine cavity became fluid-filled (Figure 3.8 
A). Fluid in the uterus was used as an additional confirmation of successful 
proestrus identification by vaginal lavage. When corrected for individual rat 
body mass, uteri remained significantly heavier at proestrus (F(3, 39)=8.035, 
P<0.001) than at all other cycle stages.
A.
Proestrus Oestrus Metestrus Diestrus
Figure 3.8. Uteri were significantly heavier at proestrus
Uteri (not to scale) became fluid filled at proestrus (A), but not at other cycle stages (B). 
(C) Intact uterus mass corrected for individual body mass (proestrus, n=12; oestrus, n=11; 
metestrus, n=9; diestrus, n=11; * P<0.05; ** P<0.01).
Representative proestrus Representative diestrus 
uterus uterus
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3.4.5.2. Body mass and food intake
The body mass of 12 animals was recorded daily at the time of oestrous 
monitoring. Where records existed and could be followed across multiple 
cycles, 4 animals showed no observable pattern in body mass change with 
cycle stage. In another 6 animals, the stages of metestrus and diestrus 
tended to coincide with an increase in body mass, but there were always 
exceptions between cycles. For example, 1 animal tended to be lighter during 
metestrus than at other cycle stages. A total of 4 animals tended to weigh 
less during oestrus.
Figure 3.9 shows that animals dissected at metestrus had significantly (F(3, 
39)=3.187, P=0.034) more (fasted) stomach contents than those dissected at 
oestrus (P=0.028). Stomach contents data were analysed against the cycle 
stage of the preceding day as the rats were fasted from the beginning of the 
cull day (from 08.00; before lights off at 11.00), therefore analysis of stomach 
contents provided an indication of food consumption during the previous 
day/cycle stage. These results could therefore suggest that animals 
consumed the least between proestrus and oestrus and the most shortly after 
the end of oestrus leading into metestrus. Differences to the fasted stomach 
contents found between cycle stages could also indicate a different rate of 
gastric emptying, which was not measured.
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Figure 3.9. Stomach contents remaining after fasting between cycle stages
(Cull cycle stages: proestrus, n=12; oestrus, n=11; metestrus, n=9; diestrus, n=11; 
P<0.05).
3.4.6. Plasma ghrelin concentrations
age
Further analysis revealed that plasma ghrelin concentrations were affected 
by age, with animals over the age of 36 weeks having a significantly reduced 
circulating ghrelin in both the fed (F(1, 40)=101.77, P<0.001) and the fasted 
(Kruskal-Wallis, x2=25.416, 1 df, P<0.001) states (Figure 3.10 and Table 3.3). 
The older animals with less circulating ghrelin had a more significant 
correlation between fed and fasted concentrations (n= 0.619, P<0.001) than 
the younger animals (n=0.583, P=0.029). Nearly half (48.3%) of the older rat 
group had a higher fasted plasma ghrelin than fed, as expected, however 
only 35.7% of the younger animals displayed this relationship. Stomach 
tissue ghrelin concentration was not significantly different between the age 
groups (Table 3.3).
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Table 3.3. Ghrelin in plasma and in stomach tissue between two age groups
Stomach tissue concentrations expressed as pg per g of wet weight of tissue (WWT (number 
of rats in brackets).
32 -  36 weeks of age 37 -  44 weeks of age
Fed plasma ghrelin 
(ng/ml)
231.5 ±9.30 
(14)
r  154.9 ±2.77 
(28)
Fasted plasma ghrelin 
(ng/ml)
220.9 ±7.82 
(14)
151.5 ±2.45 
(29)
Stomach ghrelin 
(pg/g WWT)
15.2 ±1.58 
(14)
12.6 ±0.49 
(29)
3 0 0 -
E 250-
% 200H
£V)(0
•s0) 150—
1 0 0 —
* * * AgeSp l i t
# 3 2 - 3 6  week s  of  age 
# 3 7 - 4 4  week s  of age
•  •
v f *
• •
100 150 200 250
Fasted plasma ghrelin (ng/ml)
300
Figure 3.10. Age group differences in fed and fasted plasma concentrations of ghrelin
Fed {r= -0.730, P<0.001) and fasted (r= -0.744, P<0.001) plasma ghrelin concentrations 
significantly correlated with each other. (32-36 weeks, n=14; 37-44 weeks, n=29; ***
P< 0.001).
3.5. Discussion
This study aimed to elucidate the role of the gut hormones ghrelin, PYY and 
GLP-1 in reported changes to appetite during the oestrous cycle. This work 
was carried out prior to analysis of the changes in these hormones during 
pregnancy and lactation and is the first study to explore the concentrations of
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both fed and fasted plasma and tissue concentrations of these peptides at 
each stage of the oestrous cycle.
The concentrations of total ghrelin did not change significantly with the stage 
of the cycle in either fed or fasted plasma or in stomach tissue extract. 
Ghrelin plasma concentrations were additionally found not to be significantly 
different between the fed and the fasted state at any cycle stage, which has 
not been reported previously. Plasma ghrelin concentrations were found to 
be significantly reduced after 36 weeks of age. PYY fed and fasted plasma 
and descending colon concentrations were also not significantly different 
between the cycle stages. Fed, but not fasted, plasma concentrations of 
GLP-1 changed significantly with cycle stage and were highest during 
proestrus. Descending colon GLP-1 was also significantly highest at 
proestrus, which may suggest increased satiety leading into oestrus.
3.5.1. Orexigenic gut hormone changes during the 
oestrous cycle
Although ghrelin concentrations did not significantly change with the stage of 
the cycle in either plasma or tissue, a number of findings were still of 
importance. For example, ghrelin concentrations were unexpectedly similar 
between fed and fasted plasma samples in this study, which is discussed 
below.
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3.5.1.1. Plasma ghrelin concentrations were similar in the fed and 
fasted states
As described in Chapter 1, ghrelin is secreted from the stomach in response 
to a negative energy balance and stimulates hunger and initiates food intake, 
thus it is generally accepted and widely documented that ghrelin levels are 
higher in the fasted state (Cummings et al., 2001, Stengel et al., 2009, 
Toshinai et al., 2001, Tschop et al., 2000). In these animals, a significant 
difference between fed and fasted plasma ghrelin concentrations was not 
seen, although there was a trend for fed plasma to contain more ghrelin, 
which is the opposite of what was expected. The animals were adequately 
fasted, because PYY and GLP-1 levels were significantly lower in the fasted 
state than the fed state and act as an internal control. In addition, the animals 
lost body mass during the short fasting period which provided an additional 
confirmation of adequate fasting.
One explanation for not detecting a difference in ghrelin levels in fasted and 
fed plasma could be due to the time of day at which the samples were taken. 
In this study, animals were maintained under reverse lighting, while in many 
other studies reverse lighting has not been used. Thus the samples used in 
the present study could have been taken at more physiologically relevant 
times (i.e. during the active period) than in other studies. Furthermore, the 
vast majority of studies only take fasted plasma samples to analyse ghrelin 
concentrations, without taking the fed state into consideration at all, as one 
review clearly demonstrates (Stengel et al., 2011). Some studies even fail to 
mention whether the animals were fed or fasted when sampling occurred 
(Hosoda et al., 2000).
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Another possible reason for the difference between the present and 
previously reported results is that acidification of plasma for ghrelin stability 
(Stengel etal., 2009) preserved more of the peptide, making it more accurate
and also less comparable to studies that have not used this same technique.
-\
However, Stengel et al. did report higher acyl and total ghrelin concentrations 
in plasma from 24 hour fasted than in ad libitum fed rats in samples analysed 
with and without RAPID methodology, so this does not seem to be a likely 
explanation, although a difference in results could be due to their use of male 
Sprague-Dawley rats compared to the present study using female Wistar 
rats. Another factor is that in previous work, separate animals were used for 
the fed and fasted samples (Stengel et al., 2009), so the results from this 
present study may be different from those of others due to the use of 
matched samples.
3.5.1.2. Changes in ghrelin levels during the reproductive cycle 
In this work, fasted plasma ghrelin concentrations showed a trend (P=0.056)
to be lowest at proestrus. The possibility of a reduction in circulating ghrelin
at proestrus could contribute to a decreased food intake between proestrus
and oestrus and could be caused by the inhibitory effects of oestradiol on
ghrelin, as previously detailed (reviewed by Butera, 2010).
In order to fully elucidate the actions of ghrelin during the reproductive cycle, 
further work needs to be carried out to analyse both the acyl and the desacyl 
forms of the ghrelin peptide in these samples. Although no significant 
differences were found in plasma or stomach tissue with cycle stage, it
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remains possible that the ratio of the two different peptide forms will provide 
additional detail to this work, compared with the total amount of ghrelin 
peptide.
3.5.2. The effect of age on ghrelin concentrations
In this study, plasma ghrelin levels were found to be reduced in both the fed 
and fasted state after 36 weeks of age. One animal, aged 36 weeks, was the 
only exception and also had a low concentration of circulating ghrelin, which 
may be explained by this rat having the least amount of ghrelin peptide in her 
stomach tissue of all the study animals. It may be that this particular animal 
had naturally lower ghrelin levels than the others in this study, which is 
implied by reduced ghrelin concentrations in both plasma and the stomach, 
which is the main source of circulating ghrelin. Also of note was that the older 
animals had a much tighter correlation between their fed and fasted plasma 
ghrelin concentrations than the younger animals, although the implications of 
this are unknown at this time.
The optimal reproductive performance of laboratory rats is documented to 
begin declining from around 9 months of age (Niggeschulze and Kast, 1994, 
Suckow et ai, 2006), which is the age at which reduced ghrelin 
concentrations were measured here. Although these animals were not 
particularly old (>15 months of age before reproductive senescence), there is 
an association between a reduction in ghrelin concentrations and ageing, 
which has been linked to the condition known as anorexia of ageing. One 
study has reported a decline in plasma ghrelin with age in humans, leading to
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reduced appetite and increased frailty, particularly in female participants 
(Serra-Prat etal., 2010). However, others have reported differently, with one 
study documenting that total plasma ghrelin increased slightly with age in 
mice and that plasma acyl ghrelin also demonstrated this trend (Sun et al., 
2007). In agreement with this, another study found that calorie restriction in 
mice increased both total ghrelin levels in circulation and total ghrelin 
production in the stomach with age (Yang et al., 2007).
In addition to the above findings, fewer of the younger animals had the 
expected relationship between fed and fasted ghrelin, with only 35.7%, 
compared with nearly half of the older rats, having a higher fasted ghrelin 
concentration. These findings remain to be explained, but could indicate a 
difference in the way that ghrelin regulates appetite between the younger and 
the older animals, or that ghrelin itself was being regulated differently.
Differences in reproductive hormones due to age could be related to the 
disparity found between ghrelin concentrations in the older and younger 
animals. Oestradiol has an inhibitory effect on endogenous ghrelin 
concentrations in circulation (reviewed by Asarian and Geary, 2006, Butera, 
2010, Eckel, 2011), so declining levels of oestradiol with increasing age are 
unlikely to be responsible for the decrease in plasma ghrelin concentrations 
observed. One study in human females (Sowers et al., 2008) has shown that 
plasma ghrelin levels increased during the peri-menopausal stage. Another 
study (Soni etal., 2011) complemented these findings and demonstrated that 
women who discontinued hormone replacement therapy (oestrogen and
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progesterone; HRT) showed increased plasma ghrelin levels compared with 
the group that continued HRT treatment.
In rats, oestrogen secreted from the gastric mucosa has been shown to 
induce stomach ghrelin expression (Sakata et al., 2006), but a further study 
found that gastric oestrogen was not responsible for the fasted increase of 
ghrelin mRNA expression (Zhao et al., 2008). Further investigation into 
oestrogen concentrations in the stomachs of these study animals may 
provide insights into whether reproductive ageing causes a decrease in 
gastric oestrogen, which could in turn cause a blunted ghrelin response to 
food intake. In this study, however, it is unlikely that reproductive age was a 
factor in the profound reduction of ghrelin levels. The differences were 
documented to occur from approximately 8 to 9 months of age, but 
reproductive senescence does not occur until between approximately 15 and 
20 months of age in laboratory rats (Sengupta, 2013), which is when such 
large changes in ghrelin levels may be anticipated.
3.5.3. Anorexigenic gut hormone changes during the 
oestrous cycle
Neither fed nor fasted PYY concentration in the matched plasma samples 
fluctuated to a great extent across the cycle stages. Descending colon PYY 
concentrations also varied considerably within each group. A study in OVX 
non-human primates demonstrated that intracerebroventricular infusion of 
PYY consistently reduced daily food intake during oestrogen-only treatment 
for 2 weeks (Papadimitriou et al., 2007). Following the 2 week oestrogen
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treatment, the females were given a 2 week treatment of oestrogen plus 
progesterone, and food intake was only significantly reduced during week 1 
of this treatment. These findings suggest that PYY-induced satiety may be 
affected by cycle stage, although further work would be necessary to confirm 
this.
Both fed plasma GLP-1 and descending colon GLP-1 were significantly more 
concentrated during proestrus. Like PYY plasma concentrations, GLP-1 
plasma concentrations were also significantly reduced in the fasted state, 
which demonstrates that the animals were fasted sufficiently to produce a 
difference in these gut peptide levels. One study that quantified plasma GLP- 
1 concentrations during the menstrual cycles of lean and healthy women 
(Brennan et al., 2009) found that plasma GLP-1 was significantly decreased 
during the follicular phase of the cycle after a glucose load, but baseline 
levels were not different between the follicular and luteal phases.
Significantly increased fed plasma and descending colon GLP-1 
concentrations could have increased satiety in these animals between 
proestrus and oestrus and thus reduced food intake, which was indicated by 
reduced stomach contents at this time.
3.5.4. Food intake and body mass changes during the 
oestrous cycle
As the animals used in this study were group housed, daily food intake with 
cycle stage could not be monitored, but weighing stomach contents at
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dissection provided an indication of food and water consumption. It is well 
established that oestradiol has a marked effect on food intake in females 
(reviewed by Butera, 2010, Eckel, 2004), causing a reduction in food intake 
at oestrus in rats that follows the peak in ovarian oestradiol secretion at 
proestrus. Mass of stomach contents in these study animals indicated that 
they consumed the least during the time between proestrus and oestrus and 
the most shortly after this, which is consistent with the literature (reviewed by 
Asarian and Geary, 2006, Butera, 2010, Eckel, 2011). The decreased body 
mass that has been reported to occur at oestrus (Eckel et al., 2000) only 
presented in 4 out of the 12 rats examined in this current study, so was not 
deemed a useful addition to oestrous monitoring.
3.5.5. Oestrous monitoring technique
Despite oestrous monitoring being a widely implemented technique, there is 
little recent discussion on the best ways in which to determine cycle stage. 
For this study, vaginal lavage, alongside a record of the oestrus dance and 
subsequently the uterus mass, proved successful in determining cycle stage. 
The oestrus dance in these Wistar rats was an extremely reliable and non- 
invasive way to identify proestrus, yet this behavioural aspect of the oestrous 
cycle is not widely discussed in recent literature (Adler and Feder, 1981, 
Hardy, 1972). Some studies have specified that lordosis was used as a tool 
to monitor reproductive behaviour, for example the re-establishment of 
normal display of sexual receptivity (lordosis) after oestradiol treatment in 
OVX rats (Asarian and Geary, 2002). What the literature is lacking is study of 
the lordosis behaviour in conjunction with oestrous monitoring on ovary-intact
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rats undergoing no treatment regimen to determine the exact timing of 
behavioural oestrus in comparison to the cytological appearance of oestrus. 
In these Wistar females, behavioural oestrus occurred during proestrus, as 
described by Adler and Feder (1981), but it is possible that different strains 
present differently. In addition, no literature currently exists detailing the use 
of the oestrus dance alone as a method of proestrus identification. If 
proestrus is the only desired stage for a study, for example when proestrus 
animals are used for controls, or for an accurate time-mating system, the 
oestrus dance alone could be implemented in Wistar rats under reverse 
lighting. Oestrous monitoring using only the oestrus dance was suitable for 
regularly 4 day cycling rats here and is predicted to reduce stress in these 
animals due to minimal intervention and it would dramatically reduce analysis 
time, thus greatly refining this methodology.
3.6. Conclusions
An indication of reduced food intake between proestrus and oestrus, 
provided by the reduced stomach contents in these animals, agrees with the 
findings of others (Clegg et al., 2007, Eckel, 2004, Eckel et al., 2000). 
Supporting the theory of increased satiety during oestrus were significantly 
increased fed plasma and descending colon GLP-1 concentrations during 
proestrus. Increased satiety from GLP-1 in both plasma and gut tissue was 
found to be in parallel with a trend for ghrelin to be lowest in fasted plasma at 
proestrus. Observed changes in these gut hormone concentrations at 
proestrus, leading to reduced fasted stomach contents during oestrus, could 
contribute to the reported reduction in food intake during oestrus.
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3.7. Future work
A number of questions arise from this study. Why matched fed and fasted 
plasma ghrelin concentrations were not significantly different from each other 
remains to be established. These animals were adequately fed and fasted 
when the matched plasma samples were taken as both PYY and GLP-1 
plasma concentrations were significantly higher in the fed plasma samples. 
Further study into the ratio of acyl ghrelin to desacyl ghrelin during the cycle 
would be an informative addition to this work. Why plasma ghrelin 
concentrations significantly decreased at 37 weeks of age in these animals 
would also require further study, although this finding does indicate a more 
appropriate age for Wistar females for future studies of this nature.
109
CHAPTER 4: GUT APPETITE HORMONES AND GUT 
GROWTH DURING PREGNANCY
4.1. Introduction
Pregnancy is a time of extensive maternal adaptation in order to facilitate 
foetal growth and development and also to build energy reserves in 
preparation to meet the demands of lactation. In rats, maternal body mass 
increases throughout pregnancy, starting from as early as day 3 post­
conception (Cripps and Williams, 1975), partly resulting from increased 
accumulation of adipose tissue (Lopez-Luna et al., 1991, Pujol et al., 2006), 
which is stored ready to support lactation. One study concluded that the body 
mass increase in pregnant dams was reliant on increased food intake 
(Gualillo et al., 2002). Maternal body mass of 30% food-restricted dams 
continued to decrease until day 16 of pregnancy, after which there was a 
slight body mass recovery, but not to pre-mating ad libitum fed body mass 
(Gualillo et al., 2002). Hyperphagia during pregnancy in rodents has been 
reported to increase food intake by 20% during the first week of pregnancy 
(Crean and Rumsey, 1971, Trujillo et al., 2011), peaking at between 50% 
(Crean and Rumsey, 1971) and 60% (Cripps and Williams, 1975) by the end 
of pregnancy compared to nulliparous controls. Modulation by hormones that 
regulate appetite is thought to be a key aspect of hyperphagia during 
pregnancy, and leptin has been the most widely researched appetite 
hormone in this context. As described in Chapter 1, maternal leptin 
resistance occurs as an adaptation to pregnancy (section 1.8.3). Leptin levels
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increase in proportion to the adipose reserves accumulated during 
pregnancy, and leptin resistance develops from mid-gestation to support 
hyperphagia and allow further adipose accumulation.
4.1.1. Orexigenic gut appetite hormone changes during 
pregnancy
Ghrelin levels have been shown to be suppressed by increased leptin levels 
(Ueno et al., 2004), yet Taylor et al. (2009) demonstrated, in ad libitum fed 
pregnant rats, that total ghrelin concentrations in plasma and in some gut 
tissues were not suppressed by the increased leptin levels associated with 
mid-pregnancy.
Taylor et al. (2009) reported no significant change to plasma total ghrelin 
levels in rats during pregnancy. However, another study in rats reported that 
plasma total ghrelin decreased throughout pregnancy and was significantly 
decreased by days 10 and 15 of pregnancy, when rats are hyperphagic, with 
a recovery to control levels at day 20 (Shibata et al., 2004). An additional 
study in ad libitum fed rats reported no significant change to plasma ghrelin 
between days 8 and 21 of pregnancy (Gualillo et al., 2002), although it is 
unclear whether total, acyl or desacyl ghrelin was quantified in this study. 
Human females at 14 to 18 weeks of gestation did not have different fasted 
levels of plasma acyl ghrelin when compared to non-pregnant controls 
(Moshtaghi-Kashanian et al., 2011) and a further human study found no 
difference in acyl ghrelin throughout the first, second and third trimesters 
(Valsamakis et al., 2010). Another human study conversely found that serum
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total ghrelin concentrations peaked at mid-gestation, after which serum 
ghrelin decreased until parturition (Fuglsang etal., 2005).
As previously addressed (section 1.8.3.1), one difficulty in comparing 
measurements of ghrelin between studies is the measurement of different 
forms of the peptide. One human study measured both total and acyl ghrelin 
and reported that total ghrelin concentrations were lower at weeks 22 and 35 
of pregnancy compared with postpartum values, whilst acyl ghrelin was found 
to be significantly reduced in these women (Tham et al., 2009). It was 
calculated that acyl ghrelin only accounted for 10 to 18% of total ghrelin in 
pregnancy and 48 to 54% of total ghrelin in the postpartum period (Tham et 
al., 2009). The authors suggest that pregnancy may affect the ability of 
ghrelin O-acyltransferase to acylate ghrelin, which may be caused by insulin 
resistance.
No difference has been reported in the concentrations of stomach tissue total 
ghrelin by Taylor et al. (2009), who studied days 4, 14 and 19 of pregnancy. 
Likewise, Shibata et al. (2004) found no change in stomach tissue total 
ghrelin levels in a study involving rats at days 5, 10, 15 and 20 of pregnancy.
4.1.2. Anorexigenic gut hormone changes during 
pregnancy
Despite previously identified interactions (section 1.6.4), such as attenuation 
of levels by ghrelin (Chelikani et al., 2006), PYY and GLP-1 have been less 
well studied as gut hormones of interest during pregnancy. In one human
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pregnancy study, there was no significant difference in plasma total PYY 
between the three trimesters of pregnancy (Valsamakis et al., 2010). 
However in rats, Tovar et al. (2004) found plasma levels of total PYY to 
increase from day 16 of pregnancy and peak prior to birth. Taylor et al. 
(2009) also reported a gradual increase in plasma total PYY concentrations 
during pregnancy in rats. Additionally, gradually increasing PYY 
concentrations were found in descending, but not ascending, colon and in 
rectum tissue (Taylor et al., 2009). Why PYY, a satiety hormone, appears to 
be elevated in both plasma and tissue despite pregnancy-associated 
hyperphagia remains to be established, but it may be reasonable to assume 
a degree of PYY-resistance during pregnancy, as is seen with leptin. 
Increased levels of PYY have previously been reported to increase body 
temperature in PYY transgenic male mice (Boey et al., 2008), so 
measurement of body temperature in the current study was undertaken due 
to the expected increase in PYY levels.
4.1.2.1. Insulin resistance occurs during pregnancy
The incretin GLP-1 is involved in glycaemic control (Edwards et al., 1999),
and ensures appropriate pancreatic (3-cell insulin secretion in response to
circulating glucose (Schmidt et al., 1985). It is established in the laboratory
rat that insulin resistance develops in the latter stages of pregnancy due to
reduced tissue sensitivity to insulin (Leturque et al., 1984), similar to the
response seen in humans (Vrachnis etal., 2012).
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During insulin-resistant states, such as in type 2 diabetes and in obesity, 
GLP-1 concentrations have been found to be decreased (Muscelli et al., 
2008, Toft-Nielsen et al., 2001). However, one study reported that the active 
form of GLP-1 in plasma was significantly increased by the third trimester of 
human pregnancy, being higher than during both the first and second 
trimesters (Valsamakis et al., 2010), combined with a significantly increased 
plasma insulin concentration. Leturque et al. (1984) studied the effect that 
late-stage pregnancy (19 days pregnant) had on insulin resistance in rats, 
and determined that blood glucose concentrations were lower, yet blood 
insulin concentrations were higher in the pregnant dams versus nulliparous 
matched controls. Taken together, these results suggest an altered response 
to blood glucose at day 19 of pregnancy in rats.
GLP-1 concentrations have been rarely explored in direct relation to gut L- 
cell GLP-1 secretion, yet a study using a non-obese mouse model of insulin 
resistance demonstrated the ability of chronically elevated insulin 
concentrations to impair L-cell secretion of GLP-1 (Lim et al., 2009). Lim et 
al. (2009) also found that the insulin receptor was expressed in the L-cells of 
both their mouse model and in a human L-cell line. These findings highlight 
the importance of considering the possible changes to gut peptide levels 
when studying gut-secreted peptides, and not simply just exploring circulating 
changes.
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4.1.3. Gut growth during pregnancy
Another key aspect of maternal adaptation during pregnancy involves 
structural changes to the gut, although most studies of gut size change 
during reproductive states have mainly focussed on lactation (Campbell and 
Fell, 1964, Datta et al., 1995), and often exclusively on the small intestine 
(Burdettand Reek, 1979, Datta etal., 1995).
Although Cripps and Williams (1975) documented that neither stomach wet 
nor dry tissue mass changed during pregnancy, Crean and Rumsey (1971) 
had reported differently. Stomach tissue wet weight increased steadily 
throughout pregnancy and was significant by day 14 of pregnancy, with 
hyperplasia of the gastric mucosa also evident by this stage (Crean and 
Rumsey, 1971). These authors suggested that hyperplasia of the gastric 
mucosa is unlikely to be due to increased food intake alone, and that 
something else must be influencing mucosal growth.
Cripps and Williams (1975) reported no change in the length or dry weight of 
the small intestine of pregnant rats, but the percentage of water, and 
therefore the wet weight, significantly increased compared to control tissue. 
However, another study reported significant increases to both small intestine 
wet weight and length (Burdett and Reek, 1979), with a 30 to 40% increase in 
mucosal epithelium mass greatly contributing to the overall wet weight. Colon 
tissue was also found to be significantly longer by day 21 of pregnancy 
(Cripps and Williams, 1975).
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It is clear than the maternal adaptations to pregnancy are diverse and 
complex. The aim here was to further elucidate the possible roles of ghrelin, 
PYY and GLP-1 during pregnancy by investigating changes in both plasma 
and in gut tissues. Matched fed and fasted plasma PYY and GLP-1 levels 
during pregnancy have been measured for the first time. Comprehensive 
measurement of the gut was also performed, advancing the current literature 
of gut growth during pregnancy by examining multiple gut tissues. 
Measurement of the gut alongside both plasma and tissue peptide levels 
allows investigation into whether there is a relationship between these 
parameters. Although Taylor et al. (2009) documented changes in gut growth 
and ghrelin and PYY levels during pregnancy, the current study has looked at 
gut growth in more detail, with the addition of GLP-1 measurements and 
peptide analysis in both fed and fasted plasma. Ghrelin-immunoreactive (IR) 
cells in the stomach were also studied to provide a more complete study of 
changes to ghrelin during pregnancy. The study by Taylor et al. (2009) also 
statistically analysed the peptide levels and gut size of both pregnant and 
lactating dams as a single group, which may have masked some more subtle 
changes between the stages of pregnancy, due to more overt changes 
occurring during lactation. Analysis of pregnancy alone in the current study 
aims to provide more detail to the possible changes in peptide levels and gut 
size during pregnancy.
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4.2. Objectives
Objectives for this part of the study were:
o to investigate concentration changes of the gut appetite hormones 
ghrelin, PYY and GLP-1 at defined stages of pregnancy in Wistar rats, 
by quantification of both plasma and gut tissue concentrations;
o to explore ghrelin endocrine cell density in stomach tissue to 
determine whether any changes to plasma or stomach ghrelin levels 
between mid-pregnancy and parturition could be due to a change in 
the cell density;
o to further elucidate reported changes to gut size during pregnancy;
o to determine whether a relationship exists between any changes in 
plasma or gut hormone concentrations and changes in gut size.
4.3. Methods
4.3.1. Animals
Female Wistar rats, bred in-house, were used at days 4, 12 and 18 of 
pregnancy (n=7 per group). Females were time-mated using the oestrus 
dance for accuracy (section 2.2.1); rats displaying a regular (every 4 days) 
dance were preferentially chosen. Day 4 pregnant rats were re-checked for 
the oestrus dance prior to culling. Vaginal lavage was performed to 
determine cycle stage (section 2.2) and to confirm that the pregnant animals 
had stopped cycling. Cycle stage was determined whilst rats were under
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anaesthetic prior to the tail bleed and again the following day immediately 
after decapitation. Data from proestrus nulliparous controls were used for 
comparison purposes (n=6 unless otherwise stated). Where data are 
available, proestrus mean values have been added to figures using a dotted 
line.
4.3.2. Sample collection
Samples of gut tissue and fed and fasted plasma were taken, alongside 
multiple gut measurements, as outlined in Chapter 2 (section 2.3).
4.3.3. Measurements of food intake and body mass
Body mass was monitored daily in the early stages of pregnancy as a 
method to confirm conception. Food intake could not be determined because 
rats remained group housed until approximately 2 days before birth.
4.3.4. Peptide assays
Radioimmunoassays to determine peptide concentrations of ghrelin, PYY 
and GLP-1 in plasma and tissue extracts were performed as detailed in 
Chapter 2 (section 2.5).
4.3.5. Immunofluorescence
Immunofluorescence was performed and quantified in stomach (ghrelin) as 
described in Chapter 2 (section 2.6). For this aspect of the study, a mid-
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pregnancy time point was chosen for comparison with parturition (dOL) to 
determine whether ghrelin cell density in the stomach changed over the 
course of pregnancy, in comparison to nulliparous proestrus controls.
4.4. Results
4.4.1. Total ghrelin peptide ana
4.4. 1. 1. Concentration change with
Fasted plasma ghrelin was significantly (F(2, 18)=3.767, P=0.043; Figure 4.1) 
more concentrated in day 4 pregnant dams (d4P) than in day 18 pregnant 
dams (d18P), but not day 12 pregnant dams (d12P). All pregnant dams had 
lower fasted plasma ghrelin than proestrus controls.
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d4P d12P d18P
Figure 4.1. Ghrelin concentrations in fasted plasma during pregnancy
(n=7 per stage; * P<0.05). Dotted line shows approximate proestrus control mean.
Stomach tissue concentrations (Figure 4.2) of total ghrelin peptide did not 
significantly change with the stage of pregnancy but were reduced in
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comparison to proestrus controls. Stomach ghrelin concentrations varied 
considerably within each dam group and there was no correlation between 
the concentrations of ghrelin in fasted plasma and stomach tissue.
12 - |
d12P
Figure 4.2. Ghrelin concentrations in stomach tissue during pregnancy
(n=7 per stage). Dotted line shows approximate proestrus control mean.
4.4.2. Total peptide-YY (PYY) peptide analysis
4.4.2. 1. Matched fed and fasted pl
Comparison of PYY concentration in the matched fed and fasted plasma 
samples from the whole group showed a significant difference between the 
two samples (f(20)= -11.105, P<0.001). Unexpectedly, the mean PYY 
concentration in fasted plasma (245.9 ± 16.03 pg/ml) was significantly higher 
than in fed plasma (71.9 ± 2.22 pg/ml), which is the opposite of what was 
found in Chapter 3 (likely due to method differences; see section 4.5.2).
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4.4.2.2. Concentration change with pregnancy stage 
Neither fed nor fasted plasma PYY were significantly different between the 
pregnant dam groups (Table 4.1). Fasted plasma PYY concentrations were 
all higher than in proestrus controls (172.0 ±11.84 pg/ml).
Table 4.1. PYY concentrations in fed and fasted plasma during pregnancy
(n=7 per stage).
Fed plasma 
(pg/ml)
Fasted plasma 
(pg/ml)
d4P 74.9 ± 4.03 (53.1 -8 5 .8 )
225.3 ± 12.90 
(185.5-272.5)
d12P 67.7 ±2.17  (58.6 -  75.0)
265.1 ±37.74  
(177.4-480.5)
d18P 73.1 ±4.85 247.1 ±29.10(59.1 -9 9 .5 ) (206.0-419.9)
Ascending colon (Figure 4.3 A) and descending colon (Figure 4.3 B) tissue 
concentrations of PYY also did not change with the stage of pregnancy, and 
concentrations varied considerably within each group. Ascending colon was 
not analysed for peptide concentrations in proestrus animals, but descending 
colon PYY concentrations in proestrus controls were 58% lower than in the 
d18P dams. PYY concentrations were not different between the ascending 
and descending colon in these pregnant dams, although in d12P dams there 
was a tendency (P=0.063) for the ascending colon to have a higher PYY 
content than in the descending colon.
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Figure 4.3. PYY concentrations in colon tissue during pregnancy
(A) ascending colon and (B) descending colon concentrations (n=7 per stage). Dotted line 
shows approximate proestrus control mean.
4.4.3. Total glucagon-like peptide-1 
analysis
4.4.3. 1. Matched fed and fasted pl
GLP-1 concentrations were 26 times higher (f(20)=7.463, P<0.001) in fed
plasma (164.7 ± 21.4 pg/ml) than in paired fasted plasma (6.3 ±1.13 pg/ml)
for the whole group.
4.4.3.2. Concentration change with pregnancy stage 
The concentration of GLP-1 in fed plasma was not significantly different 
between the sample groups (Figure 4.4) but was elevated 2 to 4 times during 
pregnancy compared to proestrus nulliparous controls.
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Figure 4.4. GLP-1 concentrations in fed plasma during pregnancy
(n=7 per stage). Dotted line shows approximate proestrus control mean.
Fasted plasma GLP-1 concentrations, however, were approximately 2 to 7 
times lower at each stage of pregnancy than in the proestrus controls. Fasted 
plasma GLP-1 was significantly decreased with pregnancy (F(2, 18)=3.664, 
P=0.046), with a trend (P=0.057) for d18P dams to have less fasted plasma 
GLP-1 than d4P dams (Figure 4.5).
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Figure 4.5. GLP-1 concentrations in fasted plasma during pregnancy
(n=7 per stage). Dotted line shows approximate proestrus control mean.
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GLP-1 concentrations in ascending colon tissue were not homogeneous so 
the data were transformed by a log conversion. Log of ascending colon GLP- 
1 concentrations (Figure 4.6 A) was significantly different between the 
pregnant dams (F(2, 18)=3.919, P=0.039). D18P dams had twice the 
concentration of ascending colon GLP-1 than d12P dams, although this was 
not significant (P=0.051). Descending colon tissue concentrations of GLP-1 
were not significantly different with pregnancy stage (Figure 4.6 B), but were 
approximately 2 to 4 times higher than in proestrus controls.
Ascending colon concentrations of GLP-1 were significantly higher than in 
descending colon tissue in d4P (f(6)=5.224, P -0.002), d12P (f(6)=4.466, 
P=0.004) and d18P (f(6)=4.234, P=0.005) dams.
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Figure 4.6. GLP-1 concentrations in colon tissue during pregnancy
(A) ascending colon and (B) descending colon concentrations (n=7 per stage). Dotted line 
shows approximate proestrus control mean.
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4.4.4. Total ghrelin-immunoreactive
Ghrelin-immunoreactive (IR) cells (Figure 4.7) in stomach tissue were found 
throughout the mucosa, predominantly so in the basal half of the mucosa, in 
all groups.
Luminal
Basal
Day of birthDay 12 pregnant
Figure 4.7. Ghrelin-immunoreactive cells in stomach tissue during different 
reproductive stages in female rats
Representative images of ghrelin immunoreactivity in stomach tissue of a proestrus 
nulliparous control rat, a day 12 pregnant dam and a dam on the day of birth. (Scale bars: 
200 pm; tissue presented with luminal edge of mucosa at the top of each image).
Table 4.2. Stomach tissue measurements during different reproductive stages in 
female rats
Mean measurements of mucosal area and the mean maximum mucosal and muscle 
thickness of stomach tissue sections (n=6 proestrus, n=7 day 12 pregnant and day 0 
lactating).
Mucosal area 
(mm2)
Mucosal thickness 
(mm)
Muscle thickness 
(mm)
Proestrus 11.2 ±0.83 (8 .7 -1 4 .5 )
0.8 ±0.06 
(0 .6 -1 .0 )
0.6 ±0.04 
(0 .5 -0 .8 )
d12P 10.9 ±0.50 (8 .4 -1 2 .8 )
0.8 ±0.04 
(0 .7 -1 .0 )
0.5 ±0.03 
(0 .4 -0 .7 )
dOL 11.2 ±0.53 (9 .0 -1 3 .2 )
0.8 ±0.03 
(0 .7 -0 .9 )
0.5 ±0.02 
(0 .5 -0 .6 )
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There was no difference in the mucosal area of the stomach sections 
analysed for proestrus controls, d12P and dams on the day of birth (dOL) 
(Table 4.2). The mean maximum mucosal and muscle thickness was also not 
different between the sample groups (Table 4.2). The ghrelin-IR cell density 
was significantly different between the sample groups (F(2, 17)=29.735, 
P<0.001) and increased significantly from the proestrus controls to 
pregnancy, and dams in the transition stage of parturition had a significantly 
higher ghrelin cell density than in both the other sample groups (Figure 4.8). 
Dams after parturition had more than double the ghrelin-IR cell density than 
proestrus controls.
Proestrus d12P
Figure 4.8. Ghrelin cell density during different reproductive stages in female rats
(n= 6 proestrus controls; n=7 day 12 pregnant and day 0 lactating dams; ** P<0.01; *** 
P<0.001).
4.4.5. Changes to b o d y  and g u
At the time of culling, the mean age of all animals used in this part of the 
project was 30 ± 0.68 weeks (24 -  36 weeks). Body mass of the d4P dams 
(Figure 4.9), recorded prior to the short period of fasting, was comparable
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with proestrus controls. As expected, body mass significantly increased (F(2, 
18)=12.565, P<0.001) with the advancing stages of pregnancy. Despite an 
observation that dams consumed less food and water in later stages of 
pregnancy, d18P dams lost significantly less body mass after fasting (F(2, 
18)=6.904, P=0.006) than d12P dams (P=0.005; Table 4.3).
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Figure 4.9. Fed state body mass during pregnancy
(n=7 per stage; ** P<0.01; *** P<0.001). Dotted line shows approximate proestrus control 
mean.
Table 4.3. The percentage of body mass lost during the fasting period in pregnant rats
(n=7 per stage; c>d, P<0.01).
Body mass lost on fasting (%)
d4P 2.7 ±0.33(1 .5 -4 .4 )
d12P 3.9 ± 0.65 c (2 .4 -6 .7 )
d18P 0.6 ± 0.82 d (-1 .3 -6 .7 )
Body mass was closely monitored in d4P dams to confirm pregnancy. There 
was a significant change (t{6)= -0.106, P<0.001) between the pre-mating
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body mass (253.9 ± 6.43 g) of the d4P group and their body mass at d3P 
(266.8 ± 7.58 g), both recorded prior to the fasting period.
Mass of abdominal cavity white adipose tissue (WAT) was significantly 
greater (F(2, 18)=6.248, P=0.009) in d18P dams than in d4P (P=0.034) and 
d12P (P=0.010) dams (Figure 4.10). Proestrus controls had less abdominal 
WAT than d18P dams.
c 10
d4P d12P d18P
Figure 4.10. Abdominal cavity white adipose tissue (WAT) during pregnancy
(n=7 per stage; * P<0.05). Dotted line shows approximate proestrus control mean.
Anaesthetised rectal temperature was significantly different between 
pregnancy stages (F(2, 18)=9.065, P=0.002) and d12P dams had a 
significantly higher temperature than both d4P (P=0.017) and d18P 
(P=0.002) dams (Figure 4.11).
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d4P d12P d18P
Figure 4.11. Anaesthetised rectal temperature during pregnancy
(n=7 per stage; * P <0.05; ** P<0.01).
Mean stomach tissue mass did not change throughout pregnancy (Figure 
4.12) and was similar to proestrus controls.
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Figure 4.12. Stomach tissue wet weight during pregnancy
(n=7 per stage). Dotted line shows approximate proestrus control mean.
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D18P dams had significantly heavier (F(2, 18)=4.782, P=0.022; Figure 4.13
A) and longer (F(2, 18)=5.365, P=0.015; Figure 4.13 B) small intestines than 
d4P dams. The small intestine of d18P dams also showed a trend (P=0.051) 
to be longer than in d12P dams. Small intestine lengths of d4P dams were 
comparable to those of proestrus controls, with no control data available for 
tissue mass.
5  40
& 20
d4P d12P d18P d4P d12P d18P
Figure 4.13. Small intestine size during pregnancy
(A) small intestine wet weight and (B) length (n=7 per stage; * P<0.05). Dotted line shows 
approximate proestrus control mean.
The wet weight of caecum tissue did not change significantly with the stage 
of pregnancy (Figure 4.14).
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Figure 4.14. Caecum tissue wet weight during pregnancy
(n=7 per stage).
Large intestines of d18P dams were significantly heavier (F(2, 18)=7.931, 
P=0.003) than the d4P (P=0.003) and d12P (P=0.046) groups (Figure 4.15
A). Large intestines were significantly (F(2, 18)=5.506, P= 0.014) shorter in 
d12P dams than in d4P (F=0.044) and d18P (F=0.017) dams (Figure 4.15
B). Proestrus controls had large intestine lengths (n=4) similar to the 
pregnant dams.
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Figure 4.15. Large intestine size during pregnancy
(A) large intestine wet weight and (B) length during pregnancy (n=7 per stage; * P <0.05; ** 
P<0.01). Dotted line shows approximate proestrus control mean.
Gut circumferences were not significantly different between the groups in 
duodenum or descending colon tissue (Figure 4.16). However, ascending 
colon circumference was significantly larger (F(2, 18)=3.953, P=0.038) in d4P 
dams compared with d12P dams (P=0.033). Gut circumference 
measurements taken in proestrus controls show that only descending colon 
circumference was similar to the pregnant dams, with duodenum and 
ascending colon circumferences in proestrus controls being much smaller 
than in all of the pregnant dams.
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Figure 4.16. Circumferences of duodenum, ascending colon and descending colon 
during pregnancy
(n=7 per stage; * P<0.05). Dotted lines show approximate proestrus control means.
4.4.5.1. Mass of gut contents
The mass of gut contents from various gut locations (section 2.4.1) were all 
significantly different between the sample groups (Table 4.4). Significantly 
more stomach contents (F(2, 18)=4.686, P=0.023) were found in d12P dams 
than in d4P dams (P=0.019). More stomach contents were present at all 
stages of pregnancy compared to proestrus controls (0.5 ±0.15 g). The pH of 
the stomach contents was not significantly different between the d4P (pH 4.0 
± 0.49), d12P (pH 3.8 ± 0.71) and d18P (pH 4.0 ± 0.36) dams.
The data for small intestine contents were log transformed for parametric 
statistical analysis. D18P dams had significantly (F(2, 18)=10.310, P=0.001) 
more small intestine contents than both d4P (P=0.001) and d12P (P=0.018) 
dams (Table 4.4).
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D18P dams had significantly (F(2, 18)=4.827, P=0.021) more contents in 
their caecum than d12P dams (P=0.017) and the pH of the caecum contents 
(Table 4.4 and Figure 4.17) in d18P dams was significantly (F(2, 18)=8.592, 
P=0.002) more alkaline than in d12P dams (P=0.002).
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Figure 4.17. Caecum contents pH during pregnancy
(n=7 per stage; ** P<0.01).
D18P dams also had significantly (F(2, 18)=6.251, P=0.009) more contents in 
their large intestines than d12P dams (P=0.007).
Table 4.4. Gut contents mass during pregnancy
(n=7 per stage; a>b, P<0.001; c>d, P<0.01; e>f, P<0.05, within columns).
Stomach 
contents (g)
Small 
intestine 
contents (g)
Caecum 
contents (g)
Large 
intestine 
contents (g)
d4P 1.2 ±0.24 r (0 .5 -2 .1 )
1.9 ± 0.14 
(1 .4 -2 .3 )
3.3 ±0.28 
(2 .0 -4 .2 )
2.0 ±0.23 
( 1.3 - 2 .7 )
d12P 2.2 ± 0.13 e (1 .7 -2 .7 )
2.3 ± 0 .2 2 ' 
(1 .5 -3 .3 )
2.8 ± 0 .16 ' 
(2 .3 -3 .5 )
1.1 ± 0.54 d 
(0 .0 -1 .8 )
d18P 1.6 ±0.25 (0 .8 -2 .5 )
3.4 ± 0.37 ae 
(2 .2 -4 .9 )
4.2 ± 0.43 e 
(2 .3 -5 .6 )
2.5 ± 0.32 c 
(1 .5 -3 .8 )
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4.5. Discussion
This study was the first to analyse the concentrations of ghrelin, PYY and 
GLP-1 during pregnancy in plasma and in gut tissues. This study also 
provided, for the first time, matched information about changes to Gl tissue 
size alongside ghrelin, PYY and GLP-1 plasma and tissue concentrations.
The main findings of this study were that concentrations of ghrelin and GLP-1 
were significantly different between the stages of pregnancy studied, in 
several of the samples analysed. Both fasted plasma ghrelin and GLP-1 
concentrations significantly decreased during pregnancy. GLP-1 
concentrations in ascending colon significantly increased during pregnancy. 
This suggests that there may be a change in the usual mechanisms of 
hormonal control of appetite, which increases during the late stages of 
pregnancy. This study also reported significant increases to small and large 
intestine tissue mass and length during pregnancy and further explored 
changes to gut size during pregnancy, as previously reported by others 
(Burdett and Reek, 1979, Crean and Rumsey, 1971, Cripps and Williams, 
1975).
4.5.1. Orexigenic gut hormone changes during pregnancy
Ghrelin stimulates appetite and appetite is documented to increase by 
around 60% by late pregnancy in rats (Cripps and Williams, 1975), so one 
may expect ghrelin levels to increase during pregnancy to facilitate increased 
food consumption. In this study however, fasted plasma ghrelin
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concentrations were found to significantly decrease between d4P and d18P, 
which is consistent with another rat study (Shibata et al., 2004) and human 
studies (Fuglsang et al., 2005, Tham et al., 2009) discussed previously 
(section 4.1.1). Taylor et al. (2009) reported no significant change to plasma 
total ghrelin concentrations, although differences between pregnant dams 
may have been missed due to the statistical analysis of both pregnant and 
lactating dams together, whereas this study has examined them separately.
Determining the concentration of circulating leptin would also be of interest 
for further analysis of plasma ghrelin concentrations throughout pregnancy. 
The abdominal cavity white adipose tissue in the animals studied here 
increased significantly with pregnancy, so it may be reasonable to assume 
that leptin levels also increased in these animals as described in other rodent 
studies (Shibata et al., 2004, Taylor et al., 2009, Trujillo et al., 2011), due to 
the established positive correlation between leptin and total adiposity 
(reviewed by Friedman, 2011, Ladyman et al., 2010). Increased levels of 
leptin in pregnancy have also been implicated in a successful outcome of the 
pregnancy (French et al., 2009). Previous studies have demonstrated a 
reciprocal relationship between ghrelin and leptin (section 1.8.3). One study, 
mentioned earlier, reported that ghrelin injection failed to induce feeding in 
male mice over-expressing the leptin gene in their hypothalamus 
(recombinant adeno-associated virus delivery) despite elevated plasma 
ghrelin levels, demonstrating that leptin can attenuate the feeding initiation 
effects of ghrelin (Ueno et al., 2004). Another study demonstrated the ability 
of ghrelin to abolish leptin-induced satiety in rats (Shintani et al., 2001).
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These authors reported that whilst intracerebroventricular injection of leptin 
reduced food intake of male rats in a dose-dependent manner, co-injection of 
leptin with ghrelin increased food intake dose-dependently. Increased ghrelin 
mRNA in the stomach has also been observed after chronic leptin 
administration (Toshinai et al., 2001). If leptin concentrations did increase in 
this study between each stage of pregnancy, a gradual reduction in plasma 
ghrelin concentrations could be due to suppression by increasing leptin 
levels. It is clear that more work is required to establish the relationships 
between leptin and ghrelin, but this was not a focus of this current research.
4.5.2. Anorexigenic gut hormone changes during 
pregnancy
GLP-1 levels are known to be decreased in insulin-resistant states, such as 
in diabetic and obese states (Lim et al., 2009, Muscelli et al., 2008, Toft- 
Nielsen etal., 2001). A level of pregnancy-associated insulin resistance could 
therefore explain the significant difference in fasted plasma GLP-1 between 
the pregnant groups, with a trend for decreased fasted plasma GLP-1 
between d4P and d18P.
In ascending colon tissue, GLP-1 was significantly different between the 
pregnant groups, with a non-significant trend to be higher in d18P dams 
compared with d12P dams. This is the opposite of GLP-1 concentrations in 
fasted plasma, which decreased with pregnancy duration. One group have 
shown (Lim etal., 2009) that high concentrations of insulin can directly impair 
the ability of L-cells to secrete GLP-1 both in vitro and in vivo. For this
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reason, one would expect that d18P dams with high insulin levels, presumed 
to be more insulin resistant than d4P dams, to have a low GLP-1 
concentration in colon tissue in addition to low levels of circulating GLP-1. 
Why GLP-1 showed a trend to be more concentrated at d18P than d4P in 
ascending colon tissue remains to be seen. Due to the measurement of total 
GLP-1 in this study, this result cannot be due to an alteration in GLP-1 
degradation once it reaches the circulation. One possibility could be a 
proliferation of the GLP-1 producing L-cell population as a result of gut 
growth, as d18P dams were found to have significantly heavier large intestine 
wet weights than at all other stages of pregnancy and significantly longer 
large intestines than d12P dams. Unfortunately data for the number of GLP- 
1-IR cells in the colon are not available to confirm whether gut growth 
increased the number of GLP-1 cells in the colon, which could in turn be 
responsible for increased tissue concentration of GLP-1.
PYY levels in fed and fasted plasma were not different during the stages of 
pregnancy studied, in agreement with Valsamakis et al. (2010), although 
other studies have reported that total PYY plasma concentrations increase 
with pregnancy (Taylor et al., 2009, Tovar et al., 2004).
Unexpectedly, fasted plasma PYY concentrations in this part of the study 
were higher than those of fed plasma PYY. Previous work (Chapter 3) found 
PYY to be highest in fed plasma. For the samples analysed in this chapter, 
all of the fed plasma was acidified and vacuum centrifuged (RAPID 
methodology, section 2.3.2.1) to be reconstituted when required, whereas for
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the samples analysed in Chapter 3, acidified plasma was not dried down 
prior to analysis. It is possible that reconstituting dried-down fed acidified 
plasma in distilled water back to its pre-buffer volume was not sufficient to re­
suspend all of the PYY into solution. If so, this discrepancy has prevented a 
direct comparison between the fed and fasted plasma PYY concentrations, 
however concentration changes between sample groups were still explored 
separately as all samples of fed plasma and all samples of fasted plasma 
were treated in the same way.
4.5.3. Enteroendocrine cell analysis
The density of ghrelin-IR cells was found to significantly increase as the dam 
physiology transitioned from pregnancy to parturition, despite there being no 
difference in stomach ghrelin concentration during pregnancy. It is possible 
that if additional samples had been taken daily approaching parturition, an 
increasing number of ghrelin-IR stomach cells leading up to parturition may 
have been seen. It could be hypothesised that an increase in stomach 
ghrelin-IR cells increases ghrelin production within the stomach, ready for 
release into the circulation around the time of birth to initiate the hyperphagia 
reported to occur in lactation (Cripps and Williams, 1975, Denis etal., 2004).
4.5.4. Body and gut size change with pregnancy
Pregnant rats in this study were found to have significantly increased body 
mass by day 3 of pregnancy, which is in agreement with Cripps and Williams 
(1975). The mass of abdominal cavity white adipose tissue (WAT) had also
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significantly increased by d18P compared with both d4P and d12P, matching 
what has been previously described about increased adipose tissue 
accumulation during pregnancy (Lopez-Luna et al., 1991, Pujol et al., 2006), 
facilitated by hyperphagia. Dams were group housed until near parturition 
and so an accurate measure of individual food intake was not possible, but 
an estimation was made using the mass of stomach contents that remained 
after a short period of fasting. D12P dams had significantly more fasted 
stomach contents than d4P dams, and all of the pregnant dams had more 
stomach contents remaining than proestrus controls. This finding could infer 
pregnancy-associated hyperphagia in the pregnant dams, which has been 
reported by others (Crean and Rumsey, 1971, Cripps and Williams, 1975, 
Trujillo et al., 2011), with dams drinking more or eating bedding due to 
increased hunger.
Anaesthetised rectal temperature of the dams was significantly decreased at 
d4P and d18P in comparison with d12P dams. One study of 24 hour core 
temperature in rats found a significant decrease in body temperature from 
d15P onwards and that core temperature was lowest in d20P dams (Fewell, 
1995). Fewell (1995) did not study dams prior to d10P, so it is not possible to 
compare those data with the significant increase in rectal temperature seen 
between d4P and d12P in the current study. However, a significant decrease 
in rectal temperature between d12P and d18P reported here agrees with the 
results of Fewell (1995). PYY transgenic male mice fed a high fat diet have 
been found to have significantly higher rectal temperatures than control mice 
on the same diet (Boey et al., 2008). These authors have suggested that high
140
levels of PYY has a protective effect against obesity, due to a concomitant 
decrease in adiposity, and that PYY does so by affecting thermogenesis. 
However, in the present study, no significant changes in either circulating or 
colon PYY levels were noted, despite significant pregnancy-associated 
changes in rectal temperature. It is possible that the use of rats, females or 
the pregnant state is responsible for the differences seen between the 
current study and that of Boey et al. (2008).
No difference was found in either stomach or caecum tissue mass in this 
study, which is consistent with the study by Cripps and Williams (1975), 
although their data only included one pregnancy time point (d12P to d15P) in 
comparison to controls. Crean and Rumsey (1971), however, had reported 
differently, and found stomach mass steadily increased with pregnancy stage 
in Wistar females, which reached significance by d14P. The difference in 
stomach mass reported between the current study and that of Crean and 
Rumsey (1971) is likely due to method differences, as stomachs were fixed 
before weighing in their study.
In this work, it was found that both the wet weight and length of the small 
intestine were significantly increased between d4P and d18P, by 20% and 
15% respectively. Here, it is suggested that the increase in small intestine 
size is an adaptation to increase the absorption of nutrients to support the 
dam in developing adequate adipose reserves (Lopez-Luna et al., 1991, 
Pujol et al., 2006) ready to support lactation. Cripps and Williams (1975), 
however, reported no change to small intestine length at mid-pregnancy
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(d12P to d15P) in Sprague-Dawley dams compared with nulliparous controls. 
These authors did find small intestine wet weight (but not dry weight) to be 
significantly increased (19%) by parturition, which is similar to the difference 
reported here between early and late pregnancy. Another study (Burdett and 
Reek, 1979) reported a significant increase in small intestine length (13%) 
and wet weight (41%) by late pregnancy (d18P to d20P) in Sprague-Dawley 
dams compared to controls, but did not look at any other gut areas.
This chapter also reported that large intestine mass significantly increased 
with pregnancy, although length was similar between d4P and d18P dams. 
Cripps and Williams (1975) documented the opposite, with a significant 
increase in length, but not tissue mass, in mid-pregnancy compared to 
nulliparous controls. Both Cripps and Williams (1975) and Burdett and Reek 
(1979) measured intestine length vertically, allowing the tissue to hang under 
its own weight, which may have caused the tissue to stretch. This current 
study standardised measurement by free-floating the gut tissue in PBS to 
prevent tissue stretching. It is possible that the differences reported in colon 
length between this study and Cripps and Williams (1975) is due to this 
method difference.
This work has provided additional information to previously reported gut size 
changes in pregnancy by measurement of gut circumference, which has not 
previously been reported. Although neither duodenum nor descending colon 
circumferences were found to be different between the stages of pregnancy, 
ascending colon circumferences were significantly different between the
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groups. This study has led to the suggestion that changes in circumference in 
different areas of the gastrointestinal tract may be an additional maternal 
mechanism to support pregnancy, increasing the capacity of the gut and 
possibly altering gut transit times in order to adapt to increasing nutrient 
requirements. Further study would be necessary to confirm this possibility. It 
was also interesting to note that d4P dam group tended to have the largest 
mean gut circumferences in the duodenum, ascending colon and descending 
colon compared with other pregnant dams and proestrus controls. These 
data could suggest an early maternal adaptation to increase gut capacity to 
accommodate increased food intake and possibly to optimise nutrient and 
water absorption prior to the occurrence of gut lengthening later on in 
pregnancy, which is expected to increase gut surface area.
Measurement of remaining gut contents offered an insight into gut transit 
times, because the dams were fasted for a short period prior to culling. Dams 
at d18P had significantly more contents in the small intestine than d4P dams, 
and significantly more contents in the caecum and large intestine than d12P 
dams. Thus, it is possible that gut transit was slower in the later stages of 
pregnancy, as has been documented by others (reviewed by Cullen and 
O'Donoghue, 2007).
4.5.5. Refinement of time-mating procedure
Implementing the oestrus dance to time-mate the pregnant dams was very 
successful and a distinct refinement of the time-mating procedure. Out of a 
total of 48 rats that were time-mated using only the oestrus dance, all 48
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successfully conceived. This greatly reduced the number of animals required 
for a study relying on time-mated animals for the early stage of d4P. It is 
common for numerous dams to be time-mated for each study dam required, 
which allows for the possibility of dams not conceiving. A commonly used 
method for time-mating is to use a minimum of 5 females for each dam 
required, and proven breeders will nearly always be used (Barnett, 2007). 
For this study, only the number of nulliparous females required for pregnancy 
time-points were mated, which greatly reduced and refined common practice, 
without the need to disturb the dams by either oestrous monitoring or to 
check for the appearance of a vaginal plug for mating confirmation.
4.6. Conclusions
This study explored the interactions of both fed and fasted plasma and tissue 
concentrations of appetite hormones during pregnancy in Wistar rats, and 
further elucidated previously reported changes to dam Gl physiology. This 
study is novel in the extensive number of gut areas examined for changes in 
size, mass and circumference at different stages of pregnancy and in the 
addition of GLP-1 measurements alongside ghrelin and PYY.
Fasted plasma GLP-1 and ghrelin were found to be significantly decreased in 
late pregnancy, whereas ascending colon concentration of GLP-1 was 
significantly increased. Why there was a difference between the changes in 
tissue and circulating levels of GLP-1 remains to be established, but it is 
possibly associated with an increase in Gl size during pregnancy. Although 
fasted plasma ghrelin significantly decreased with the stage of pregnancy,
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with no change in stomach tissue ghrelin concentration, the density of 
stomach ghrelin-IR cells was significantly increased between d12P and 
control dams. From this study, it is thought that an increase in the number of 
stomach ghrelin cells may be an important maternal adaptation prior to 
lactation, in readiness to help create a hyperphagic state after parturition to 
support lactation.
One aim of this study was to further explore when increases to gut size begin 
to occur in preparation to support lactation. Small and large intestine lengths 
and small intestine tissue mass increased steadily throughout the stages of 
pregnancy studied, reaching significance by d18P. Taken together, these 
results suggest that by d18P, the maternal gut is actively adapting to the 
pregnant state and is already hypertrophic, as is documented by others to 
occur during lactation (Burdett and Reek, 1979, Campbell and Fell, 1964, 
Crean and Rumsey, 1971, Cripps and Williams, 1975, Datta etal., 1995).
4.7. Future work
Future work to quantify GLP-1-IR cells in the colon would aim to further 
investigate whether the increased GLP-1 concentration seen locally within 
the colon is due to an increased number of GLP-IR cells. One avenue for 
future analysis on samples from this study could be to determine the 
concentrations of acyl and desacyl ghrelin to determine whether the 
significant decrease found in plasma total ghrelin was initially driven by a 
decrease in ghrelin acylation by ghrelin O-acyltransferase as has been 
suggested by others (Tham et al., 2009). Stomach tissue concentration of
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ghrelin did not change significantly through pregnancy, which is in agreement 
with others (Shibata etal., 2004, Taylor et al., 2009).
In addition to the above, investigation of gut dry weights as well as gut wet 
weights may further clarify the process of gut growth during pregnancy. A 
difference was found between the current study and what was reported by 
Cripps and Williams (1975), in the increase in wet weight of colon tissue 
during pregnancy. Thus it may be worth replicating the study with the addition 
of dry gut weights to examine the process of maternal gut adaptations in 
further detail.
From this work, it is unclear whether a relationship exists between peptide 
concentrations and gut growth, as gut growth was only found to occur 
significantly by the last stage of pregnancy studied here. Further work 
studying additional late pregnancy time points may further elucidate this 
possible connection.
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CHAPTER 5: GUT APPETITE HORMONES AND GUT 
GROWTH DURING LACTATION
5.1. Introduction
Multiple maternal changes take place in the early stages of lactation, 
enabling adaption to the physical demands of the lactation period. Body 
mass rapidly recovers after birth in rats, increasing beyond both control and 
early to mid pregnancy values. Cripps and Williams (1975) reported 
significant body mass gains from the third day of lactation in rats compared to 
nulliparous controls, with body mass remaining constant from day 12 of 
lactation. Maternal food intake during lactation in rats is reported to peak 
during the third week of lactation to approximately 250 to 300% that of 
nulliparous controls (Crean and Rumsey, 1971, Cripps and Williams, 1975, 
Denis et al., 2004). Hyperphagia during lactation may be, in part, supported 
by a significant reduction of leptin levels, which is associated with a 
significantly decreased maternal adipose pad mass by day 15 of lactation 
compared to nulliparous controls (Woodside et al., 2000). It has been 
documented that there is an approximate 60% loss of maternal whole body 
adipose tissue by day 16 of lactation in comparison with values obtained at 
day 2 of lactation, and this occurred on both a high and low protein maternal 
diet (Naismith et al., 1982). As diet did not affect adipose tissue utilisation, 
this finding suggested that hyperphagia during lactation was not entirely 
under dietary control, implicating appetite-regulatory hormones.
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There have been fewer studies documenting the role of gut appetite 
hormones during lactation compared to during pregnancy (Chapter 4). Many 
studies focus on the effects of maternal diet in the offspring, with metabolic 
programming during the early postnatal period being a key focus of this 
research area (see section 1.8.1 and additional reviews by Innis, 2011, 
Martin-Gronert and Ozanne, 2010, Singhal and Lanigan, 2007).
5.1.1. Orexigenic gut hormone changes during lactation
Shibata et al. (2004) documented that plasma total ghrelin levels were similar 
between dams at days 3 and 8 of lactation, but were significantly lower than 
at day 20 of pregnancy. These authors also reported that ghrelin mRNA 
levels in the hypothalamus tended to be decreased in lactation compared to 
during pregnancy, suggesting a systemic reduction in ghrelin levels after 
birth. In another rat study, plasma acyl ghrelin levels were found to be 
unchanged at days 5 and 15 of lactation compared to nulliparous controls 
(Suzuki et al., 2014). Total ghrelin levels were measured by Taylor et al. 
(2009) in lactating rats and there was no difference between the groups in 
either plasma or stomach tissue levels. However in that study, stomach total 
ghrelin levels were significantly lower by day 25 of lactation (5 days after 
weaning) than they had been during pregnancy and in the nulliparous 
controls, which may suggest a post-lactation normalisation in appetite 
regulation.
In humans, llcol and Hizli (2007) found that serum total ghrelin levels were 
lowest at the onset of lactation (0 to 3 days postpartum) and rapidly
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increased between days 4 and 14 of lactation before a gradual decrease 
throughout the remainder of the lactation period (180 days, study end). The 
same authors also measured acyl ghrelin levels in serum which, conversely 
to total ghrelin levels, were highest at the start of lactation before a significant 
decrease during the rest of lactation. A study in lactating sows similarly 
documented that plasma acyl ghrelin levels decreased steadily during 
lactation, and were significantly reduced compared with the acyl ghrelin peak 
at day 30 of an approximate 114 days of pregnancy (Govoni et al., 2007). 
However, an additional human study found that acyl plasma ghrelin levels 
increased between days 1, 10 and 15 of lactation, but remained lower than 
non-lactating age-matched control women at each stage (Aydin et al., 2006). 
The differences between these two human studies could be due to one study 
measuring acyl ghrelin levels in serum (llcol and Hizli, 2007) and the other in 
plasma (Aydin et al., 2006), making direct comparisons difficult. In summary, 
ghrelin levels in rats have been found to decrease or remain unchanged, and 
in humans, levels appear to briefly peak early on and then decrease during 
lactation. Ghrelin levels appear to be lower during lactation than during 
pregnancy (Govoni etal., 2007, Shibata etal., 2004).
5.1.2. Anorexigenic gut hormone changes during 
lactation
There are limited data available on possible changes in the concentrations of 
maternal PYY during lactation, with no studies to date exploring circulating or 
gut tissue concentrations of GLP-1 during lactation. Taylor et al. (2009) 
reported significantly increased plasma total PYY levels at day 5 of lactation,
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in rats when compared to nulliparous controls, which was paralleled by 
significantly increased descending colon and rectum tissue PYY levels, but 
no change to the levels in ascending colon tissue. Another study in lactating 
rats reported significantly increased plasma total PYY at day 5 of lactation, in 
conjunction with a significant increase in hypothalamic PYY mRNA at both 
days 5 and 15 of lactation compared to nulliparous controls (Suzuki et al., 
2014), so it seems possible that elevated PYY plays an important role in rats 
at day 5 of lactation.
5.1.3. Maternal gut growth during lactation
Chapter 4 reported findings similar to the work of others (Burdett and Reek, 
1979, Crean and Rumsey, 1971, Cripps and Williams, 1975) in that there 
was significant gut growth by the later stages of pregnancy in rats. Growth of 
the maternal gut during the lactation period was once a focus of this earlier 
research, after observations that the small intestine in particular increases in 
size.
Significant increases in both stomach wet and dry weights have been 
documented to occur during lactation, peaking in late lactation in rats (Cripps 
and Williams, 1975, Taylor et al., 2009) and in mice (Campbell and Fell, 
1964). However, one study found stomach tissue mass only increased early 
in lactation, decreasing thereafter (Crean and Rumsey, 1971). Most studies 
have focussed on the small intestine, as alluded to earlier. Cripps and 
Williams (1975) found a 27% increase in small intestine length by late 
lactation in rats compared to controls and this increase in length was found to
150
be the main contributor to the significant increase in both the wet and dry 
weight of the same tissue. Examination of the anatomy of the small intestine 
revealed that by day 10 of lactation, there was a significant increase in both 
villus height (approximately 55%) and muscle layer thickness (approximately 
75%) (Cripps and Williams, 1975). Datta et al. (1995) also reported 
significant increases to small intestine lengths and wet and dry weights in 
lactating rats, with Burdett and Reek (1979) finding that increased mass of 
the mucosal epithelium (140 to 150% increase) was the main contributor to 
increased small intestine wet weight. Taylor et al. (2009) investigated several 
lactation time-points in rats and found that at day 20 of lactation, the small 
intestine was significantly longer than all lactation groups except day 15 of 
lactation, showing a rapid increase in length from around mid lactation. A 
significantly increased surface area of the small intestine during lactation in 
rats has also been documented (Boyne et al., 1966, Penzes and Regius, 
1985). In mice, small intestine wet weight was found to increase by 79% 
compared to nulliparous controls (Campbell and Fell, 1964), showing that gut 
growth during lactation is not restricted to rats.
The distal gastrointestinal tract has also been found to significantly increase 
in size with lactation in rodents. Cripps and Williams (1975) reported 
significantly increased caecum wet weight of 127% and dry weight of 57% in 
day 21 lactating rats compared to nulliparous controls, with Taylor et al. 
(2009) finding a significant increase in caecum wet weight occurring from day 
10 of lactation onwards. An additional study in mice found a 34% increase in 
caecum wet weight compared to controls (Campbell and Fell, 1964) showing
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that the caecum may not increase in size in mice as considerably as is 
reported in rats. The colon has also been found to increase in both length 
and wet and dry weight with lactation (Cripps and Williams, 1975).
Gut growth has been investigated in relation to the hyperphagia of lactation, 
to investigate the hypothesis that gut growth occurs in response to increased 
food intake. In lactating rats on restricted diets, Campbell and Fell (1964) 
found that small intestines were dilated to the same degree, but showed only 
partial hypertrophic changes in comparison to ad libitum fed rats. These 
authors additionally found that the absorptive capacity of the small intestine 
did not differ between nulliparous and lactating rats showing varying levels of 
gut hypertrophy, hypothesising that changes to the small intestine size during 
lactation are proportionate to requirements. Datta et al. (1995) also reported 
that food restriction in lactating rats prevented small intestine hypertrophy.
Here, one aim was to further elucidate the possible roles of ghrelin, PYY and 
GLP-1 during lactation by investigating changes in both plasma and in gut 
tissues. Taylor et al. (2009) reported changes to both the gut peptides ghrelin 
and PYY and to gut growth during the lactation period. This current study 
included the analysis of GLP-1 levels in plasma and in gut tissue, and also 
aimed to update and advance documented changes to gut growth during 
lactation, with the inclusion of additional measurements, such as gut 
circumferences, aiming to provide more detail to potential changes and when 
they might occur. Measurement of the gut alongside both plasma and gut
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tissue peptide levels aimed to explore whether any relationship may exist 
between the gut peptides and gut growth during lactation.
5.2. Objectives
Objectives for this part of the study were:
o to investigate whether levels of the gut appetite hormones ghrelin, 
PYY and GLP-1 change at defined stages of lactation in Wistar rats, 
by quantification of plasma and gut tissue concentrations;
o to further elucidate reported changes to gut size during lactation;
o to determine whether any relationship may exist between any changes 
in plasma or gut hormone concentrations and changes in gut size.
5.3. Methods
5.3.1. Animals
Female Wistar rats, bred in-house, were used for the time-points of days 0 
(day of birth), 5, 10 and 25 of lactation (n=7 per group). All litters were 
standardised to 8 pups each by day 2 postpartum and pups remained with 
dams throughout the study. Dams used on the day of birth (dOL) had their 
litters standardised shortly after birth when a nest had been established and 
were sacrificed approximately 4 to 5 hours after birth. Data from proestrus 
nulliparous controls were used for comparison purposes (n=6 unless
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otherwise stated). Where data are available, proestrus mean values have 
been added to figures using a dotted line.
5.3.2. Sample collection
Samples of gut tissue and fed and fasted blood were taken, alongside 
multiple gut measurements, as outlined in Chapter 2 (section 2.3).
5.3.3. Measurements of food intake and body mass
Rats were weighed a minimum of once a month throughout the study. Dams 
for lactation time-points were separated from their home cage approximately 
20 days into pregnancy, allowing daily food intake monitoring by weighing the 
food hopper at the same time each day. In heavily pregnant dams, a sudden 
decrease in food intake coupled with a plateau in body mass gain was an 
indicator of imminent birth and both food intake and body mass were 
monitored closely for dams intended for the day 0 of lactation (dOL) sample 
group. Estimations of food intake usually ended at approximately day 10 to 
15 postpartum, when the pups opened their eyes and began to eat small 
amounts of solid food.
5.3.4. Peptide assays
Radioimmunoassays to determine peptide concentrations of ghrelin, PYY 
and GLP-1 in plasma and tissue extracts were performed as previously 
detailed (section 2.5).
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5.4. Results
5.4. 1. Total ghrelin peptide ana
5.4.1.1. Concentration change with
The concentration of total ghrelin in fasted plasma samples significantly 
changed during lactation (F(3, 24)=4.546, P=0.012) and increased beyond 
proestrus control concentrations from day 10 of lactation (d10L). Day 25 
lactating (d25L) dams had significantly more ghrelin in fasted plasma than 
day 0 lactating (P=0.023; dOL) and day 5 lactating (P=0.017; d5L) dams and 
had 20% more fasted plasma ghrelin than proestrus controls (Figure 5.1).
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Figure 5.1. Ghrelin concentrations in fasted plasma during lactation
(* P<0.05; n=7 dams per stage). Dotted line shows approximate proestrus control mean.
Stomach tissue ghrelin concentration (Figure 5.2) was significantly (Kruskal- 
Wallis, x2=10-057, 3 df, P=0.018) increased in dOL dams, with a significant 
decrease by d25L (P=0.025). Although dOL dams had the highest
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concentration of ghrelin in their stomach tissue out of all of the lactating 
dams, this concentration was similar to those found in the proestrus controls.
dOL d5L d10L d25L
Figure 5.2. Ghrelin concentrations in stomach tissue during lactation
(* P <0.05; n=7 dams per stage, except d5L where n=5). Dotted line shows approximate 
proestrus control mean.
5.4.2. Total peptide-YY (PYY)
5.4.2.1. Concentration change with
Due to the differences in sample preparation between the fed and fasted 
plasma discussed in Chapter 4 (section 4.5.2), paired analysis was not 
carried out to compare PYY concentrations in the fed and fasted states. 
Neither fed nor fasted plasma concentrations of PYY were significantly 
different between the stages of lactation (Table 5.1). Fasted plasma PYY was 
30 to 63% more concentrated during lactation than in the proestrus control 
animals (172.3 ±11.84 pg/ml).
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Table 5.1. PYY concentrations in fed and fasted plasma during lactation
(n=7 dams per stage, except fed plasma d25L (n=6)).
Fed plasma PYY (pg/ml) Fasted plasma PYY (pg/ml)
dOL 102.7 ±3.22 (92.9-117.3)
223.3 ±16.31 
(187.4-311.5)
d5L 101.0 ±4.90 (80.1 -  116.6)
247.1 ±20.83 
(179.5-322.1)
d10L 106.7 ±2.77 (97.0-116.5)
280.5 ± 27.76 
(181.8-395.4)
d25L 104.1 ±3.68 (92.6-117.7)
239.1 ±11.17 
(180.9-270.9)
Ascending colon tissue concentration of PYY was significantly (F(3, 
22)=4.638, P=0.012) higher at d5L than at d25L (P=0.012; Figure 5.3 A). 
Concentrations of descending colon PYY (Figure 5.3 B) varied considerably 
within each group. There was no significant difference between the 
concentrations of PYY in paired samples from ascending and descending 
colon tissue at any stage of lactation.
A. B.
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Figure 5.3. PYY concentrations in colon tissue during lactation
(A) ascending colon and (B) descending colon concentrations (* P<0.05; n=7 dams per 
stage, except d5L where n=5). Dotted line shows approximate proestrus control mean.
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5.4.3. Total glucagon-like peptide-1 (GLP-1) peptide 
concentrations
5.4.3.1. Matched fed and fasted plasma comparison
Paired analysis of GLP-1 concentrations in fed and fasted plasma samples 
from the whole group showed that GLP-1 was 4.8 fold more concentrated 
(f(24)=5.502, P<0.001) in the fed state (249.4 ± 25.78 pg/ml) than in the 
fasted state (51.5 ± 17.77 pg/ml).
5.4.3.2. Concentration change with stage of lactation
All of the lactating dams had higher fed plasma GLP-1 than proestrus 
controls by 173 to 534%. Fed plasma GLP-1 was significantly (F(3, 
21)=5.505, P=0.006) more concentrated in dOL dams than in both d10L 
(P=0.010) and d25L (P=0.025) dams (Figure 5.4).
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Figure 5.4. GLP-1 concentrations in fed plasma during lactation
(* P<0.05; n=7 dams per stage, except d10L where n=6 and d25L where n=5). Dotted line 
shows approximate proestrus control mean.
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GLP-1 concentration in fasted plasma varied considerably within each
sample group and was not significantly different between the dams (Figure
5.5).
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Figure 5.5. GLP-1 concentrations in fasted plasma during lactation
(n=7 per stage). Dotted line shows approximate proestrus control mean.
Ascending colon GLP-1 concentrations (Figure 5.6 A) decreased as lactation 
progressed and were significantly (F(3, 22)=4.164, P=0.018) higher in dOL 
dams than in d25L dams (P=0.016). GLP-1 concentrations in descending 
colon tissue had to be log transformed for parametric statistical analysis. Log 
of descending colon GLP-1 was significantly different (F(3, 22)=4.493, 
P=0.013) between the dam groups, which were highest at dOL and d5L 
before a sharp decrease by d10L (P=0.020), with a significant decrease also 
found between dOL and d10L (P=0.030) dams (Figure 5.6 B). Descending 
colon GLP-1 concentrations appeared to be higher than in the proestrus 
controls at dOL and d5L.
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Ascending colon GLP-1 concentrations were significantly higher than 
descending colon GLP-1 concentrations at dOL (f(6)=3.651, P=0.011) and 
d10L (f(6)=4.369, P=0.005), but not significantly higher at d5L and d25L.
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Figure 5.6. GLP-1 concentrations in colon tissue during lactation
(A) ascending colon and (B) descending colon concentrations (* P<0.05; n=7 dams per 
stage excluding d5L where n=5). Dotted line shows approximate proestrus control mean.
5 .4 .4 .  C h a n g e s  t o  b o d y  a n d  gu
The mean age of the lactating dams was 28.5 ± 0.94 weeks ( 1 8 - 3 7  weeks) 
of age at the time of culling. Body mass of the animals prior to the tail bleed 
(fed state) was obviously highest in dOL dams, as this was a day before birth, 
and so these dams were excluded from fed state body mass analysis. In the 
fed state, d5L dams were significantly (F(2, 18)=12.942, P<0.001) lighter 
than d10L (P<0.001) and d25L (P=0.003) dams (Figure 5.7).
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Figure 5.7. Fed state body mass during lactation
(n=7 per stage, with dOL excluded due to mass of pups; ** P<0.01; *** P<0.001). Dotted line 
shows approximate proestrus control mean.
Body mass recorded after the fasting period, however, was not significantly 
different between any of the groups, including dOL dams (Figure 5.8). D5L 
dams, in both the fed and the fasted state, had a similar body mass to the 
proestrus controls.
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Figure 5.8. Fasted state body mass during lactation
(n=7 per stage). Dotted line shows approximate proestrus control mean.
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The percentage of body mass lost during the fasting period (excluding dOL 
dams who gave birth during this time; Figure 5.9) was also significantly 
different between the dam groups (F(2, 18)=6.086, P=0.010) and those at 
d5L lost around the same mass as proestrus controls, which was significantly 
less body mass than the d25L (P=0.008) dams lost.
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Figure 5.9. The percentage body mass lost after the fasting period in lactating rats
(n=7 dams per stage; ** P<0.01). Dotted line shows approximate proestrus control mean.
Food intake of the dams was monitored in the days leading up to birth and 
into lactation. It was only possible to closely monitor daily food intake in a 
small number of rats, and 4 dams that were monitored for the most 
consecutive days are displayed in Figure 5.10. These 4 dams halved their 
food intake from 3 days peripartum (prior to birth; d3PP) to 1 day peripartum 
(d1PP). Food intake rapidly increased into the lactation period, doubling from 
d 1L to d2L. Food intake continued to increase in the dams and was highest 
at d8L, when monitoring stopped. The d8L dams studied here consumed 
approximately 248% more than the mean daily food intake of all of the 
cycling animals (n=43) in Chapter 1.
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Figure 5.10. Food intake of dams leading up to birth and into lactation
The food intake of 4 dams monitored for 12 consecutive days through the peripartum (PP) 
period and into lactation (L). Dotted line shows approximate mean daily food intake of 
nulliparous cycling females (n=43).
Anaesthetised rectal temperature was not significantly different between the 
groups, with dOL (36.7 ± 0.06 °C), d5L (37.0 ± 0.23 °C), d10L (37.2 ± 0.18 
°C) and d25L (37.3 ± 0.24 °C) dams all having similar temperatures.
The mass of abdominal cavity white adipose tissue (WAT) was significantly 
(F(3, 24)=13.899, P<0.001) heaviest in dOL dams when compared with d5L 
(P=0.005), d10L (P<0.001) and d25L (P<0.001) dams (Figure 5.11). Dams at 
d25L had less than half of the abdominal cavity WAT mass compared to 
nulliparous proestrus controls.
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dOL d5L d10L d25L 
Figure 5.11. Abdominal cavity white adipose tissue (WAT) during lactation
(** P<0.01; *** P<0.001; n=7 dams per stage). Dotted line shows approximate proestrus 
control mean.
Stomach tissue wet weight significantly increased in late lactation (Kruskal- 
Wallis, x2=15.015, 3 df, P=0.002), with d25L dams having significantly 
heavier stomachs than dOL (P=0.018) and d5L (P=0.002) dams (Figure 
5.12). The stomach tissue wet weight at d25L was approximately 31% 
heavier than in proestrus controls.
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Figure 5.12. Stomach tissue wet weight during lactation
(* P<0.05; ** P<0.01; n=7 dams per stage, except d25L where n=6). Dotted line shows 
approximate proestrus control mean.
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Small intestine wet weight (Figure 5.13 A) was significantly heavier (F(2, 
18)=39.220, P<0.001) in d10L dams than in dOL (P<0.001) and d5L 
(P<0.001) dams. Additionally, d5L dams had significantly heavier small 
intestines than dOL (P=0.022) dams. Due to differences in sample collection 
(see section 2.4.1), small intestine wet weight is not available for comparison 
with the d25L dam group or the proestrus controls. The small intestine also 
significantly increased in length in later lactation (F(3, 24)=17.944, P<0.001), 
being significantly longer in both d25L and d10L dams than in dOL (P<0.001) 
and d5L (P<0.001) dams (Figure 5.13 B). D10L dams had approximately 
48% longer small intestines than proestrus controls and dOL and d5L dams 
had similar small intestine lengths to controls.
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Figure 5.13. Small intestine size during lactation
(A) small intestine wet weight and (B) length during lactation (n=7 per stage; * P<0.05; 
P<0.001).
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Caecum tissue (log transformed) was significantly heavier (F(3, 24)=40.888, 
P<0.001) in both the d10L and d25L dams than in the dOL (P<0.001) and d5L 
(P<0.001) dams (Figure 5.14).
dOL d5L d10L d25L
Figure 5.14. Caecum tissue wet weight during lactation
(*** p<0.001; n=7 dams per stage).
Large intestine wet weight (Figure 5.15 A) significantly increased in late 
lactation (F(3, 19)=19.322, P<0.001). Dams at the end of the lactation period 
(d25L) had significantly heavier large intestine tissue (log transformed) than 
dOL (P<0.001), d5L (P<0.001) and d10L (P=0.001) dams. Dams also had 
significantly shorter (F(3, 24)=15.519, P<0.001) large intestines at dOL 
(P<0.001) and d5L (P=0.001) compared to d25L dams, with dOL dams also 
having shorter large intestines than d10L (P=0.004) dams (Figure 5.15 B). 
D5L dams had similar large intestine lengths to the proestrus controls.
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Figure 5.15. Large intestine wet weight during lactation
(A) large intestine wet weight and (B) length during lactation. Wet weight: n=4 dOL; n=7 d5L 
and d10L; n=5 d25L. Length: n=7dams per stage ** P<0.01; *** P<0.001). Dotted line shows 
approximate proestrus control mean.
All gut circumferences were significantly different between the sample groups
(Figure 5.16).
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Figure 5.16. Circumferences of duodenum, ascending colon and descending colon 
during lactation
(n=7 per stage; * P<0.05; ** P<0.01). Dotted lines show approximate proestrus control mean 
in each tissue.
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Duodenum circumference (F(3, 24)=3.052, P=0.048) was significantly 
smaller in d25L than in d10L (P=0.046) dams and all lactating dams 
appeared to have larger duodenum circumferences than proestrus controls. 
Ascending colon circumference (F(3, 24)=6.506, P=0.002) was significantly 
increased in dOL (P=0.045), d5L (P=0.035) and d10L (P=0.001) dams 
compared to d25L dams, which had circumferences similar to proestrus 
controls. Circumference of descending colon (F(3, 24)=4.346, P=0.014) was 
also significantly smaller in d25L than in d10L (F=0.012) dams, with 
proestrus control values most similar to dOL dams.
5.4.4.1. Mass of gut contents
Neither the mass nor the pH of the stomach contents (Table 5.2) changed 
significantly with the stage of lactation, although more stomach contents were 
present at each stage of lactation than in proestrus controls (0.5 ±0.15 g).
Table 5.2. Stomach contents wet weight and pH during lactation
(n=7 dams per stage, except stomach contents wet weight d25L (n=6) and pH dOL (n=6) and 
d25L (n=5)).
Stomach contents (g) Stomach contents pH
dOL 2.6 ±0.79 4.3 ±0.51(0 .3 -6 .3 ) (1 .9 -5 .4 )
d5L 2.0 ± 0.40 (0 .6 -3 .8 )
3.2 ±0.50  
(1 .9 -5 .4 )
d10L 1.8 ±0.23  (0 .7 -2 .4 )
3.4 ± 0.34 
(2 .5 -5 .1 )
d25L 1.0 ± 0.13 (0 .5 -1 .4 )
4.4 ± 0.39 
(3 .0 -5 .3 )
No data are available for the mass of small intestine contents in d25L dams 
due to differences in sample collection. Small intestine contents (Table 5.4) 
were significantly (F(2, 18)=16.540, P<0.001) heavier in d10L dams than in
dOL (P<0.001) and d5L (P=0.011) dams. Caecum contents of d10L dams 
were significantly (Kruskal-Wallis, x2=14.462, 3 df, P=0.002) heavier than in 
dOL dams (P=0.001; Table 5.3). The pH of caecum contents was also 
significantly more acidic (F(3, 24)=4.458, P=0.013) in d10L dams than in dOL 
(P=0.020) and d5L (P=0.029) dams (Table 5.3). The mass of the contents 
from the large intestine was not significantly different between the groups 
(Table 5.4).
Table 5.3. Caecum contents wet weight and pH during lactation
(n=7 dams per stage; c>d, P<0.01; e>f, P<0.05, within columns).
Caecum contents (g) Caecum contents pH
dOL 2.6 ± 0.25 a (1 .7 -3 .3 )
6.6 ± 0.07 r 
(6 .3 -6 .8 )
d5L 5.6 ±1.02  (2 .3 -9 .0 )
6.6 ± 0.09 T 
(6 .3 -6 .8 )
d10L 7.8 ±0.31 0 (6 .8 -8 .8 )
6.2 ±0.12 8 
(6 .0 -6 .8 )
d25L 5.6 ± 0.65 6.3 ±0.11(2 .9 -8 .0 ) (6 .0 -6 .9 )
Table 5.4. Small and large intestine contents during lactation
(n=7 dams per stage, except large intestine contents dOL (n=4) and d25L (n=5); a>b, 
P<0.001; e>f, P<0.05, within columns).
Small intestine contents (g) Large intestine contents (g)
dOL 2.0 ± 0.33 D 1.0 ± 0.11(1 .0 -3 .2 ) (0 .7 -1 .3 )
d5L 4.4 ± 0.92 T 2.7 ± 0.23(1 .3 -7 .5 ) (2.0 -  3.8)
d10L 7.7 ± 0 .7 6 ae 3.1 ±0.65(4 .5 -1 0 .6 ) (0 .5 -4 .8 )
d25L No data 3.2 ± 0.97 (0 .3 -6 .2 )
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5.5. Discussion
This chapter aimed to investigate reported changes to the levels of the gut 
peptides ghrelin, PYY and GLP-1 during lactation in rats, studying matched 
plasma and tissue samples for the first time. This chapter also aimed to 
further elucidate reported gut growth during lactation, and whether this may 
occur in relation to possible changes in the corresponding gut peptide levels.
Fasted plasma ghrelin was significantly increased in late lactation, however 
stomach tissue ghrelin concentrations were significantly decreased after dOL. 
Both fed plasma GLP-1 and ascending colon GLP-1 significantly decreased 
between early and late lactation, with ascending colon PYY being 
significantly more concentrated at d5L than at d25L. Descending colon GLP- 
1 levels were significantly decreased at d10L compared with earlier in 
lactation. All tissue wet weights and lengths measured significantly increased 
by late lactation, with caecum and small intestine wet weights and small 
intestine length increasing significantly between d5L and d10L after PYY and 
GLP-1 levels appeared to be maximal in the ascending and descending 
colon respectively.
5.5.1. Orexigenic gut hormone changes during lactation
Total ghrelin concentration in fasted plasma significantly increased from early 
lactation to d25L in this study, and d25L dams had 20% higher fasted plasma 
ghrelin than proestrus controls. Taylor et al. (2009) also measured total 
ghrelin plasma concentrations, although reported no significant difference
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between similar stages of lactation in rat fasted plasma. Shibata et al. (2004) 
reported no significant changes to fed plasma total ghrelin in rats between 
d5L and d15L. One study that measured total ghrelin levels during lactation 
in humans found that serum total ghrelin was lowest at the onset of lactation, 
increased rapidly for the first 14 days of lactation and steadily decreased 
thereafter for 180 days (llcol and Hizli, 2007). These authors also measured 
acyl ghrelin serum levels in the same participants and documented the 
opposite findings, in that acyl ghrelin was highest at lactation onset and then 
significantly decreased at each time point. The remainder of the studies of 
ghrelin during lactation have measured acyl ghrelin levels only, which is the 
‘active’ portion of the peptide (see section 1.6.1.1). In rats, acyl ghrelin levels 
in plasma were not found to change in d5L and d15L rats compared to 
nulliparous controls (Suzuki et a/., 2014) and likewise no difference has been 
documented between early (d7L) and late (d21L) lactation in sows (Govoni et 
al., 2007). Another study in lactating women found that acyl ghrelin levels in 
plasma increased from d1L to d10L and d15L but remained less 
concentrated than the non-pregnant control women at all stages (Aydin et al., 
2006). The collective results of others appear variable, which is not helped by 
the measurement of different forms of the ghrelin peptide. Although Taylor et 
al. (2009) reported no changes in total ghrelin plasma concentrations at 
similar stages of lactation, this may be due to the statistical analysis also 
including pregnant groups, as described earlier.
Whilst there was an increase in fasted plasma ghrelin in later lactation, 
stomach tissue ghrelin levels were significantly decreased at d25L compared
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with dOL levels, which were comparable to proestrus control levels. Only one 
other study has previously documented stomach tissue total ghrelin 
concentrations during lactation. Taylor et al. (2009) reported a significant 
decrease in stomach total ghrelin levels in d25L dams compared to proestrus 
controls. However, pups were weaned 5 days prior to maternal sampling at 
d25L, so this result is not comparable to the currently reported findings.
The significant increase in plasma ghrelin levels in the present study could be 
related to the significant decrease in abdominal cavity white adipose tissue 
(WAT) at the late stages of lactation, as described in more detail later 
(section 5.5.3). In lactating Wistar rats, others have reported a concomitant 
significant decrease in adiposity and circulating leptin levels (Taylor et al., 
2009, Woodside et al., 2000), which is logical due to leptin levels being 
directly proportionate to whole body adiposity (reviewed by Friedman, 2011, 
Ladyman et al., 2010). The orexigenic effects of ghrelin have been 
documented to be suppressed when leptin levels are high in the circulation, 
by injection of ghrelin in male mice over-expressing leptin (Ueno etal., 2004). 
So, it is possible that the increase in plasma ghrelin levels seen here by late 
lactation may have occurred due to a reduction in adiposity and thus of leptin 
levels. A lactation-associated reduction in leptin levels is also a possible 
explanation for the significant reduction in stomach tissue ghrelin levels 
between dOL and d25L dams. If leptin restraint of ghrelin occurred in the 
circulation early in lactation, it is possible that the stomach up-regulated 
production of ghrelin as a compensatory mechanism to increase circulating 
ghrelin to increase food intake by promoting hyperphagia. This requirement
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would reduce as leptin levels reduce and ghrelin levels become unrestrained 
in the circulation; this could explain a significant reduction in stomach tissue 
ghrelin whilst there is a significant increase in plasma ghrelin. It is also 
possible that an increase in stomach ghrelin levels at dOL was a typical 
physiological response in order to initiate lactation-associated hyperphagia. 
Measurement of leptin levels in plasma would be of interest for future work to 
further explore the relationship between leptin and ghrelin during lactation. It 
would also be of interest to quantify the acyl and desacyl forms of ghrelin in 
these samples, as llcol et al. (2007) reported differences between total and 
acyl ghrelin levels in the same samples, indicating that there may be 
differences in the regulation of the different ghrelin forms during lactation.
5.5.2. Anorexigenic gut hormone changes during 
lactation
As introduced earlier, there are limited data available on the possible 
changes of PYY and no data on GLP-1 levels during lactation. Neither fed 
nor fasted plasma total PYY were different between the stages of lactation in 
this study, although fasted plasma PYY was 63% higher than proestrus 
control values at d10L. Suzuki et al. (2014) reported significantly higher fed 
plasma PYY levels at d5L and d15L compared to nulliparous control rats and 
PYY levels were highest at d5L. Taylor et al. (2009) also documented 
maximal fasted plasma PYY levels at d5L compared to all other pregnant, 
lactating and nulliparous controls studied. The findings of those two studies 
indicate that, for measurement of plasma PYY levels, the feeding status of 
lactating dams may not be important, as the PYY peak reported by Suzuki et
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al. (2014) was also documented by Taylor et al. (2009) even after a 12 hour 
fasting period, which would normally be expected to reduce PYY to baseline 
levels.
Ascending colon concentrations of PYY were found to peak in d5L dams, 
with a decrease by d10L, which reached significance (a 65% decrease) by 
d25L. Descending colon PYY was not significantly different between the 
stages of lactation studied. Taylor et al. (2009) reported no difference in 
ascending colon concentrations between similar stages of lactation in rats, 
however did document a significant d5L PYY peak in descending colon and 
an increase in PYY from early to mid lactation in rectum tissue. The 
differences reported between PYY levels in ascending and descending colon 
tissues in this study and their study may arise from differences in statistical 
analysis. Taylor et al. (2009) analysed lactating dams alongside pregnant 
and control animals, which may result in some of the more subtle differences 
between lactating groups being missed, particularly as there appeared to be 
a lot of variation in the concentrations between the groups. However, what 
seems consistent between these studies is that PYY levels in colon tissue 
appeared to be highest at d5L and decreased from d5L to late lactation.
In addition to the above, Suzuki et al. (2014) have also reported a significant 
increase in arcuate nucleus PYY mRNA at both stages of lactation studied 
(d5L and d15L) in comparison with nulliparous control rats, suggesting that a 
lactation-associated increase of PYY in rats also occurs at the hypothalamic 
level.
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There are no other studies that have explored the concentrations of GLP-1 in 
lactating dams; the focus has mainly been on insulin resistance during 
pregnancy (see Chapter 4). In this study, there was a significant decrease in 
fed plasma GLP-1 from dOL to d10L and d25L towards the levels seen in 
proestrus controls, which may represent a normalisation of maternal GLP-1 
into lactation. Ascending colon GLP-1 levels decreased throughout lactation, 
with concentrations at d25L being significantly lower than in dOL dams. 
Between d5L and d10L, there was a significant reduction (85%) in GLP-1 
concentration in descending colon. Why the highest levels of both PYY and 
GLP-1 appeared to occur early in lactation remains to be established, as food 
intake was 199% higher by d5L compared to nulliparous controls. The 
accepted role of PYY and GLP-1 is to rise in response to food intake and 
signal fullness, causing a reduction in appetite (section 1.6).
5.5.3. Changes in food intake, body size and body 
temperature during lactation
In this study, the fed state body mass of lactating dams recovered to values 
similar to proestrus controls by d5L, significantly increased by d10L and then 
remained constant until d25L. These findings are in line with previous 
studies. Cripps and Williams (1975) reported an increase in maternal body 
mass from d3L to d12L, which then remained constant until d18L and Crean 
and Rumsey (1971) documented a significant increase in body mass at d7L, 
d14L and d21L in comparison with nulliparous controls. In the fasted state, 
there was no significant difference in body mass between the dams, which 
may suggest that body mass was influenced by short term food intake and
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may be linked with lactation-associated hyperphagia. Dams in the present 
study became more susceptible to losing body mass after the short period of 
fasting at d25L. As solid food was removed from the cage for the fasting 
period, this result may be due to increased pup persistence to feed from their 
mothers, with 25 day old pups potentially feeding more than the younger 
pups. This finding could also indicate that the dams were consuming less 
during the light period, with appetite levels normalising.
The dams studied for food intake demonstrated a rapid increase in food 
intake after birth, consistent with the reported hyperphagia of lactation (Crean 
and Rumsey, 1971, Cripps and Williams, 1975, Denis et al., 2004). After a 
decrease leading up to birth, food intake recovered to control values the day 
after birth and doubled after a further 24 hours. By d8L (end of sampling), 
food intake was 248% higher than in controls, which is consistent with the 
findings of others, where food intake has been documented to increase by 
250 to 300% by late lactation (Crean and Rumsey, 1971, Cripps and 
Williams, 1975, Denis et al., 2004). Dams at all stages of lactation also had 
more stomach contents remaining after the fasting period compared to 
proestrus controls, which could indicate more food intake during the light 
period prior to food removal, or be due to the ingestion of more water and/or 
bedding material after the diet was removed.
As food intake significantly increased, abdominal cavity WAT significantly 
decreased in the dams. Naismith et al. (1982) reported a significant reduction 
in whole body adiposity by d16L compared to d2L. Another study also
176
documented a decrease, although not significant, in maternal adipose pad 
mass from d5L through to d25L (Woodside et al., 2000). In agreement, the 
present study found that abdominal cavity WAT was significantly increased at 
dOL compared to all other stages of lactation, which is consistent with the 
hypothesis that rodents utilise adipose reserves as a key energy source to 
support lactation (Naismith etal., 1982).
In this study, there were no significant differences in anaesthetised rectal 
temperature between the lactating dams, which is in agreement with results 
from a previous study in rats between days 2 and 10 of lactation (Fewell, 
1995). As previously described (section 4.5.4), increased PYY levels have 
been associated with increased thermogenesis and decreased adiposity in 
obese PYY transgenic male mice (Boey et al., 2008). It is possible that the 
up-regulation of thermogenesis by PYY requires high PYY levels in the 
circulation, which were not found in the present study. Boey et al. (2008) 
suggested that increased serum PYY in their animals may have affected 
thyroid hormones which, in turn, increased thermogenesis. It is also possible 
that there are sex differences in this proposed mechanism, and/or that the 
physiology of lactation changes this potential action of PYY.
5.5.4. Increased gut size during lactation
Stomach tissue wet weights were significantly increased by d25L in this 
study. Cripps and Williams (1975) studied rats at d21L and reported a 50% 
increase in stomach wet weight compared with nulliparous controls, which 
was greater than reported in this study between d25L and proestrus controls
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(31%). Additionally, Taylor et al. (2009) documented a significant difference 
in stomach wet weights between all lactating rat groups and the proestrus 
controls. It is possible that due to the proestrus control rats in the present 
study being slightly older than would have been optimal for comparison 
purposes (see section 3.5.2), the difference between their stomach tissue 
mass and those of the slightly younger lactating dams was reduced in 
comparison to other studies, although neither of the above studies report rat 
age. Further work using age matched controls would have to be carried out 
to verify this possibility. Another study in Wistar rats only documented an 
increase in stomach mass from d7L to d14L, with a decrease by d21L, but 
this is likely due to methodology differences as the authors fixed stomachs 
before weighing them (Crean and Rumsey, 1971).
As described earlier, most studies of gut growth during lactation in rodents 
have focussed on the small intestine. This study reported a significant 
increase in both the wet weight and the length of the small intestine in the 
later stages of lactation. Compared with proestrus control values, the small 
intestines of d10L dams increased in length by approximately 48%. Without 
control values available due to method differences, small intestine wet weight 
increased by approximately 34% between dOL and d10L dams. In their rats, 
Cripps and Williams (1975) reported a 27% increase in small intestine length 
between d21L dams and nulliparous controls and Datta et al. (1995) 
documented a 28% increase at the same stage of lactation. For small 
intestine wet weight, those separate authors reported a 107% increase and 
an 84% increase respectively. In comparison to these two studies, it is
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unclear why there was a more modest increase in wet weight, yet a clear 
increase in length of small intestines in the present study. However, Taylor et 
al. (2009) also reported much larger growth than those studies, with a mean 
small intestine length in d20L rats of 151 cm, which is approximately 45% 
longer than found in this study at a comparable stage of lactation. As 
described in Chapter 2, complete standardisation of gut length 
measurements using the calcium channel blocker nicardipine was not 
possible for this study, and could be one avenue for future work to fully 
elucidate the growth seen in this tissue during lactation.
Caecum wet weight was also found to significantly increase during lactation 
in this study, and the major increase occurred between d5L and d10L (112%) 
with a 200% increase by the end of the lactation period. Previously, a 127% 
increase in caecum wet weight has been documented between d21L and 
nulliparous controls (Cripps and Williams, 1975). Taylor et al. (2009) 
documented a significantly increased caecum wet weight from d10L, where it 
was significantly different from d<1L and d5L dams, which is in agreement 
with what is reported in the current study.
In addition to the increase in size seen in the small intestine, both large 
intestine lengths and wet weights were significantly increased at d25L in 
comparison to all other lactation groups studied. Large intestines were 33% 
longer in d25L dams compared to proestrus controls. Only one other study 
has documented changes to length and wet weight of the colon in lactating 
rats, and that study documented a 23% increased colon length (Cripps and
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Williams, 1975), which is similar to what is reported here. Cripps and 
Williams (1975) also reported a 73% increase in colon wet weight in d21L 
dams compared with controls. Due to differences in measurement (described 
in section 2.4.1), it was not possible to compare proestrus control intestine 
wet weights to the dams in this chapter, however, large intestine wet weight 
increased by 119% from dOL to d25L. As outlined earlier, to be completely 
certain of large intestine length measurements during lactation, further work 
with maximally relaxed intestinal tissue would have to be done.
Gut circumferences of lactating rats have been measured here for the first 
time. In the duodenum, ascending and descending colon tissues, there was a 
non-significant increase in circumference leading up to d10L, with a 
significant decrease in circumference from d10L to d25L. As previously 
discussed, intestinal tissue was heaviest and longest in the d25L dams. 
Taylor et al. (2009) documented decreased gut size 5 days after weaning in 
their rats, so it is hypothesised here that by the end of the lactation period, 
when the gut is no longer required to adapt to increased food intake, the gut 
circumferences become smaller prior to further gut hypotrophy. Chapter 6 will 
go on to explore effects on maternal gut size after different postpartum 
outcomes.
5.5.4.1. Peptide changes in the large intestine may be related to 
gut growth
Reported here are high levels of PYY in ascending colon tissue at d5L, which 
are significantly higher than levels found at d25L. Others have additionally
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reported a significantly increased level of PYY in plasma, descending colon 
and rectum tissues and in the hypothalamus in d5L dams compared to 
nulliparous controls (Suzuki et al., 2014, Taylor et al., 2009). From d5L, 
caecum wet weight and small intestine wet weight and length significantly 
increased into later lactation. Caecum wet weight increased by 112% 
between d5L and d10L and small intestine wet weight increased significantly 
by 30% between d5L and d10L dams and was 31% longer between the 
same groups. In other gut tissue (stomach, large intestine) the increase in 
wet weight and length was more gradual between the stages, all peaking in 
late lactation.
PYY has previously been linked with gut growth. Gomez et al. (1995) 
reported that PYY mRNA was highest in the colon during postnatal 
development in rat pups and peaked between day 7 and 13 of age. These 
authors treated 7 day old male and female rat pups with 3 times daily 
intraperitoneal injections of PYY for 14 days and reported a significant 
increase in small intestine wet weight, total DNA content and total protein 
content compared with vehicle-treated control litter mates, and the effect was 
most profound in the males. There were no trophic effects seen in the colon 
of either male or female pups. In adult female mice, the same group reported 
the ability of PYY to stimulate growth of both proximal and distal small and 
large intestinal tissue in a dose-dependant manner. The small intestine was 
most affected by PYY injection, with significant increases to wet weight, DNA 
content and protein content at many of the PYY concentrations tested, 
whereas the colon wet weight and DNA content only increased with higher
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PYY doses. Their study only included previously optimised PYY doses and 
reported that PYY treatment did not significantly affect body or organ masses 
and that there were no changes to the normal histology of the gut (Gomez et 
al., 1995). Collectively, their results suggest that PYY is a direct cause of gut 
growth and that this may be both age and sex dependant.
Tovar et al. (2004) found that a significant pregnancy-associated rise in PYY 
levels was completely suppressed in dams on 30% food restriction. Both 
Campbell and Fell (1964) and Datta et al. (1995) have studied the effects of 
food restriction in lactating rats, as detailed earlier (section 5.1.3), and have 
reported that food restriction prevents small intestine hypertrophy, but does 
not affect its absorptive capacity. It would be of interest to reproduce these 
studies and investigate the effect of food restriction on PYY levels and gut 
growth during lactation in rats. It may be that PYY levels are suppressed 
during food restriction to facilitate increased food intake, but if gut growth 
during lactation is a result of increased PYY then there may be no lactation- 
associated gut growth seen in food restricted lactating rats.
GLP-2 is co-secreted from gut L-cells (Mojsov et al., 1986) alongside GLP-1 
and PYY and has also been implicated in gut growth. It has been 
documented that GLP-2, but not GLP-1, can cause small intestine 
hypertrophy by subcutaneous injection of the peptide, twice daily, into male 
mice (Drucker et al., 1996). A time course experiment demonstrated the 
ability of GLP-2 to increase small intestine wet weight and mucosal villus 
height after just 4 days of GLP-2 treatment, and these results were
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comparable to those seen in mice with tumours positive for GLP-2 (Drucker 
et al., 1996). Subsequent work by this group showed that GLP-2-induced 
small intestine hypertrophy increased the capacity for nutrient absorption in 
male mice (Brubaker et al., 1997). A case study of a male patient with a 
neuroendocrine tumour immunopositive for PYY, GLP-1 and GLP-2 reported 
that the tumour was responsible for an increased level of these hormones in 
the circulation and also marked small intestine hypertrophy (Byrne et al., 
2001). Ghatei et al. (2001) reported that in male rats receiving total 
parenteral nutrition (TPN), which causes gut hypotrophy, both GLP-1 and 
GLP-2 infusion (separately) through a jugular catheter increased stomach, 
small intestine, caecum and colon wet weights, although the result was most 
marked in the rats receiving GLP-2 doses. GLP-2 administration to TPN rats 
was able to increase small intestine size beyond that of the orally fed 
controls, leading to a suggestion by the authors that gut secretion of GLP-2 
may be key in the control of intestinal hypertrophy, keeping hypertrophy 
proportionate to food intake (Ghatei etal., 2001).
It is evident from these studies that PYY and GLP-2 can cause substantial 
intestinal hypertrophy, with possible small increases in gut size caused by 
GLP-1. Due to its co-secretion with GLP-1 and PYY from intestinal L-cells, it 
may be reasonable to predict that GLP-2 levels also increase in early 
lactation. Future work to measure GLP-2 during lactation in relation to gut 
growth would be necessary to determine whether this occurs. It would also 
be of interest to further elucidate the role of the L-cell in gut hypertrophy.
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5.6. Conclusions
This chapter focussed on changes to the levels of ghrelin, PYY and GLP-1 in 
matched plasma and gut tissue in lactating Wistar rats, and further explored 
documented changes to gastrointestinal growth. This work is novel in the 
study of GLP-1 levels in lactating dams and is the first to measure all three of 
the aforementioned gut peptides in conjunction with the study of lactation- 
associated gut growth. Key findings included a significant increase in fasted 
plasma ghrelin with significantly decreased fed plasma GLP-1 in late 
lactation, coupled with significantly increased food intake during lactation. 
However, stomach tissue ghrelin significantly decreased from dOL. 
Ascending colon PYY and descending colon GLP-1 levels were significantly 
increased in d5L dams compared with later stages of lactation, and it is 
suggested that this could be a signal that resulted in a significant increase in 
gut growth from mid-lactation.
5.7. Future work
To progress this work, additional peptides could be measured. As discussed 
earlier, leptin has the potential to alter ghrelin levels and so this would be one 
avenue for future work in order to further elucidate the possible causes of 
ghrelin changes during lactation. Quantifying the acyl portion of ghrelin may 
also provide more information to the changes and regulation of ghrelin levels 
during lactation, with previous work by others (llcol and Hizli, 2007) indicating 
that acyl ghrelin levels may change differently to total ghrelin levels. In 
addition to circulating and tissue levels of the peptides, hypothalamic peptide 
levels would be of interest to measure in future, as Suzuki et al. (2014)
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reported similar changes to PYY levels in the hypothalamus and circulation. It 
is also possible that receptor levels change in the hypothalamus during 
lactation (Suzuki et a/., 2014) to adapt to the large increase in food intake 
and investigation of this possibility would be another interesting addition to 
this work.
As discussed in detail earlier, an extension of the work by others (Campbell 
and Fell, 1964, Datta et al., 1995, Tovar et al., 2004) on gut growth and its 
relation to food intake would also be of interest for future studies. Using pair- 
fed rats, it would be possible to explore changes to gut growth when lactating 
dams have their food intake restricted to control levels. This kind of 
experiment would aim to further the understanding of the relationship 
between gut peptides and gut growth, whilst food intake is controlled for.
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CHAPTER 6: CHANGES IN MATERNAL GUT 
APPETITE HORMONES AND GUT GROWTH DUE TO 
LACTATION LITTER SIZE
6.1. Introduction
The work described in the previous two chapters showed that changes in 
maternal gut peptides and gut size occur during pregnancy (Chapter 4) and 
lactation (Chapter 5). Here, the possibility that the changes seen during 
lactation are influenced by the size of the litters being suckled was 
investigated. Such additional postpartum changes may occur to aid maternal 
adaptation to feeding different litter sizes.
As described in Chapter 1 (section 1.8.2), data suggest that maternal 
changes that occur to support pregnancy and lactation may persist into later 
life in humans, and may then influence the risk of developing obesity and 
subsequent obesity-related illness, such as type 2 diabetes. A 20 year 
prospective study reported that a longer lactation period was associated with 
a decreased risk of developing the metabolic syndrome in women with and 
without a history of gestational diabetes, presumably partly due to reduced 
maternal adiposity as a result of lactation (Gunderson et al., 2010). Studies 
have also begun to explore levels of ghrelin and PYY in women with different 
durations of breastfeeding. One study has reported a significantly decreased 
level of fasted ghrelin in 4 to 5 week postpartum women compared to never- 
pregnant controls, with the authors suggesting that ghrelin may play a role in
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the regulation of postpartum maternal body mass (Larson-Meyer et al., 
2010). Another study conducted in women 3 years postpartum reported that 
a longer lactation period resulted in increased levels of both total ghrelin and 
PYY in fasted plasma and concluded that this may contribute to reducing the 
risk of later life metabolic diseases (Stuebe et al., 2011).
Work described in this chapter is the first to explore whether additional 
maternal lactation-associated changes to gut peptides and gut size occur as 
a result of litter size at the end of a complete lactation period in rats.
6.2. Objectives
Objectives for this part of the study were to:
o determine whether dams feeding different litter sizes have different 
levels of ghrelin, PYY and GLP-1 in either gut tissue or in circulation;
o establish whether the gut growth of dams observed during the 
lactation period is changed by the number of pups being suckled.
6.3. Methods
6.3.1. Animals
Two groups of dams had their litters manipulated to 4 pups (n=7 dams) or 12 
pups (n=6 dams) by cross-fostering. Cross-fostering was achieved by 
distraction of the dam whilst her litter was manipulated. Groups of dams were 
always mated at the same time in order to obtain multiple births on the same
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day to aid this work. Only pups of the same age were cross-fostered, 
preferably between litters of sister dams, with minimal intervention.
Samples were taken from the dams at day 25 of lactation (d25L) and the data 
were compared with those obtained in Chapter 4 from dams with litters 
standardised to 8 pups. Data from proestrus nulliparous controls were also 
used for comparison purposes (n=6 unless otherwise stated). Where data 
are available, proestrus mean values have been added to figures using a 
dotted line.
6.3.2. Sample collection
Blood and gut tissue was collected and measured from dams as described in 
Chapter 2 (section 2.3).
6.3.3. Peptide assays
Radioimmunoassays on plasma and tissue extracts were performed for total 
ghrelin, PYY and GLP-1 as described in Chapter 2 (section 2.5).
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6.4. Results
6.4. 1. Total ghrelin peptide ana
6.4.1.1. Concentration change with
Fed plasma ghrelin concentration (Figure 6.1) was significantly different 
between the dam groups (F(2, 9)=8.412, P=0.009). Dams feeding 12 pups 
had significantly reduced fed plasma ghrelin compared to the dams feeding 8 
(P=0.007) pups.
Feeding n=4 Feeding n=8 Feeding n=12
Figure 6.1. Ghrelin concentrations in fed plasma of dams with different lactation litter 
sizes
(n=4 dams per group; ** P<0.01).
Maternal concentrations of ghrelin in fasted plasma (Figure 6.2) did not 
change with the number of pups they were feeding. Concentrations of ghrelin 
in fed and fasted plasma could not be directly compared due to sample 
preparation differences (see section 2.5.3). The concentrations of ghrelin in 
stomach tissue extracts (Figure 6.3) were significantly (F(2, 17)=8.882,
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P=0.002) higher in dams feeding 12 pups compared with the dams feeding 
the control litter size of 8 pups (P=0.002). Dams feeding 4 pups had similar 
stomach ghrelin concentrations to proestrus controls.
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Figure 6.2. Ghrelin concentrations in fasted plasma of dams with different lactation 
litter sizes
(n=7 dams feeding 4 and 8 pups; n=6 dams feeding 12 pups). Dotted line shows 
approximate proestrus control mean.
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Figure 6.3. Ghrelin concentrations in stomach tissue of dams with different lactation 
litter sizes
(n=7 dams feeding 4 and 8 pups; n=6 dams feeding 12 pups; ** P<0.01). Dotted line shows 
approximate proestrus control mean.
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6.4.2. Total peptide-YY (PYY) peptide analysis
6.4.2.1. Concentration change with lactation litter size 
Neither fed nor fasted plasma PYY changed significantly in the dams feeding 
different litter sizes and there were a number of outliers (Table 6.1). All of the 
dams had higher levels of PYY in fasted plasma than the proestrus controls 
(172.0 ±11.84 pg/ml).
Table 6.1. PYY concentrations in fed and fasted plasma of dams with different 
lactation litter sizes
(n=7 dams feeding 4 and 8 pups, except fed plasma where n=6 dams feeding 8 pups; n=6 
dams feeding 12 pups).
Fed plasma 
(pg/ml)
Fasted plasma 
(pg/ml)
Feeding 104.5 ±4.58 227.0 ± 8.25
n=4 (89.1-117.7) (201.1 -266.0)
Feeding 104.1 ±3.68 239.1 ±11.17
n=8 (92.6-117.7) (180.9-270.9)
Feeding 115.9 ± 11.19 316.9 ±93.55
n=12 (91.4-116.8) (192.2-780.2)
Ascending colon PYY concentrations were also not significantly different 
between the dams (Figure 6.4 A). However, descending colon PYY, log 
transformed, was significantly (F(2, 17)=4.437, P=0.028) higher in dams with 
the control litter size of 8 pups than in dams feeding 4 (P=0.045) pups 
(Figure 6.4 B). All dams had more descending colon PYY than proestrus 
controls.
There was no significant different between the concentration of PYY in the 
ascending colon and the descending colon regions in any of the dams.
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Figure 6.4. PYY concentrations in colon tissue of dams with different lactation litter 
sizes
(A) ascending and (B) descending colon concentrations (n=7 dams feeding 4 and 8 pups; 
n=6 dams feeding 12 pups; * P <0.05). Dotted line in (B) shows approximate proestrus 
control mean.
6.4.3. Total (GLP-1) peptide analysis
6.4.3.1. Matched fed and fasted plasma comparison
Paired analysis of plasma samples found that GLP-1 was significantly more 
concentrated (f(16)= 5.241, P<0.001) in fed (328.9 ± 52.98 pg/ml) plasma 
than in fasted (44.1 ± 9.56 pg/ml) plasma, as expected.
6.4.3.2. Concentration change with litter size
There were no significant differences between the concentrations of plasma 
GLP-1 in any of the groups (Table 6.2). In fed plasma, GLP-1 concentration 
was considerably higher in the lactating dams than in the proestrus controls
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(56.2 ± 25.66 pg/ml), yet fasted plasma GLP-1 levels were similar to the 
proestrus controls (28.9 ± 8.60 pg/ml).
Table 6.2. GLP-1 concentrations in fed and fasted plasma of dams with different 
lactation litter sizes
(n=7 dams feeding 4 pups; fed plasma: n=5 dams feeding 8 and 12 pups; fasted plasma: 
n=7 dams feeding 8 pups and n=6 dams feeding 12 pups).
Fed plasma (ng/ml) Fasted plasma (ng/ml)
Feeding 499.8 ± 98.83 47.5 ± 15.51
n=4 (166.5-879.7) (12 .6-132 .8)
Feeding 168.8 ±37.60 25.6 ± 9.20
n=8 (78.8-259 .1) (3.0 -  70.2)
Feeding 319.8 ±68.57 45.6 ± 19.95
n=12 (180.3 -562.2 (6 .0 -126 .0 )
There was no difference in either ascending or descending colon GLP-1 
concentration between the groups (Figure 6.5). Dams feeding 4 (f(6)=3.909, 
P=0.008) and 12 (f(5)=4.837, P=0.005), but not 8 (P=0.267) pups, had a 
significantly higher concentration of GLP-1 in their ascending colon than the 
descending colon.
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Figure 6.5. GLP-1 concentrations in colon tissue of dams feeding different lactation 
litter sizes
(A) ascending and (B) descending colon concentrations (n=7 dams feeding 4 and 8 pups; 
n=6 dams feeding 12 pups). Dotted line shows approximate proestrus control mean. (Note y 
axes scale difference).
6 .4 .4 .  C h a n g e s  t o  b o d y  a n d  gu
different litter sizes
The mean age of all dams was 31.6 ± 1.26 weeks (24 -  39 weeks) of age at 
the time of culling. Body mass recorded before and after the short fasting 
period was not significantly different between the groups, and all of the dams 
lost a similar percentage of their body mass during fasting (Table 6.3).
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Table 6.3. Fed and fasted state body mass and the percentage of body mass lost 
during the fasting period of dams with different lactation litter sizes
(n=7 dams feeding 4 and 8 pups; n=6 dams feeding 12 pups).
Fed state body 
mass (g)
Fasted state body 
mass (g)
Body mass lost on 
fasting (%)
Feeding
n=4
294.4 ± 5.34 
(281.1 -319 .1 )
268.7 ± 5.02 
(250.1 -292 .0 )
8.7 ±1.01 
(3 .6 -1 2 .3 )
Feeding
n=8
300.3 ±5.96 
(275.4-317.3)
267.5 ± 5.85 
(239.9-284.3)
10.9 ± 1.25 
(6 .9 -1 6 .5 )
Feeding
n=12
306.2 ±11.63 
(264.9 -  346.3)
275.8 ± 10.32 
(241.6-304.2)
9.8 ±0.92 
(8 .0 -1 3 .2 )
The mass of abdominal cavity white adipose tissue (WAT) was similar 
between the dams feeding different litter sizes (Figure 6.6), but was 
approximately 50% less in comparison to proestrus control animals. 
Anaesthetised rectal temperature was also not different between the dams 
(Figure 6.7).
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Figure 6.6. Abdominal cavity white adipose tissue (WAT) of dams with different 
lactation litter sizes
(n=7 dams feeding 4 pups; n=4 dams feeding 8 pups; n=6 dams feeding 12 pups). Dotted 
line shows approximate proestrus control mean.
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Figure 6.7. Anaesthetised rectal temperature of dams with different lactation litter 
sizes
(n=7 dams feeding 4 pups; n=4 dams feeding 8 pups; n=6 dams feeding 12 pups).
The wet weight of stomach tissue (Figure 6.8) was not significantly different 
between the dam groups but was 20 to 40% increased compared to 
proestrus controls.
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Figure 6.8. Stomach tissue wet weight of dams feeding different lactation litter sizes
(n=7 dams feeding 4 pups; n=6 dams feeding 8 and 12 pups). Dotted line shows 
approximate proestrus control mean.
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Small intestines were significantly lighter (t( 11)= -2.596, P=0.025) in dams 
feeding 4 pups compared with dams feeding 12 pups (Figure 6.9 A). Due to 
differences in sample collection, the wet weight of small intestine tissue is not 
available for the dam group feeding the control litter size of 8 pups or 
proestrus controls (see section 2.4.1). Small intestines were also significantly 
shorter (F(2, 17)=6.222, P=0.009) in dams feeding 4 pups than in dams 
feeding 8 pups (P=0.007; Figure 6.9 B). All of the dams had small intestines 
that were, on average, 1.3 times longer than in the proestrus controls.
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Figure 6.9. Small intestine size of dams with different lactation litter sizes
(A) small intestine wet weight and (B) length (n=7 dams feeding 4 and 8 pups; n=6 dams 
feeding 12 pups; * P <0.05; ** P<0.01). Dotted line shows approximate proestrus control 
mean.
Log transformation of caecum wet weight showed a significant difference 
between the groups (F(2, 16)=31.512, P<0.001), with dams feeding the 
control litter size having significantly heavier caecum tissue than dams
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feeding the small (P<0.001) and large (P=0.001) litter sizes. Caecum wet 
weight was also significantly lighter in dams feeding small litters than those 
feeding large litters (P=0.036; Figure 6.10).
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Figure 6.10. Caecum tissue wet weight of dams with different lactation litter sizes
(n=7 dams feeding 4 and 8 pups; n=6 dams feeding 12 pups; * P<0.05; ** P<0.01; *** 
P< 0.001).
Large intestine tissue (Figure 6.11 A) was significantly heavier (Kruskal- 
Wallis, x2=13.111, 2 df, P=0.001) in dams feeding 8 pups than in dams 
feeding 4 pups (P=0.001). The large intestine was significantly longer (F(2, 
17)=10.042, P=0.001) in dams feeding 8 pups when compared with those 
feeding 4 (P=0.001) and 12 (P=0.039) pups (Figure 6.11 B). The large 
intestine length of proestrus controls (n=4) was similar to the dams feeding 
litters of 4 pups.
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Figure 6.11. Large intestine size of dams with different lactation litter sizes
(A) large intestine wet weight and (B) length (n=7 dams feeding 4 and 8 pups, except wet 
weight, where n=5 dams feeding 8 pups; n=6 dams feeding 12 pups; * P<0.05; ** P<0.01). 
Dotted line shows approximate proestrus control mean.
Duodenum (F(2, 17)=6.961, P=0.006), ascending colon (F(2, 17)=9.576, 
P=0.002) and descending colon (F(2, 17)=9.998, F=0.001) circumferences 
were significantly different between the dam groups (Figure 6.12). Duodenum 
circumference was significantly smaller in dams feeding 8 pups compared 
with dams feeding 12 pups (P=0.005). In both ascending and descending 
colon, circumferences were significantly smaller in dams feeding 8 pups 
compared with both dams feeding 4 and 12 pups.
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Figure 6.12. Circumferences of duodenum, ascending and descending colon of dams 
with different lactation litter sizes
(n=7 dams feeding 4 and 8 pups; n=6 dams feeding 12 pups; ** P<0.01). Dotted lines show 
approximate proestrus control mean.
6.4.4.1. Mass of gut contents
The mass and pH (Table 6.4) of fasted stomach contents in the dams did not 
change significantly with litter size.
Table 6.4. Stomach contents wet weight and pH of dams with different lactation litter 
sizes
(n=5 dams feeding 4 and 8 pups; n=4 dams feeding 12 pups).
Stomach contents (g) Stomach contents pH
Feeding 0.9 ±0.15 3.3 ±0.25
n=4 (0 .4 -1 .5 ) (2 .4 -3 .9 )
Feeding 1.0 ± 0.13 4.5 ±0.39
n=8 (0 .5 -1 .4 ) (3 .0 -5 .3 )
Feeding 0.9 ±0.15 3.8 ±0.54
n=12 (0 .4 -1 .4 ) (2 .3 -4 .8 )
The mass of caecum contents were significantly (F(2, 16)=7.921, P=0.004) 
heavier in dams feeding the largest litter size than in those feeding 4 
(P=0.004) and 8 (P=0.020) pups (Figure 6.13). However, the pH of caecum
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contents was not significantly different between the dams feeding small (6.8 
± 0.15 pH), control (6.3 ± 0.11 pH) and large litter (6.8 ± 0.15 pH) sizes.
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Figure 6.13. Caecum contents wet weight of dams with different lactation litter sizes
(n=7 dams feeding 4 and 8 pups; n=5 dams feeding 12 pups; * P<0.05; ** P<0.01).
Small and large intestine contents were not different between the dam 
groups (Table 6.5).
Table 6.5. Small and large intestine contents of dams with different lactation litter 
sizes
(n= 7 dams feeding 4 pups; n=6 (stomach) and n=5 (large intestine) dams feeding 8 pups; 
n=6 dams feeding 12 pups).
Small intestine contents (g) Large intestine contents (g)
Feeding 2.8 ±0.51 3.4 ±0.98
n=4 (1 .8 -5 .7 ) (0 .0 -7 .7 )
Feeding
n=8 No data
3.2 ±0.97 
(0 .3 -6 .2 )
Feeding 4.2 ±0.84 2.4 ±0.92
n=12 (2 .2 -6 .8 ) (0 .2 -6 .6 )
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6.5. Discussion
The work described in this chapter was intended to extend that of the 
previous chapter, which established changes to gut hormone levels and gut 
size at different stages of lactation. Here, the aim was to determine whether 
the changes in ghrelin, PYY and GLP-1 levels and gut size during lactation 
are influenced by the number of pups the dams were feeding.
Ghrelin in fed plasma was significantly reduced and stomach tissue ghrelin 
was significantly increased in dams feeding 12 pups compared to dams 
feeding the control litter size of 8 pups. Although there were no changes in 
plasma PYY levels, PYY in descending colon was significantly reduced in 
dams feeding 4 pups compared to those feeding 8 pups. No significant 
differences were found in GLP-1 levels in any of the samples. No differences 
were evident in body mass, temperature or abdominal white adipose tissue 
(WAT), but there were changes in some gut tissues. The small intestine was 
significantly lighter in dams feeding 4 pups compared to those feeding 12, 
and significantly shorter in dams feeding 4 than those feeding 8 pups. The 
wet weight of caecum tissue was significantly lightest in dams feeding the 
smallest litter size. The large intestine was also significantly lighter in dams 
feeding 4 pups than those feeding 8, and was significantly longer in dams 
feeding 8 pups than the other dams. Despite not having the longest or 
heaviest gut, dams feeding 12 pups had significantly larger gut 
circumferences than the dams feeding 8 pups.
6.5.1. Orexigenic gut hormone changes resulting from 
lactation litter size
There was no difference in fasted plasma ghrelin levels, but in fed plasma, 
ghrelin levels were significantly lower in dams feeding 12 pups compared 
with dams feeding 8 pups. It seems reasonable to speculate that the dams 
feeding the most pups would eat more and/or more frequently, which may 
explain why they had significantly reduced plasma ghrelin in the fed state 
when they may have been expected to have increased plasma ghrelin to 
increase food intake. Stomach tissue ghrelin was significantly increased in 
the same dams after the short period of fasting, which is suggestive of more 
stored ready for release, with potential to increase food intake most in the 
dams feeding the most pups.
One question that arose from the results described in Chapter 3 was whether 
the rats were adequately fasted, due to no significant difference being found 
between fed and fasted plasma ghrelin levels in the matched samples 
(section 3.5.1.1). Although absolute concentration differences cannot be 
explored here with a paired t-test (discussed in section 2.5.3), the results in 
this chapter suggest that fasting may have standardised ghrelin levels 
between the dams due to a significant difference found in fed, but not fasted 
plasma ghrelin levels. However, fed plasma ghrelin was only quantified in 4 
dams, to match with their pups analysed in the next chapter, so this result 
would need to be replicated using a greater number of dams. In the fasted 
state, significantly increased stomach tissue ghrelin in the absence of any 
increase in plasma ghrelin in the dams feeding 12 pups may also suggest
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that the fasting length was adequate in these animals. The fasting period was 
for a long enough period to cause increased ghrelin production by the 
stomach, before a more chronic starvation pattern presented, where one may 
additionally expect increased ghrelin levels in the plasma to increase food 
intake.
6.5.2. Anorexigenic gut hormone changes resulting from 
lactation litter size
Despite there being no differences in the levels of PYY in the circulation 
between the dams, descending colon levels were significantly higher in dams 
feeding 8 pups compared to those feeding 4 pups. Dams feeding 12 pups 
also had reduced descending colon PYY levels in comparison to dams 
feeding 8 pups, but this difference was not significant. It is possible that the 
increased level of descending colon PYY in dams feeding 8 pups is linked 
with increased gut size in this group compared to the other dams; this will be 
discussed later (section 6.5.3).
There were no significant changes in GLP-1 levels in either plasma or gut 
tissue between the dams feeding different litter sizes. This finding may 
indicate that feeding different litter sizes did not have a great effect on 
glucose regulation in the dams because GLP-1 levels are known to change 
for instance, in insulin-resistant states (Lim et al., 2009, Muscelli et al., 2008, 
Toft-Nielsen etal., 2001). Similar to the data reported in the previous chapter, 
all of the dams here had fed plasma GLP-1 levels that were 200 to 789% 
elevated compared to proestrus controls, which reduced after fasting to just
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above control levels (11 to 64% increase). This finding may suggest that 
GLP-1 was increased appropriately in the fed state in response to food 
intake. Assuming that food intake in these dams was considerably higher 
than in nulliparous controls, as has previously been reported during late 
lactation (Crean and Rumsey, 1971, Cripps and Williams, 1975, Denis et al., 
2004), these dams may not have been as sensitive to the satiating effects of 
increased levels of GLP-1, which may suggest a level of resistance to it, as is 
seen during pregnancy with resistance to increased leptin levels (Friedman, 
2011, Ladyman eta!., 2010).
6.5.3. Maternal gut size changes resulting from lactation 
litter size
No changes were found in body mass, abdominal cavity WAT or 
anaesthetised rectal temperature between the dam groups. One study 
reported no significant differences in total abdominal adiposity in women with 
different lactation durations, but did report a significant difference in visceral 
adiposity (McClure et al., 2012). It is therefore possible that adiposity may 
have been altered in different areas of the body in the study dams, and this 
possibility could be one avenue for future study.
The work described in the previous chapter established that significant gut 
growth occurred from mid-lactation onwards and measurements were highest 
at day 25 of lactation, which is the stage at which the dams in this chapter 
were sacrificed. There was no significant difference in the wet weight of the
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stomach tissue, although all dams had heavier stomachs than proestrus 
controls, which is consistent with the findings from the previous chapter.
The wet weight of the small intestine was significantly reduced in the dams 
feeding 4 pups compared to dams feeding 12 pups, but there were no data 
for the dams feeding control litter sizes of 8 pups. The length of the small 
intestine was significantly reduced in the dams feeding 4 pups compared to 
those feeding 8 pups but was, surprisingly, similar in length in the dams 
feeding litters of 12 pups. Only one other study has explored the effects that 
halving litter size has on maternal small intestines. Datta et al. (1995) 
reported that dams with a restricted litter size of 4 pups had small intestines 
that were not significantly different in length or wet weight than the lactating 
dam group with control litter sizes of 8 pups. It is possible that the difference 
between the present study and that of Datta et al. (1995) is a rat strain 
difference or due to method differences, as these authors standardised 
length measurement differently to this study by stretching the tissue.
Empty caecum mass was significantly reduced in dams feeding 4 pups 
compared to the other dams, however, dams feeding 8 pups had significantly 
increased caecum mass compared to those feeding 12 pups. Again, this 
finding was surprising as it indicates significant tissue hypertrophy in the 
dams feeding 8 pups compared to dams feeding 12 pups and one may 
expect gut size to increase in proportion to the increased demand of suckling 
more pups. Why dams feeding 8 pups had significantly increased gut size 
compared to dams feeding 12 pups remains to be established. Although the
206
dams feeding 12 pups had significantly lighter empty caecums compared to 
the dams feeding 8 pups, they had 45% more contents in their caecums. 
This, combined with significantly increased stomach tissue ghrelin, may 
indicate that the dams feeding the large litter sizes had a more profound 
hyperphagia and consumed more food prior to the fasting period. Future 
work would have to determine dam food intake, independently of any diet 
that the pups may consume, to confirm this suggestion.
In addition to having larger small intestines and caecums, dams feeding 8 
pups had heavier and longer large intestines compared to dams feeding 4 
pups and longer large intestines than dams feeding 12 pups. The decreased 
small intestine, caecum and large intestine size in the dams feeding 4 pups 
may represent a reduced requirement to physically adapt to lactation, as the 
metabolic drain would be reduced in comparison to that of dams feeding 
more pups. However, it was the dams feeding 8 pups, not those feeding 12, 
that had the most increased gut measurements, when it was hypothesised 
that the gut would increase in size in relation to the number of pups the dam 
was feeding. It is possible that the dams feeding 12 pups were simply too 
energy deficient to be able to support gut growth as an adaptation to 
lactation. An increased level of gut growth in the dams feeding 8 pups could 
be related to a significantly increased level of descending colon PYY in the 
same animals. The possibility of colonic PYY being involved in increased gut 
growth during the latter stages of lactation was discussed in detail in Chapter 
5 (section 5.5.4.1), with the work of Gomez et al. (1995) suggesting that 
increased PYY is a direct cause of gut growth.
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As previously discussed (section 5.5.4.1), studies in rats have shown that 
food restriction prevents small intestine hypertrophy in lactating rats 
(Campbell and Fell, 1964, Datta et al., 1995). It may be reasonable to 
assume that although not food restricted, the dams feeding 12 pups were 
probably less able than the other dams to match food intake and nutrient 
absorption to their nutritional requirement and may therefore have been more 
energy deficient. If this was the case, energy deficiency could prevent 
increased gut growth in dams feeding 12 pups in a similar way as is reported 
to occur in food restricted dams; the dams feeding litter sizes of 8 pups may 
have more of an energy reserve to enable support of gut growth. 
Measurement of gut circumferences provides support for this possibility. The 
dams feeding 12 pups had significantly increased circumferences in the 
duodenum, ascending and descending colon compared to the dams feeding 
8 pups. Increasing gut capacity appears to be a key adaptation during 
lactation and it could be that the dams feeding 12 pups have achieved this by 
increasing gut circumference without increasing gut length, which could be a 
less energetically costly adaptation. Also in support of this hypothesis was a 
larger ascending and descending colon circumference in dams feeding 4 
pups compared to dams feeding 8 pups. Dams feeding the small litter sizes 
also had reduced gut growth in comparison to those feeding 8 pups. In their 
case, it may be that whilst they have reduced requirement to optimise 
nutrient absorption compared to dams suckling more pups, they may have 
similar requirements to excrete additional waste and thus have increased 
colon circumference compared to the dams feeding 8 pups that are more 
able to accommodate their waste material with longer gut tissue. Future
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study to establish the cause of changes in gut circumference would have to 
be undertaken to further this work, microscopically examining and measuring 
each layer of the gut. Gut circumference could be changed by thickening or 
thinning of the muscle and/or the epithelial layers. Determining exactly what 
changed the gut circumference would further the understanding of maternal 
gut changes as an adaptation to lactation.
6.6. Conclusions
This study has, for the first time, explored the effects that suckling different 
litter sizes had on gut peptide levels and gut size in rat dams. Dams feeding 
4 pups had significantly smaller small intestine, caecum and large intestine 
tissues compared with dams feeding 8 pups and it is suggested that this was 
due to a reduced suckling demand. It is likely that significantly increased 
descending colon PYY in dams with 8 pups is linked with increased gut size 
in these dams. Despite no increase in gut length or wet weight, dams feeding 
12 pups had significantly increased gut circumferences, which may represent 
an alternative adaptation to lactation that requires less available energy. 
Energy insufficiency is thought to be the reason why dams feeding 12 pups 
did not have increased gut size compared to the dams feeding 8 pups. This 
work additionally highlights the importance of standardising litter size very 
early in lactation when studying the dams, as unseen changes to the 
metabolic status and gut size of the dam may occur early in lactation. It is 
possible that similar changes to gut size may occur in humans during the 
lactation period, and that duration of lactation, or a multiple birth, or even 
overlap, may additionally affect gut growth.
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6.7. Future work
It would be of great interest to quantify the food intake of dams feeding 
different litter sizes, to see whether it is increased in proportion to the number 
of pups in the litter. This would require special cages that kept the pups 
separated from the cage diet but not their mothers. Examination of adiposity 
in different areas of the body may also provide additional information to the 
results from this study.
Replicating this experiment, but sacrificing dams at time-points throughout 
lactation would also be a direction for future study. Determining exactly when 
the differences become evident between the dams feeding different litter 
sizes may provide useful information for other studies on timings of litter 
manipulation, for instance. To further elucidate the possible reasons for 
increased gut growth during lactation, analysis of gut transit times in the 
dams would aim to determine whether changes to gut circumference may be 
a mechanism to alter gut transit time in the absence of gut growth. Such work 
could be supported by additional groups of dams, with different litter sizes, 
that are food restricted to differing degrees to test the possibility that gut size 
is reduced in the dams feeding 12 pups compared to those feeding 8 pups 
due to energy insufficiency. It would also be of interest to explore whether the 
structural adaptations found in dams feeding 8 pups remain after the lactation 
period and whether this could contribute to, or refine, adaptation to future 
pregnancies and lactation periods.
210
CHAPTER 7: CHANGES IN OFFSPRING GUT 
APPETITE HORMONES AND STOMACH SIZE DUE TO 
LACTATION LITTER SIZE
7.1. Introduction
Having established that differences occurred in maternal gut peptides and 
gut size when dams were feeding different lactation litter sizes, this chapter 
presents data on their male and female offspring. Chapter 1 (section 1.8.1) 
reviewed some of the studies that have established the adverse effects that 
maternal under- or over-nutrition has on the health of their offspring, but this 
was not a focus of this chapter. Here, dams were fed ad libitum on a 
standard diet with the only difference being lactation litter size. The effects of 
being raised in different lactation litter sizes were studied in both the levels of 
gut appetite hormones and in the body and gut size of male and female 
offspring at weaning age, without any other manipulation.
7.1.1. Body size is affected by lactation litter size
A number of studies have examined the effects that litter size has on the 
physical size of pups, with studies often only reporting results for males. One 
study (Widdowson and McCance, 1963) explored the effects that small (n=3, 
male pups only) and large (15 to 20, males and females) litter sizes had on 
body size in male rat pups. Pups suckled in large litters had reduced body 
mass in comparison to pups from the small litters, a difference that continued 
past 40 weeks of age, which demonstrated that the effects of litter size on
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pups during lactation affects body mass into adulthood. Body length was also 
increased in rats from small litter sizes compared to those from large litters 
when measured at 6, 9 and 12 weeks of age. A later study also reported 
significantly increased body mass in male rat pups from small litters (n=3 to 
4) compared to controls (n=12 per litter) throughout their study (until 8 
months of age), however found no body mass difference between pups from 
large (n=20 to 24) and control litter sizes into adulthood, suggesting that pups 
from large litter sizes may not be as affected by litter size differences as 
those from small litters (Plagemann et al., 1992). A further study by this 
group (Plagemann et al., 1999) found that differences in body mass were 
evident from 8 days of age. By 21 days of age (weaning) in that study, pups 
from small litters (n=3) were significantly heavier and longer than controls, 
with body mass relative to body length also having significantly increased.
Results from the above studies suggest that male rat pups from small litters 
have increased body size than those from large litters, and that this 
difference may persist into adulthood. This change may lead to increased 
susceptibility to obesity later in life.
It has been reported that male rats from small litters (n=4) had significantly 
increased body adipose content than rats from large litters (n=16) at both 
weaning and 12 weeks of age (Balonan and Sheng, 2000). Indeed, another 
study documented that male rats at weaning had 3 times greater total 
adipose mass and double the percentage adiposity when from small litters 
(n=4) compared to control litters (n=10 to 12) (Schmidt et al., 2001), which
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was in agreement with an earlier study (Faust et al., 1980). Faust et al. 
(1980) reported that male rats from the small litters (n=4, male pups only) 
weighed significantly more and had significantly increased adiposity than 
male rats from large litters (n=20, mostly male pups) at weaning and at 11 
months of age. When fed a HFD from 6 months of age, all rats in that study 
gained in both body mass and percentage adiposity, but there was no 
significant difference by litter size and all pups had similar plasma insulin 
levels. However, the wet weight of adipose tissue from the major adipose 
depots (epididymal, retroperitoneal and subcutaneous adipose tissue) was 
significantly increased in male rats from small litter sizes (Faust et al., 1980). 
Collectively, these data suggest that male rats from small litter sizes may be 
more likely to have increased body mass and adiposity into adulthood than 
those from larger litter sizes, with increased susceptibility to becoming 
overweight.
Adding to the data on pup adiposity as a result of litter size is a study that 
reported a significantly increased rate of whole body adipose mass 
accumulation throughout each day of the lactation period in pups (males and 
females) from small litters (n=4) compared to pups from control (n=10) and 
large (n=16) litters (Fiorotto etal., 1991).
7.1.2. Other pup changes due to lactation litter size
Some studies have additionally reported metabolic changes in pups as a 
result of their lactation litter size. Faust et al. (1980) reported no change in 
insulin concentrations between pups from small and large litter sizes at 11
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months of age, however others have documented differences in younger 
rats. In two studies, Plagemann et al. found that plasma insulin 
concentrations were significantly increased in male pups from small litters in 
comparison to pups from the control litter sizes at 15 and 21 days old 
(Plagemann et al., 1999, Plagemann et al., 1992). Balonan and Sheng 
(2000) similarly reported that plasma insulin levels were significantly reduced 
in male rat pups from large litters (n=16) than in control (n=10) and small 
(n=4) litters at weaning, but that this difference was not seen at 12 weeks of 
age. Plagemann et al. (1999) and Schmidt et al. (2001) additionally reported 
that plasma leptin concentrations were significantly different between pups 
from the litter size groups, positively correlating with body mass.
Further data from Plagemann et al. (1992) additionally showed that the larger 
male rats suckled in small litters had significantly higher systolic blood 
pressure than rats from control and large litters. Glucose regulation of the 
males raised in small litters was also more affected after a small dose of the 
pancreatic (B-cell-toxic drug streptozotocin in adulthood, which the authors 
suggest demonstrated an increased susceptibility to the development of 
diabetes compared to the rats suckled in control litter sizes.
7.1.3. Potential differences in appetite regulation due to 
lactation litter size
Analysis of the orexigenic hypothalamic peptide neuropeptide-Y (NPY) in 
both the arcuate nucleus (ARC) and paraventricular nucleus (PVN) found 
significantly increased NPY levels and significantly more NPY-positive
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neurons in the ARC of pups from large litters (n=18) compared to control 
litters (n=10), with no difference in pups from small litters (n=3) compared to 
controls (Plagemann et al., 1999). These authors suggest that no change in 
hypothalamic NPY in rats from small litters compared to controls, despite 
hyperleptinaemia and hyperinsulinaemia, which would usually cause a down- 
regulation of NPY, demonstrated a potential resistance that is similar to that 
seen in obese adult rats, thus inferring a susceptibility to an obese phenotype 
in male rat pups from small litters.
It is clear from previous work in this area that pups are affected by their 
lactation litter size, both in body size and, most importantly, metabolically. It 
is possible that the effects outlined here may persist into adulthood. The 
current study aims to add to this research by establishing whether the 
appetite hormones ghrelin, PYY and GLP-1 in the circulation and relevant gut 
tissues are affected by altering the lactation litter size. Analysis of both male 
and female pups additionally aims to determine whether there are sex 
differences to the body size changes reported by others, as the vast majority 
of studies only report findings from male offspring.
This type of study has the potential to change the way future laboratory 
studies on, for example, obesity are carried out, because results on appetite 
hormone concentrations in adult animals from these studies may be biased 
by the simple fact that they came from different sized litters during lactation. 
Breeding study animals in-house may be the optimal way to obtain animals 
for such studies, to ensure that peri- and postnatal growth is controlled for.
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7.2. Objectives
Objectives for this chapter were to:
o determine whether male and female pups from different lactation litter 
sizes have different levels of ghrelin, PYY and GLP-1 in either gut 
tissue or circulation at weaning age;
o examine the body size of male and female pups at the end of the 
suckling period to establish how lactation litter size affects pup growth 
and whether this is sex specific.
7.3. Methods
7.3.1. Animals
For each dam used at day 25 of lactation (d25L), 2 male and 2 female pups 
(where possible) were dissected alongside the dam. As described in Chapter 
6 (section 6.3.1), dams had their lactation litter size adjusted to either 4 pups 
(n=7; small litters), 8 pups (n=7; control litters) or 12 pups (n=6; large litters) 
by minimal cross-fostering.
7.3.2. Sample collection
Gut tissue was collected from pups as described in Chapter 2 (section 2.3). 
Due to time restrictions, only measurements of body mass, body length and 
stomach tissue wet weight were possible (section 2.4). 1 male and 1 female 
pup from each litter were used to bank fixed tissue for future experiments and 
the second male and female pup had gut tissue frozen for peptide extraction.
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Trunk blood was obtained from all pups and classed as a fed sample 
because pups were kept with dams throughout dam fasting.
7.3.3. Peptide assays
Radioimmunoassays on pup plasma and tissue extracts were performed as 
described in Chapter 2 (section 2.5). Plasma and gut tissue from 8 pups for 
each litter size sample group (1 male and 1 female pup per litter) were 
analysed for ghrelin, PYY and GLP-1.
7.4. Results
7.4.1. Total ghrelin peptide analysis
Fed plasma ghrelin was not significantly different between pups from different 
sized litters for the whole group (Figure 7.1) or when split by sex (Table 7.1).
1 0 0  -i
Small litter Control litter
(n=4) (n=8) (n=12)
Figure 7.1. Ghrelin concentrations in fed plasma of pups from different lactation litter 
sizes
(n=8 pups per group).
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Table 7.1. Ghrelin concentrations in fed plasma of male and female pups from 
different lactation litter sizes
(n=4 pups per sex per group).
Fed plasma ghrelin (ng/ml)
Male pups Female pups
Small litter 
(n=4)
86.6 ± 1.64 
(82 .6 -89 .6 )
85.1 ±2.82 
(79 .7 -92 .7 )
Control litter 
(n=8)
90.8 ±6.57 
(7 8 .3 - 106.7)
88.2 ±9.09 
6 9 .0 -  108.6)
Large litter 
(n=12)
90.4 ± 3.93 
(82 .6 -97 .9 )
85.0 ±4.53 
(7 2 .7 -93 .0 )
Stomach tissue ghrelin concentrations were also not different between the
pups (Figure 7.2; Table 7.2).
7 -i
Small litter Control litter
(n=4) (n=8) (n=12)
Figure 7.2. Ghrelin concentrations in stomach tissue of pups from different lactation 
litter sizes
(n=8 pups per group).
Table 7.2. Ghrelin concentration in stomach tissue of male and female pups from 
different lactation litter sizes
(n=4 pups per sex per group).
Stomach tissue g hrelin (pg/g WWT)
Male pups Female pups
Small litter 5.2 ±0.31 4.9 ±0.27
(n=4) (4 .4 -6 .0 ) (4 .4 -5 .5 )
Control litter 5.1 ±0.21 5.2 ±0.18
<n=8) (4 .6 -5 .6 ) (4 .7 -5 .4 )
Large litter 5.8 ±0.57 5.6 ±0.52
(n=12) (4 .6 -7 .2 ) (4 .4 -6 .9 )
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7.4.2. Total peptide-YY (PYY)
Fed plasma PYY was not significantly different between the pups from litters 
of different sizes either analysed as a whole group (Figure 7.3) or split by sex 
(Table 7.3).
6 i
Small litter Control litter
(n=4) (n=8) (n=12)
Figure 7.3. PYY concentrations in fed plasma of pups from different lactation litter 
sizes
(n=8 pups per group).
Table 7.3. PYY concentrations in fed plasma of male and female pups from different 
lactation litter sizes
(n=4 pups per sex per group).
Fed plasma PYY (ng/ml)
Male pups Female pups
Small litter 4.7 ±0.19 4.7 ±0.20
(n=4) (4 .2 -5 .1 ) (4.1 -5 .1 )
Control litter 4.9 ±0.15 5.1 ±0.31
(n=8) (4 .6 -5 .2 ) (4 .6 -5 .9 )
Large litter 4.6 ±0.14 4.8 ±0.16
(n=12) (4 .3 -5 .0 ) (4 .5 -5 .2 )
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Ascending colon PYY concentration was also not different between the pups 
from lactation litters of different sizes when data were analysed either for the 
whole groups (Figure 7.4) or when the data were split by the sex of the pups 
(Table 7.4).
Small litter Control litter
(n=4) (n=8) (n=12)
Figure 7.4. PYY concentrations in ascending colon tissue of pups from different 
lactation litter sizes
(n=8 pups per group).
Table 7.4. PYY concentrations in ascending colon tissue of male and female pups 
from different lactation litter sizes
(n=4 pups per sex per group).
Ascending colon tissue PYY (ng/g WWT)
Male pups Female pups
Small litter 
(n=4)
915.0 ± 124.25 
(686 .0 - 1263.2)
832.1 ± 144.81 
(5 39 .3 - 1224.4)
Control litter 
(n=8)
870.2 ± 181.57 
(329 .7 - 1104.0)
1105.1 ± 106.25 
(8 77 .0 - 1288.5)
Large litter 
(n=12)
906.2 ± 172.08 
(411.4-1193.7)
1023.9 ±112.45 
(777.9-1249.4)
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PYY in descending colon tissue was significantly different between the pups 
from litters of different sizes (F(2, 21)=5.580, P=0.011) and was significantly 
less concentrated in pups from the large litter size compared to pups from the 
small (P=0.047) and control (P=0.013) litter sizes (Figure 7.5).
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Small litter Control litter Large litter 
(n=4) (n=8) (n=12)
Figure 7.5. PYY concentrations in descending colon tissue of pups from different 
lactation litter sizes
(n=8 pups per group; * P<0.05).
When the data were split to analyse the difference between the sexes, only 
the male pups (F(2, 9)=7.222, P=0.013; Figure 7.6 A) had significantly 
reduced descending colon PYY concentrations when from the largest litter 
size, with no difference found between the females (P=0.244; Figure 7.6 B).
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Figure 7.6. PYY concentrations in descending colon tissue of male and female pups 
from different lactation litter sizes
(A) male; (B) female (n=4 pups per group; * P<0.05).
7.4.3. Total glucagon-like peptide-1 
analysis
Fed plasma concentrations of GLP-1 were very low in all samples and were 
below the detection limit of the radioimmunoassay (3 pmol/l) despite an 
extraction process (recommended by kit protocol) that was adapted to double 
the concentration of GLP-1 obtained.
Concentrations of GLP-1 in ascending colon tissue were significantly (F(2, 
21)=5.034, P=0.016) reduced in pups from the smallest litter size compared 
to pups from control (P=0.024) and large (P=0.043) litters (Figure 7.7).
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Figure 7.7. GLP-1 concentrations in ascending colon tissue of pups from different 
lactation litter sizes
(n=8 pups per group; * P<0.05).
No significant difference remained in ascending colon GLP-1 concentrations
when the data were split by pup sex, although pups from the small litters still
had numerically lowest concentrations (Table 7.5).
Table 7.5. GLP-1 concentrations in ascending colon tissue of male and female pups 
from different lactation litter sizes
(n=4 pups per sex per group).
Ascending colon tissue GLP-1 (ng/g WWT)
Male pups Female pups
Small litter 
(n=4)
64.2 ± 18.41 
(13 .0 -94 .2 )
82.2 ± 13.99 
(47 .9 -114 .7 )
Control litter 
(n=8)
137.8 ± 15.15 
(104.9-164.4)
118.4 ± 12.95 
(9 0 .0 - 143.1)
Large litter 
(n=12)
109.5 ±30.20 
(4 9 .6 - 184.9)
136.1 ±21.69 
(91.1 -  177.9)
Descending colon GLP-1 concentrations for all of the pup groups were not 
significantly different (Figure 7.8). In the males, descending colon GLP-1 was 
significantly reduced (F(2, 9)=4.351, P=0.048; Figure 7.9 A) in pups from
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large litters compared to pups from small litters (P=0.045), with no
differences and more variation between the females (Figure 7.9 B).
40 -i
Small litter Control litter
(n=4) (n=8) (n=12)
Figure 7.8. GLP-1 concentrations in descending colon tissue of pups from different 
lactation litter sizes
(n=8 pups per group).
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Figure 7.9. GLP-1 concentrations in descending colon tissue of male and female pups 
from different sized lactation litters
(A) male; (B) female pups (n=4 pups per group; * P<0.05).
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7 .4 .4 .  B o d y  s i z e  c h a n g e  i n  pups
l i t t e r  sizes
Body mass of all of the pups (Figure 7.10) was significantly different (F(2, 
81)=50.659, P<0.001), being highest in pups from the small litter size of 4 
pups compared to the other groups.
* * *
Small litter Control litter
(n=4) (n=8) (n=12)
Figure 7.10. Body mass of all pups from different lactation litter sizes
(n=28 pups per group; *** P<0.001).
The body mass of both the male (F(2, 39)=32.523, P<0.001) and female 
(F(2, 39)=21.080, P<0.001) pups was equally affected by litter size (Figure 
7.11).
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Figure 7.11. Body mass of male and female pups from different lactation litter sizes
(A) male; (B) female (n=14 pups per group; *** P<0.001).
Pups from large litters were significantly shorter (F(2, 81 )=19.414, P<0.001) 
compared to other litter size groups (Figure 7.12 and Figure 7.14).
10.0 n
Small litter Control litter Large litter 
(n=4) (n=8) (n=12)
Figure 7.12. Body length of all pups from different lactation litter sizes
(n=28 pups per group; *** P<0.001).
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Similar to body mass, the body length of both male (Kruskal-Wallis, 
X2=14.490, 2 df, P=0.001) and female (F(2, 39)=10.910, P<0.001) pups 
appeared to be similarly affected by litter size (Figure 7.13 and Figure 7.14).
10.0 -
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Small Control 
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Fig
(A)
ure 7.13. Body length of male and female pups from different lactation litter sizes
male; (B) female (n=14 pups per stage; * P<0.05; ** P<0.01; *** P<0.001).
The largest difference in both the mean body mass and mean body length 
were found between pups from the small and large litters. In males, the 
difference in body mass between the small and large litters (17.4 g) was 
larger than the difference between female pups from the small and large 
litters (13.6 g). Likewise, the difference in mean body length of males from 
small and large litters (1.0 cm) was larger than in females from the same litter 
sizes (0.9 cm).
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Figure 7.14. A representative image showing body sizes of pups from different 
lactation litter sizes
(A) males and (B) females from large (left) and small (right) litters.
7 .4 .5 .  S t o m a c h  t i s s u e  s i z e  i n
l i t t e r  s i z e s
Stomach tissue wet weight (Figure 7.15) was significantly different between 
the pups (F(2, 80)=27.319, P<0.001), significantly decreasing as litter size 
increased.
When from a small lactation litter size, both male (F(2, 38)=17.030, P<0.001) 
and female (F(2, 39)=14.524, P<0.001) pups had significantly increased 
stomach tissue wet weight (Figure 7.16).
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Small litter Control litter Large litter 
(n=4) (n=8) (n=12)
Figure 7.15. Stomach tissue wet weight of all pups from different lactation litter sizes
(n=28 pups from small and large litters; n=27 pups from control litters; ** P<0.01; *** 
P<0.001).
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Figure 7.16. Stomach tissue wet weight of male and female pups from different 
lactation litter sizes
(A) male; (B) female (n=14 pups per stage, except control litter males where n=13; * P<0.05; 
** P<0.01; *** P<0.001).
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The mass of stomach contents was not different between the pups from 
different litter sizes, either for the whole group or when split by pup sex 
(Table 7.6).
Table 7.6. Stomach contents of male and female pups from different lactation litter 
sizes
(n=14 pups per stage, except control litter males where n=13).
Stomach contents (g)
Male pups Female pups
Small litter 0.5 ±0 .08 0.6 ± 0.06
(n=4) (0.5 -  0.8) (0 .5 -0 .7 )
Control litter 0.5 ±0 .08 0.5 ± 0.05
(n=8) (0.5 -  0.7) (0 .5 -0 .6 )
Large litter 0.7 ±0 .17 0.6 ±0 .12
(n=12) (0 .5 -0 .6 ) (0.5 -  0.6)
7.5. Discussion
This study has been the first to examine the effects on gut appetite hormones 
at weaning age in both male and female pups raised in litters of different 
sizes. Concentrations of ghrelin, PYY and GLP-1 were quantified in both 
plasma and gut tissue to establish whether appetite regulation was altered as 
a result of being in different litter sizes during the suckling period. 
Measurements of body and stomach tissue size provided additional 
information on the physical changes that occurred between the pups for 
comparison with the studies of others.
There were no changes in ghrelin or PYY in fed plasma between pups in 
litters of different sizes, with plasma concentrations of GLP-1 being too low to 
quantify using the radioimmunoassay kit. Stomach tissue ghrelin and 
ascending colon PYY concentrations were not different between the pups
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from different litter sizes. Descending colon PYY was significantly reduced in 
pups from large litter sizes analysed as a group, but when split by sex, this 
was only found to occur in the male pups. Conversely, ascending colon GLP- 
1 was significantly reduced in the entire group of pups from small litter sizes, 
but no differences were found when males and females were separately 
analysed. GLP-1 in descending colon was also only significantly different in 
the males, and was reduced in pups from large litters. Both body mass and 
body length were significantly reduced in all pups from large litters. Stomach 
tissue was also significantly lighter in all pups from large litters.
7.5.1. Gut peptide changes in pups from different 
lactation litter sizes
Although there were no differences in either plasma or stomach tissue ghrelin 
concentrations between the pups, there was evidence of an altered satiety 
profile. Plasma concentrations of PYY were not different, and plasma GLP-1 
could not be analysed using the same technique, but significant colon tissue 
changes in these two satiety hormones were found, which may suggest that 
more of these hormones were being synthesised by the gut L-cells. Due to 
the pups remaining with their mothers until culling, without any solid diet 
available, it is possible that variable fed states were seen between pups from 
differently sized litters and was representative of how much they were fed by 
their mothers, which may affect plasma levels of all of the appetite hormones.
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7.5.1.1. Changes in gut satiety hormones were only found in male 
offspring
PYY levels in the ascending colon were similar between the pups, but 
descending colon concentrations were significantly different. When all of the 
pups were analysed together, those from the large litter sizes had 
significantly reduced descending colon PYY, however this only remained in 
the males when the data were split by pup sex. Males from the large litters 
had significantly less descending colon PYY compared to males from both 
the small and control litters, and had 45% less PYY in this tissue than their 
female littermates, which could suggest a reduced level of satiety in the 
males. Concentrations of descending colon PYY between male and female 
pups from the small and control litter sizes were much more similar, which 
suggests that coming from a large litter size may affect future PYY levels or 
regulation in males. This may result in male pups from larger than average 
litter sizes having reduced satiety in order to achieve catch-up growth 
through increased nutrient intake, in a similar way as has been described in 
human growth-restricted offspring (Ounsted and Sleigh, 1975). As described 
earlier, Plagemann et al. (1999) found increased hypothalamic NPY in male 
pups from large litters compared to pups from control litters, which could 
indicate increased appetite, perhaps to aid increased nutrient intake. 
Supporting this possibility is the observation that pups from large litter sizes 
were significantly smaller than other pups, which will be discussed in more 
detail below (section 7.5.2).
GLP-1 concentrations in ascending colon tissue were significantly reduced in 
pups from the smallest sized litters compared to those in both the control and
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large sized litters. However, when the data were split by pup sex, this 
difference was no longer seen in either sex. It is possible that adding more 
male and female pups to the individual data sets would reveal a sex 
difference, as a large range of concentrations were measured in these 
samples.
The opposite trend was found in descending colon GLP-1 levels in 
comparison to the ascending colon levels. No significant difference was 
found between the pups from different litter sizes, however when analysed 
separately, the male pups from large litters had significantly reduced 
descending colon GLP-1 compared to males from small litters. The female 
pups had very large concentration variations between the groups, which 
masked overall pup differences when analysed alongside the males.
7.5.2. Body size and stomach mass were increased in 
pups from small lactation litters
Body mass of pups from the control and large litter sizes were similar to each 
other, but pups from small litters were significantly heavier at weaning. Both 
the male and female pups had similar body masses. Body length followed a 
similar pattern between the pups, being significantly increased in pups from 
small litter sizes, however the female pups from small and control litter sizes 
appeared to be shorter than their male littermates. The reduced body length 
of the pups from control compared to large litter sizes was more significant in 
the males than in the females, suggesting that the growth of males could 
have been most affected by the increased litter size. The results presented
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here on increased body size are in line with the studies described earlier, 
which found that body mass, length and adiposity of pups from small litters 
was significantly increased compared to other litter size groups studied 
(Balonan and Sheng, 2000, Faust et a/., 1980, Fiorotto et al., 1991, 
Plagemann et al., 1999, Plagemann et al., 1992, Schmidt et al., 2001, 
Widdowson and McCance, 1963), although mainly male offspring have been 
reported on in previous studies.
Stomach tissue wet weight was similar between male and female littermates 
and was significantly decreased in pups from large litters compared to pups 
from control litters. Additionally in male pups, there was a significant 
reduction in stomach mass between control and large litters, which was not 
present in the females, again suggesting that males may be more affected by 
litter size. Although the stomach tissue changed in size, there was no 
difference in ghrelin levels, suggesting that stomach tissue size is not 
necessarily related to ghrelin levels in pups. Future work to quantify the 
number of ghrelin-IR cells in the stomach tissue of these pups would aim to 
establish whether there are any changes to ghrelin cell number as a result of 
increased stomach size.
7.6. Conclusions
Decreased satiety was indicated by decreased levels of PYY and GLP-1 in 
the descending colon of male pups from large litter sizes. As suggested 
earlier, this could be a mechanism to increase food intake to increase body 
size, which is significantly reduced in these animals. No such effect was seen
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in female offspring, suggesting that males and females are affected 
differently, even before sexual maturation.
This work additionally shows the importance of standardising litter size as 
early as possible, as coming from a different lactation litter size can affect 
both body size and appetite hormone profile and the differences outlined in 
this chapter may become evident at an earlier age. For Wistar females, litter 
sizes of 12 are not uncommon and all of the dams had 12 nipples, so the 
findings described here are not a result of dams being unnaturally 
metabolically compromised.
7.7. Future work
There are a number of questions that arise from this study that would require 
further work to answer. For instance, it would be of interest to study the levels 
of the gut appetite hormones in the hypothalamus, and whether levels of their 
receptors are altered here due to being suckled in different litter sizes. As 
described earlier (section 7.1.3), Plagemann et al. (1999) suggested that the 
absence of an appropriate change to the levels of hypothalamic NPY showed 
potential for the development of an obese phenotype in male pups from small 
litters, so it is possible that other changes occur in the appetite-regulatory 
centres of the hypothalamus.
Detailed gut measurements of the pups from different litter sizes would also 
be of interest in the future. Stomach tissue mass was significantly decreased 
in pups from large litters, and it is hypothesised that the rest of the gut would
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be reduced to a similar extent, possibly linked with overall body size. The 
pups from the small litters that had the largest bodies and stomach tissue 
also had the most PYY in descending colon tissue. It is possible that this 
increased PYY is linked to increased gut size (discussed in detail in section 
5.5.4.1), which is why detailed analysis of gut size between the pup groups 
would add to this work. Different levels of PYY and GLP-1 in colon tissue 
could be due to changes in the number of cells secreting these peptides, and 
so quantification of these cells would aim to further elucidate the significant 
reduction in PYY and GLP-1 in male pups from large litter sizes.
Another addition to this area of research could be to include analysis of gut 
hormones and gut size in pups from different lactation litter sizes at different 
stages of development to determine at what age the previously described 
changes occur. A continuation of that study could be to investigate whether 
changes that occurred due to being suckled in different litter sizes persist into 
later life, alongside analysis of food intake and perhaps food preference into 
adulthood.
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CHAPTER 8: GENERAL DISCUSSION
8.1. Introduction
Obesity and its associated comorbidities are known to adversely affect the 
health of pregnant and lactating women and can developmental^ and 
epigenetically programme their offspring to be more susceptible to metabolic 
disorders and obesity in later life (section 1.8). Further elucidating how 
appetite regulation by gut peptide hormones is altered during these times 
may allow better interventions and treatment to improve mother and offspring 
health but prior to this, investigation of normal appetite regulation during the 
reproductive cycle is paramount. The majority of studies exploring gut 
hormones and appetite are performed in males, due to known changes in 
steroid hormones and the fluctuating appetite of mammals during the 
reproductive cycle presenting additional experimental factors to control for. 
Some preliminary studies during the reproductive cycle, pregnancy and 
lactation have looked at gut appetite hormones, but more detailed work is 
necessary to elucidate the mechanisms influencing substantial appetite 
changes during these times and has formed the focus for studies described 
in this thesis.
Studies that have explored appetite during the female reproductive cycle 
have established that a reduction in appetite leading up to ovulation is 
facilitated by high levels of oestradiol (reviewed by Asarian and Geary, 2006) 
and that high levels of oestrogens have an inhibitory effect on the orexigenic
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gut hormone ghrelin, supporting this reduction in appetite (reviewed by 
Butera, 2010). Studies exploring changes in ghrelin during pregnancy and 
lactation are more contradictory, with both rodent and human studies often 
presenting differing findings (section 1.7). Fewer studies have investigated 
the potential roles that gut satiety hormones may have in appetite changes 
during the reproductive cycle, pregnancy and lactation. PYY may be most 
effective at reducing appetite when there are high levels of oestradiol 
(Papadimitriou et al., 2007, Parker et al., 1996), which may support the 
reduction in appetite around ovulation. In rats, studies agree that PYY levels 
increase throughout pregnancy and into early lactation (Suzuki et al., 2014, 
Taylor et al., 2009, Tovar et al., 2004), although this contradicts PYY’s 
peripheral role as a satiety hormone, due to the large increase in food intake 
seen at these times. GLP-1 levels have generally been overlooked with 
regards to appetite regulation, with the main research focus on its role as an 
incretin (discussed in section 1.8.3.3) and thus until now, there have been no 
studies on GLP-1 levels during a complete reproductive cycle, pregnancy or 
lactation. In addition to the above, many studies often only consider 
circulating levels of gut hormones, with limited information available on 
possible concentration changes in gut tissue.
The main aims of this work were therefore to study the plasma and gut tissue 
levels of the total peptide forms of ghrelin, PYY and GLP-1 at each stage of 
the rat oestrous cycle (Chapter 3) and at defined stages of pregnancy 
(Chapter 4) and lactation (Chapter 5). As gut growth was observed by others 
in lactating rodents many decades ago (described in section 5.1.3), this work
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has been repeated and extended with more detailed gut measurements 
taken from pregnant and lactating dams to determine whether changes in gut 
size may be related to changes in gut hormone levels. Chapter 6 addressed 
whether changes in maternal gut hormone levels and gut size were affected 
by the lactation litter size of the dams, leading into Chapter 7, which studied 
changes that had occurred in male and female pups from these different litter 
sizes by weaning age.
8.2. Gut appetite hormone changes during the 
reproductive cycle, pregnancy and lactation
As described in detail in Chapter 1 (section 1.7.1), decreased food intake is 
seen in rats during oestrus due to an earlier peak in ovarian oestradiol 
secretion at proestrus. A key finding from Chapter 3 was that concentrations 
of GLP-1 in fed plasma were significantly increased at proestrus, which could 
indicate increased satiety in these animals. This suggestion was supported 
by the findings of significantly decreased fasted stomach contents in the rats 
shortly after the onset of oestrus and a non-significant decrease in fasted 
plasma ghrelin levels during proestrus. Increased GLP-1 and a potential 
decrease in ghrelin levels during proestrus would favour an anorexigenic 
tone between proestrus and oestrus. Thus, the results from Chapter 3 
suggest a potential explanation contributing towards how food intake is 
decreased around ovulation by gut appetite hormones.
Although the hyperphagia of pregnancy and lactation is well established 
(described in Chapters 4 and 5), the potential role of the gut appetite
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hormones during these times was largely uncharacterised. This study has 
identified a significant decrease in fasted plasma ghrelin levels by late 
pregnancy, coupled with a decline in food intake leading up to birth. On the 
day of birth, approximately 5 hours after birthing began, there was a peak in 
stomach tissue ghrelin concentrations, which may act as a feeding initiator at 
this stage. Fasted plasma ghrelin was lowest in early lactation and 
significantly increased in late lactation. In Chapter 6, dams with large 
lactation litters had significantly increased stomach tissue ghrelin compared 
to dams feeding the control litter size. These combined data on ghrelin levels 
during pregnancy and lactation support its role as an orexigenic gut hormone, 
with high plasma levels at the end of lactation when food intake has been 
reported to be maximal and high stomach tissue levels when there was a 
greater requirement to initiate and sustain feeding. A significant reduction of 
GLP-1 levels in fed plasma and in both PYY and GLP-1 levels in ascending 
colon tissue were seen in late lactation, which could also support the marked 
hyperphagia documented to occur in late lactation by a reduction in satiety.
8.3. Gut size changes during pregnancy and lactation
The detailed gut measurements described here have added to the body of 
knowledge of how rat Gl organs and tract change in size and capacity during 
pregnancy and lactation. The vast majority of studies of maternal gut size 
changes have focussed on lactation, with less information available on 
changes occurring during pregnancy. Here, it was hypothesised that reported 
gut size changes in lactating dams may begin to develop during pregnancy, 
which was confirmed in the small and large intestine with significant changes
240
in their lengths and wet weights. These measurements increased further and 
peaked in late lactation, where stomach and caecum tissue wet weights were 
additionally significantly increased. Dams feeding small litters had 
significantly reduced small and large intestine lengths and wet weights in 
comparison to dams feeding the control litters, which may demonstrate the 
occurrence of gut growth in proportion to the metabolic demand of lactation. 
These results suggest that maternal gut growth starts during pregnancy and 
continues during lactation to increase the absorptive area of the gut, further 
optimising nutrient uptake in relation to lactation demand.
Although dams at day 25 of lactation had significantly increased intestine 
lengths and wet weights, they had significantly reduced circumferences in 
duodenum, ascending and descending colon tissue. It is thought that a 
reduction in gut circumference may be linked to a small decrease in maternal 
demand by this stage, with pups feeding on solid food and a decrease in milk 
yield reported from day 21 of lactation in Wistar rats (Knight et al., 1984). 
Other evidence in support of this suggestion is that dams feeding 12 pups 
had significantly increased gut circumferences in the absence of significant 
length or wet weight increases in comparison to dams feeding 8 pups. In 
Chapter 6 the possibility is discussed that the dams feeding 12 pups were too 
energy deficient to structurally increase their gut length, with significantly 
reduced gut measurements compared to the dams feeding control litter sizes 
of 8 pups (section 6.5.3). An increase in gut circumference may represent a 
less energetically costly adaptation in the dams feeding 12 pups in order to 
increase gut capacity to physically support the hyperphagia of lactation.
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Assuming human gut size increases by a similar mechanism to support 
pregnancy and the lactation period, an important aspect in terms of human 
health would be to know whether changes to the gut persist long after the 
end of pregnancy and/or lactation. An increase in rat stomach size by the day 
of birth occurred with a significantly increased number of cells 
immunopositive for ghrelin compared to proestrus controls and in mid­
pregnancy in the present study (section 4.5.3). It is possible that permanent 
changes in appetite regulation may occur as a result of pregnancy, which 
could then be further altered by lactation demands and in humans, by 
variable lactation length.
Another question that arises from the finding of increased gut size, and the 
possibility of growth persisting indefinitely, is whether this changes the 
adaptations to future pregnancies, which may in turn make optimal 
postpartum weight management different in women who have had single or 
multiple births. Although the dams in Chapter 6 with different sized litters 
during lactation appeared the same externally, with similar body sizes, there 
were a number of changes internally to gut size and gut appetite hormones, 
as described above. Preliminary work with a group of multiparous dams that 
were used to set up the breeding colony provided an insight into what occurs 
in the later postpartum period. Multiparous dams gave birth to two litters, and 
after the 25 day lactation period of the second litter, dams were left to 
normalise for a period of two weeks prior to dissection. The multiparous 
dams were found to have a significantly reduced gut size in comparison to 
primiparous dams feeding the control litter size at day 25 of lactation
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(appendix 2). These data suggest that gut hypotrophy in rats may occur after 
the pup stimulus is removed and food intake reduces back to control levels. 
Further support was provided by another preliminary test group of dams who 
were pregnant but did not lactate due to loss of their litter soon after birth. 
These pregnant/no lactation dams, also dissected 25 days postpartum, did 
not show gut hypertrophy, again suggesting that increased food intake during 
lactation, in combination with the pup suckling stimulus, may be responsible 
for gut hypertrophy and, in their absence, gut growth does not occur. It is 
unknown whether intestinal growth during pregnancy and lactation increases 
the number of ECs secreting appetite-regulatory hormones and it remains 
possible that EC density in the small and large intestine increases in line with 
gut growth, as was reported here in stomach tissue with ghrelin-IR cells 
(section 4.5.3). It may be reasonable to assume that similar gut growth is 
seen in human females, which could change the current advice on controlling 
body mass during pregnancy and lactation to equally include advice about 
food quantity and meal frequency in order to control potential gut size 
modifications and EC changes.
The results described in Chapter 5 revealed a possible link between 
significant gut growth by late lactation and paradoxical high levels of PYY in 
gut tissue during late pregnancy and early lactation (section 5.5.4.1). Gomez 
et al. (1995) reported that intraperitoneal injection of PYY into adult female 
mice significantly increased gut growth and that growth of the small intestine 
was the most significant. That finding is comparable to what has been 
reported here, with a 44% increase in length and a 67% increase in wet
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weight of the small intestine between early pregnancy and late lactation. A 
longer lactation period has been associated with increased circulating levels 
of PYY in humans at 3 years postpartum (Stuebe et al., 2011) and it is 
possible that PYY is increased due to an increase in gut growth associated 
with the duration of lactation.
In humans, it may be that the nearest possible direct comparison that can be 
made between increased circulating PYY and gut growth is post-gastric 
bypass surgery (section 1.5). It is possible that chronically elevated PYY 
levels post-gastric surgery may be, in part, due to an adaption to regenerate 
gut tissue to overcome malabsorption after the surgery has shortened the 
amount of intestine to which nutrients are exposed. This suggestion has 
parallels with that outlined above for this study, in that gut hypertrophy during 
nutritionally uncompromised pregnancy and lactation may occur as a 
mechanism to increase gut size in order to optimise nutrient uptake. To 
confirm, human studies would have to evaluate gut length before and 
immediately after gastric bypass surgery, perhaps by magnetic resonance 
imaging (MRI), and then again several years later in order to evaluate 
whether increased levels of PYY are correlated with an increase in gut size. 
Indeed, one study demonstrated that Roux-en-Y gastric bypass (RYGB) 
resulted in increased circulating levels of PYY and GLP-2 in diet-induced 
obese male rats and in obese female humans (le Roux et al., 2010). In that 
study, RYGB male rats had a significantly increased number of intestinal cell 
crypt mitoses and significantly more cells in S-phase of the cell cycle, which 
the authors suggest indicates increased crypt cell proliferation. In addition to
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this, intestinal thickening was macroscopically noted in the RYGB rats 
compared with the control group. These authors suggest that a similar 
increase in gut size in humans, years after gastric bypass, could be 
responsible for a limit to body mass loss in the long term (see section 1.5).
It is possible that PYY may play a more important role in preparing the gut for 
digestion and absorption of optimal amounts of nutrition than as a true satiety 
signal, which may explain its increase after RYGB to potentially overcome 
malabsorption caused by the procedure by partially restoring gut size. 
Similarly, one study has challenged ghrelin’s role as a true hunger signal, 
instead suggesting that its role is more likely to be in the signalling of energy 
availability, increasing as a result of a negative energy balance rather than to 
directly stimulate appetite (Borer et al., 2009). As it is difficult to fully separate 
the precise roles of each individual gut hormone in response to hunger, 
appetite and energy homeostasis, more in depth study is required to say with 
certainty whether PYY is raised to create a pause in hunger signalling or to 
prepare the gut for dealing with quantities of food sensed by the upper Gl 
tract. As described previously (section 5.5.4.1), food restriction in lactating 
dams prevents gut hypertrophy and in pregnant dams, food restriction 
suppresses PYY levels to non-pregnant levels (Campbell and Fell, 1964, 
Datta et al., 1995, Tovar et al., 2004), which supports the possibility of PYY’s 
role as a gut modifier.
Another implication of significantly elevated levels of PYY in early lactation is 
that appetite may actually be increased as a result. Described in section
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1.6.2.1 is a review (Ballantyne, 2006) of a number of studies that have 
demonstrated an injection of PYY directly into the brain can cause a more 
profound hyperphagia than is seen with injection of its orexigenic family 
member NPY. The review author suggests that it is the full peptide form 
PYYi_36 that is causing an orexigenic effect, whereas the ‘active’ form PYY3.36 
induces satiety by binding to different Y receptor subtypes. The paradoxical 
PYY increase reported to occur here during early lactation may actually be 
supporting hyperphagia by acting in this manner, rather than acting as a 
satiety hormone. Further work to establish any changes in circulating peptide 
forms and PYY and Y receptor levels in the brain would have to be done to 
confirm this suggestion.
8.4. Changes in body mass and adiposity as a result 
of pregnancy and lactation
A further health implication in humans is retention of increased body mass 
long after lactation has ended (see section 1.8.2). Preliminary analysis of a 
pregnancy/no lactation group (see above) showed that these dams had 
significantly increased abdominal white adipose tissue (WAT) compared to 
dams that lactated for 25 days (appendix 2). This may be expected, due to 
the accumulation of adipose reserves ready to support lactation; no lactation 
would require limited use of these adipose reserves and may have health 
implications for women who cannot or who choose not to breastfeed. In 
addition to this preliminary finding, the multiparous group of dams used for 
setting up the breeding colony (see above) also had significantly increased 
abdominal WAT, two weeks after normalisation, in comparison to the dams at
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the end of the lactation period (appendix 2). These findings could indicate 
that there is rapid accumulation of adipose tissue after pups are removed, 
possibly with some time taken for appetite to return to control levels, or that 
multiple births with or without lactation leads to a progressive accumulation of 
adipose tissue. The latter suggestion has implications for human health and 
may affect the ability of women to maintain an appropriate body mass and/or 
level of adiposity after multiple pregnancies, and thus may require different 
interventions for successful postpartum body mass loss, particularly if gut 
size and gut ECs have additionally been altered (see section 8.3).
8.5. Gut appetite hormones in pups from different 
lactation litter sizes
Human studies have explored the health implications of being born small for 
gestational age (SGA) compared to those born appropriate for gestational 
age (AGA). It is thought that the accelerated catch-up growth shown in SGA 
babies may lead to an increased risk of altered glucose metabolism and 
obesity in later life. At 6 years of age, children who were SGA have been 
found to have significantly increased visceral adiposity, without body mass 
differences, compared to AGA children, and they also had significantly higher 
fasted insulin levels (Ibanez et al., 2008). Differences in glucose regulation 
have been found to occur very early in the life of SGA babies and one study 
documented a significant occurrence of hypoglycaemia in SGA compared to 
AGA babies, which was most significant during the first 12 hours of life 
(Mazumder et al., 2012).
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In an attempt to further elucidate the possible mechanisms behind increased 
adiposity and increased obesity risk in adults born SGA, a recent study 
analysed the genotype of SGA babies and documented that genes 
associated with obesity played a smaller role in relation to body mass index 
in SGA babies compared to AGA babies at 3.5, 7 and 11 years of age (Han 
et al., 2013). These authors suggest that this finding indicates that 
accelerated postnatal growth and subsequent increased risk of obesity in 
SGA babies may be largely governed by other non-genetic and 
environmental factors.
For the first time, gut hormone levels were examined in both male and female 
littermates from small, control and large lactation litter sizes at weaning age 
(Chapter 7). No differences were found in ghrelin levels between the pups, 
but levels of the satiety hormones PYY and GLP-1 were found to be altered 
in colon tissue. In descending colon, PYY and GLP-1 concentrations were 
significantly lower in male, but not female, pups from the large litter size. 
Physically, the pups fed in the large litter size were significantly shorter and 
lighter and had significantly lighter stomach tissue. It was thus suggested that 
the significantly smaller male pups may have had significantly reduced 
satiety as a mechanism to achieve catch-up growth into adulthood. It is 
unclear whether females may show similar adaptations but at a later stage. 
This study demonstrated that differences between males and females were 
evident even before sexual maturation.
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A number of studies follow-up SGA babies a couple of years into life, but one 
study has explored the health of SGA babies at 20 years of age. Those 
authors reported that at a mean age of 20.6 years, height, body mass and 
head circumference were significantly lower in men and women who were 
SGA (Leger et al., 1997). Results of an oral glucose tolerance test 
demonstrated that plasma glucose levels at 30 minutes and serum insulin 
levels up to 120 minutes were significantly higher in adults who were SGA. 
Furthermore a sex difference was noted, with significantly higher fasted 
baseline insulin levels in SGA women but not in SGA men compared to AGA 
controls, which, combined with the findings of Chapter 7, may indicate that 
females are affected later and in different ways to males.
The findings of the present study may suggest that a difference in appetite 
regulation may occur simply as a result of changing the early postnatal 
environment, by postpartum manipulation of litter size. One may expect 
offspring that were growth restricted in utero during key stages of 
development could be more at risk of changes in glucose regulation and 
adiposity. Studies of SGA and even large for gestational age (LGA) offspring 
next need to establish levels of appetite hormones to further elucidate 
adulthood obesity risks and whether early alterations in appetite regulation 
may be partly responsible for these increased risks. Further work could then 
explore whether manipulating litter sizes, or modifying lactation duration in 
humans, can modify the risks of being born SGA or LGA.
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8.6. Limitations of study
There were a number of limitations to this study that would need to be 
addressed in future studies. In Chapter 3, it was found that plasma total 
ghrelin levels in both the fed and the fasted state were significantly reduced 
in rats after 36 weeks of age, with only one exception (section 3.5.2). It 
remains unclear why this occurred, but it is possible that there was an early 
decline in reproductive efficacy by this age in the rats (Niggeschulze and 
Kast, 1994, Suckow et al., 2006), which could in turn alter the way in which 
ghrelin is regulated, or how ghrelin regulates appetite, between younger and 
older rats. The age of these animals also meant that the proestrus controls 
used for comparison purposes for subsequent chapters were not age- 
matched, which would have been desirable, particularly after the finding of 
altered plasma ghrelin concentrations with age.
Another key limitation of this study was that the rats had to be group housed 
due to the number of study animals required, thus daily individual food intake 
could not be accurately measured. It was possible to use fasted stomach 
contents as an indication of food consumed leading into the beginning of the 
fasting period. The findings of Chapter 3 demonstrated that fasted stomach 
contents may be an accurate representation of food consumed, as results 
were in agreement with others in that cycling rats consumed the least leading 
up to oestrus (section 1.7.1).
At the beginning of the study, one aim was to compare gut hormone levels 
between fed and fasted plasma samples from each individual animal. Due to
250
a limitation in available funds and the findings of Chapter 3, it was decided to 
exclude analysis of ghrelin in fed plasma as fed concentrations were similar 
to fasted plasma ghrelin concentrations in the cycling rats (section 3.5.1.1), 
and made more fed sample available for PYY and GLP-1 analysis.
Another issue was that the volume of plasma obtained from the tail bleed 
was limited, even after the sample was diluted in buffer and acidified for 
optimal peptide preservation (see section 2.3.2.1), thus the decision was 
made from Chapter 4 onwards to follow the RAPID methodology described 
by Stengel etal. (2009), which involved drying down acidified plasma using a 
vacuum centrifuge in order to concentrate the sample and improve peptide 
yield, which was especially important for GLP-1 analysis. Replicating this 
sample preparation, however, appeared to reduce the peptide yield in this 
study. When comparing the concentration of PYY in reconstituted fed 
acidified plasma with concentrations in non-acidified non-dried down fasted 
plasma, PYY levels were significantly reduced in the fed rather than the 
fasted plasma (section 4.5.2), which was not found in Chapter 3 when 
acidified fed and non-acidified fasted plasma samples were not dried down. It 
was also not possible to directly compare fed and fasted plasma ghrelin 
levels for dams in Chapter 6, as it was unclear whether the reduced levels of 
ghrelin in the fed plasma were a true reflection of peptide concentration, or 
whether they were artificially reduced as was seen with PYY concentrations.
One limitation to how informative the analysis of the fed plasma samples can 
be is that there was no measure of precisely how much food the animals had
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consumed. The lighting schedule and timing of sample collection (figure 2.4) 
was designed to control for food intake as an influencing factor as much as 
possible, but it may be necessary in the future to explore this design further. 
A preliminary test could be done using multiple timed plasma samples to 
demonstrate when levels of PYY and GLP-1 peak after lights out at 11.00. 
The results of such a study, done using a large enough number of animals, 
would allow a sampling window to be set where the majority of animals show 
peak levels of PYY and GLP-1. Having a clearly defined sampling window for 
fed plasma analysis of PYY and GLP-1 would allow more confidence to be 
placed in the findings of the study because it is thought that this would 
reduce the likelihood of some animals being ‘more fed’ than others.
8.7. Future directions
The data described in this thesis have provided key insights into appetite 
regulation by the gut hormones ghrelin, PYY and GLP-1, as well as additional 
physiological changes that occur during pregnancy and lactation, such as 
increased gut size. There are a number of ways in which this research could 
be progressed, some of which are described below and involve samples that 
were banked as part of this study.
To replicate (in the dark phase) or provide an explanation for the unexpected 
finding that there was no difference between fed and fasted plasma levels of 
ghrelin (section 3.5.1.1), despite an appropriate fasting response from PYY 
and GLP-1, more study is required. A longer fasting period could be 
attempted in normally cycling females to see whether this result still remains.
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Section 2.3.1 outlines that many studies of appetite hormones standardise 
their measurements by fasting for 24 hours and sometimes even longer. It 
was important for this work that fasting time was reduced, as comparisons 
were to be made between reproductively cycling females and pregnant and 
lactating dams. Pregnant dams in particular could not have been subjected to 
a prolonged period of fasting. A future study in cycling females only could 
determine whether ghrelin levels are changed by increasing fasting length.
Additionally, more sensitive methods of analysis, such as LC/MS-MS, would 
allow a fed and fasted state plasma hormone comparison with additional 
quantification of the different forms of each peptide, as was intended at the 
onset of the study. Despite sample collection for the analysis of different 
peptide forms, unfortunately this was not possible. Using a technique such as 
LC/MS-MS would also have the advantages of allowing gut hormone analysis 
using a smaller volume of plasma.
Another way in which gut peptide measurements in this study could be made 
more robust is to repeat the experiments using an AccuSampler, which could 
take small repeated blood samples daily. During such a fast-moving oestrous 
cycle, for example, hourly peptide measurements at each cycle stage would 
provide additional information about appetite changes during the cycle that 
would otherwise be overlooked. A study such as that could also use the 
AccuSampler to directly compare reproductive hormone levels with appetite 
hormone levels at any given time.
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As outlined earlier (section 8.6), one of the key limitations to this work was 
the inability to measure individual rat daily food intakes throughout the study. 
The most ideal way to overcome this issue would be the use of metabolic 
cages that could accurately measure both fluid and food consumed. Another 
use for metabolic cages would be to replicate and extend the work of Eckel et 
al. (2000) in determining activity levels to provide another insight into body 
mass regulation during the reproductive cycle, pregnancy and lactation. If this 
work were to be implemented in the future, the metabolic cages would have 
to keep pups separate from the cage diet so that accurate dam food intake 
could be established. In future studies, another way in which the limitation of 
not being able to measure food intake could be taken into account is to 
explore markers of energy intake and metabolism using the blood samples. 
Levels of glucose and insulin could be quantified to further clarify the energy 
status of the rats at the sampling times and would be of most interest to 
measure in the day 18 pregnant dams, which were presumed insulin 
resistant. If the effects of certain diets given to the rats during pregnancy and 
lactation were to be explored in a prospective study, measurement of 
circulating macronutrients could be considered.
To further elucidate the process of gut growth in pregnancy and lactation, 
additional experiments could be carried out, such as inclusion of dry gut 
masses to examine the process of maternal gut adaptations in further detail 
(section 4.7). Pair-feeding pregnant and lactating dams to control levels 
would also be of interest in more closely exploring the link between increased 
food intake and the increase seen in gut size. It is thought that restricting
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food intake to control levels in pregnant and lactating dams would alter gut 
size changes from what have been presented here, and information from an 
experiment like this would provide a more robust link between gut peptides 
and gut growth to be examined in more detail. In addition, measurement of 
gut transit times in pregnant and lactating dams would increase the 
understanding behind the changes in gut size and the role of gut peptides 
during these times.
Continued analysis of banked gut samples for cells immunopositive for 
ghrelin, PYY and GLP-1 would add to this work, and it is possible that there 
may be changes in the properties or density of other gut cells, such as 
enterocytes (section 1.4) during different reproductive stages. It was 
established that ghrelin cell density in the stomach significantly increased 
from proestrus controls to pregnant rats and even further in rats shortly after 
parturition. Unfortunately staining did not work in the colon tissue for PYY 
and GLP-1 (see section 2.6.5), which would have provided additional detail 
about the role of these peptides during pregnancy and lactation. The work of 
subsequent chapters would also be made more robust with the addition of 
gut cell counts to determine whether intestinal lengthening increases the 
number of ECs positive for gut hormones and whether this is further changed 
in dams feeding different litter sizes and in their pups. A question remains as 
to whether possible changes in EC density are retained in mothers into the 
future and permanently change appetite regulation, and the same question is 
asked concerning their offspring. Does early life nutrition affect gut EC
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density during childhood and affect appetite regulation and nutrient utilisation 
into adulthood?
For the animals included in this study, samples of hypothalamus, stomach, 
ascending and descending colon were taken and prepared for mRNA 
extraction and subsequent quantification using RNAIater Solution (Life 
Technologies). This approach would provide a more in depth understanding 
of how ghrelin, PYY and GLP-1 may be up- or down-regulated during 
different reproductive states by investigation of the synthesis of these gut 
hormones in the areas of the gut where their concentration is reported to be 
maximal. When collecting hypothalamic tissue, the main aim was to quantify 
any changes that may occur to hypothalamic neuropeptides and receptors for 
gut appetite hormones, as this would provide evidence of central appetite 
regulation during different reproductive states. Future work should aim to 
localise and quantify levels of the neuropeptides in the arcuate nucleus of the 
hypothalamus (samples banked) and other brain regions (e.g. paraventricular 
nucleus) to determine what changes in appetite regulation may occur at this 
level during pregnancy and lactation. Recent work by Suzuki et al. (2014) 
reported that mRNA levels of orexigenic agouti-related protein (AgRP) were 
significantly increased and that anorexigenic pro-opiomelanocortin (POMC) 
was significantly decreased in the arcuate nuclei of lactating rats. These 
findings suggest central mechanisms by which hyperphagia during lactation 
is facilitated.
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More detailed information could be obtained by quantifying receptor levels in 
gut and hypothalamic tissues alongside their ligands to further clarify some of 
the reported changes occurring during pregnancy and lactation. Samples 
could be analysed in a number of ways, such as staining for the desired 
receptors with subsequent image analysis or RNA could be quantified using 
polymerase chain reaction (PCR). Such work in the later postpartum period 
could explore whether changes at the hypothalamic level persist and could 
contribute to future changes in appetite and body mass regulation in both rats 
and humans. With all of this information, it would be easier to establish a 
difference between synthesis (gut peptide mRNA analysis), storage (gut 
peptide analysis) and release (plasma peptide analysis) of the gut hormones 
from tissues and would be a valuable and very interesting addition to this 
work.
As outlined in a number of the results chapters, the measurement of leptin 
would be interesting in future studies of this nature, not only due to the 
changing adiposity and leptin resistance that is associated with pregnancy 
and lactation but because of the relationship that leptin may have with ghrelin 
(see section 1.8.3). Finally, a clear expansion of this study would be to 
include the analysis of additional gut appetite hormones to further elucidate 
the mechanisms behind changes in appetite and food intake during the 
reproductive cycle, pregnancy and lactation.
257
8.8. Conclusions
In conclusion, the results from the studies presented in this thesis have 
further elucidated the control of appetite by ghrelin, PYY and GLP-1 in female 
rats during their reproductive cycle, pregnancy and lactation, with additional 
work focussing on both maternal and offspring adaptations to a decreased or 
increased litter size. Studies here have also examined changes in gut size 
during pregnancy and lactation and have built on existing knowledge 
surrounding lactation-associated gut hypertrophy and found that these 
changes are initiated during pregnancy. The main findings in this thesis were:
o Fasting did not significantly increase ghrelin concentrations in plasma 
at any stage of the reproductive cycle.
o Circulating ghrelin levels were significantly reduced after 36 weeks of 
age in normally cycling rats.
o GLP-1 significantly increased at proestrus supporting a decreased 
appetite leading into oestrus, which was further corroborated by 
significantly reduced food intake, as indicated by fasted stomach 
contents, and a trend for ghrelin to be decreased at proestrus.
o The density of ghrelin-positive stomach cells was significantly 
increased by parturition, alongside stomach tissue ghrelin 
concentration.
o Levels of PYY and GLP-1 were paradoxically highest during late 
pregnancy and early lactation when food intake was high, which may 
be linked with significant gut growth from mid-lactation.
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o By late lactation, when nutritional requirement and food intake were
high, ghrelin levels were significantly increased and both PYY and 
GLP-1 levels were decreased.
o Maternal gut size increased from late pregnancy onwards and
appeared to be proportional to maternal demand.
o Male, but not female, pups from large litters were smaller and have
decreased descending colon levels of PYY and GLP-1 at weaning.
From the findings reported in this thesis, it is possible that maternal changes 
in appetite regulation and in gut size that occur during pregnancy and 
lactation may continue long after the end of lactation and be further altered 
by lactation duration and parity. Increased postpartum PYY in humans 
(Stuebe et a/., 2011) may be associated with an increase in gut size, 
proportional to lactation duration. Maternal obesity and insulin resistance may 
additionally alter these adaptations to pregnancy and lactation, which in turn 
could affect the health of their offspring. It is clear that more work is required 
to further elucidate the appetite-regulatory system during these times, which 
may lead to more effective preventative measures and treatments to avoid 
health complications in both mothers and their offspring.
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CHAPTER 10: APPENDICES
Appendix 1. Selected ion flow tube mass spectrometry (SIFT-MS) of caecum contents
In d12P dams, acetonitrile (f(7.574)=3.438, P=0.010) and isoprene levels (f(12)=2.346,
P=0.037) (in parts per trillion (ppt)) were significantly higher than in d10L dams. Proestrus 
controls used as a non-statistical comparison. (Precursor ion used: H30+).
Acetonitrile (ppt) Isoprene (ppt)
Proestrus 2.7 ±0.98 1.3 ±0.70
(n=2) (1 .7 -3 .7 ) (0 .6 -2 .0 )
d12P 5.5 ± 1.22 3.1 ±0.52
(n=7) (0.6 -  9.2) (1 .3 -4 .8 )
d10L 1.0 ±0.45 1.6 ±0.38
(n=7) (0 .3 -3 .6 ) (0.1 -3 .0 )
These findings may indicate that there could be quantifiable changes to the 
gut microbiota between pregnancy and lactation, although the group sizes 
are small for this study. Potential future work could aim to establish 
differences in contents from different gut locations, urine and faeces to 
further elucidate the maternal changes that occur to support pregnancy and 
lactation.
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Appendix 2. Changes in maternal body and gut size resulting from different 
postpartum outcomes
Despite being of similar body mass, control primiparous dams at day 25 of lactation (1) had 
significantly reduced abdominal cavity white adipose tissue (WAT) and increased gut size 
compared to (2) dams who gave birth but did not lactate (dissected 25 days postpartum) and 
(3) dams who had two litters, with a recovery period of two weeks prior to dissection. (Group 
1 dams: n=7, except for stomach mass where n=6 and large intestine mass where n=5. 
Group 2 dams: n=4, except for large intestine mass where n=3. Group 3 dams: n=8, except 
for large intestine mass where n=7. * P<0.05; ** P<0.01; *** P<0.001).
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Appendix 3. Product suppliers
Abbott - Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, 
Berkshire, SL6 4XE
Abeam - 330 Cambridge Science Park, Cambridge, CB4 OFL
Acorus Therapeutics Ltd - Office Village, Chester Business Park, Chester, 
CH49QZ
Agar Scientific - Elektron Technology UK Ltd, Unit 7, M11 Business Link, 
Parsonage Lane, Stansted, Essex, CM24 8GF
Bayer UK/Ireland - Bayer House, Strawberry Hill, Newbury, Berkshire, RG14 
1JA
Fisher Scientific UK Ltd - Bishop Meadow Road, Loughborough, LE11 5RG
Hanna Intruments - Eden Way, Pages Industrial Park, Leighton Buzzard, 
Bedfordshire, LU7 4AD
Harlan Laboratories UK - Shaws Farm, Station Road, Blackthorn, Bicester, 
Oxfordshire, 0X25 1TP
Life Technologies Ltd - 3 Fountain Drive, Inchinnan Business Park, Paisley, 
PA4 9RF
Millipore UK Ltd - Suite 3 & 5 Building 6, Croxley Green Business Park, 
Watford, Hertfordshire, WD18 8YH
Phoenix Pharmaceuticals, inc. - UK distributer: Phoenix Europe GmbH, 
Viktoriastrasse 3-5, D-76133 Karlsruhe, Germany
Santa Cruz Biotechnology, inc. - UK distributer: Insight Biotechnology Ltd, 
PO Box 520, Wembley, HA9 7YN
Sigma-Aldrich Company Ltd - The Old Brickyard, New Road, Gillingham, 
Dorset, SP8 4XT
Smith & Nephew Medical Ltd - Healthcare House, 101 Hessle Road, Hull, 
HU3 2BN
TekLab - 9 Dorothy Terrace, Sacriston, County Durham, DH7 6LG
Vector Laboratories Ltd - 3 Accent Park, Bakewell Road, Orton Southgate, 
Peterborough, PE2 6XS
Vet-Tech Solutions Ltd - Unit 17, Daneside Business Park Congleton, 
Cheshire, CW12 1UN
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VetXX Ltd - The Malthouse, Mill Lane, Scotsgrove, Thame, Oxfordshire, 
0X9 3RP
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